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Abstract 
 
Introduction 
Earlier studies have shown the popularity of herbal products among people as traditional, 
complementary or alternative medication. One of the major clinical risks in the concomitant 
administration of herbal products and prescription medicine is pharmacokinetic herb-drug interaction 
(HDI). This is brought about by the ability of phytochemicals to inhibit or induce the activity of 
metabolic enzymes and transport proteins. The aim of this study was to investigate the potential of the 
crude extracts of popular medicinal herbs used in South Africa to inhibit major cytochrome P450 
(CYP) enzymes and transport proteins through in vitro assessment. 
 
 
Methods  
Medicinal herbs were obtained from traditional medical practitioners and 15 were selected for this 
study. The selected herbal products were extracted and incubated with human liver microsomes to 
monitor the following reactions as markers for the metabolic activities of the respective CYP: 
phenacetin O-deethylation (CYP1A2), diclofenac 4‟-hydroxylation (CYP2C9), S-mephenytoin 4‟-
hydroxylation (CYP2C19) and testosterone 6β-hydroxylation (CYP3A4). In addition, the influence of 
Lessertia frutescens (formerly Sutherlandia frutescens) and Hypoxis hemerocallidea was investigated 
on more isozymes: coumarin 7-hydroxylation (CYP2A6), bupropion hydroxylation (CYP2B6), 
paclitaxel 6α-hydroxylation (CYP2C8), bufuralol 1‟-hydroxylation (CYP2D6), chlorzoxazone 6-
hydroxylation (CYP2E1) and midazolam 1‟-hydroxylation (CYP3A4/5). The generation of the CYP-
specific substrates/metabolites were monitored and quantified with the aid of LC-MS/MS. The 
metabolic clearance of midazolam using cryopreserved hepatocytes was monitored in the presence of 
Lessertia frutescens and Hypoxis hemerocallidea. The potential of both to inhibit human ATP-binding 
cassette (ABC) transporter activity was assessed using recombinant MDCKII and LLC-PK1 cells over-
expressing human breast cancer resistant protein (BCRP) and human P-glycoprotein (P-gp), 
respectively. Similarly, the potential for interactions with human organic anion transporting polypeptide 
(OATP1B1 and OATP1B3) was assessed using recombinant HEK293 cells over-expressing 
OATP1B1 and OATP1B3, respectively. 
 
 
Results  
Bowiea volubilis, Kedrostis Africana, Chenopodium album, Lessertia frutescens (methanolic extract), 
Hypoxis hemerocallidea, Spirostachys africana and Lessertia frutescens (aqueous extract), in 
ascending order of potency demonstrated strong inhibition of CYP1A2 activity (IC50 = 1-100 g/mL). 
Similarly, Emex australis, Alepidea amatymbica, Pachycarpus concolor, Lessertia frutescens, 
Capparis sepiaria, Kedrostis africana and Pentanisia prunelloides inhibited CYP2C9 with IC50 less 
than 100 g/mL. The following demonstrated strong inhibition of CYP2C19 with IC50 values less than 
100 g/mL: Acacia karroo, Capparis sepiaria, Chenopodium album, Pachycarpus concolor, 
Ranunculus multifidus, Lessertia frutescens and Zantedeschia aethiopica. CYP3A4 was inhibited by 
Lessertia frutescens, Hypoxis hemerocallidea, Spirostachys Africana, Bowiea volubilis, Zantedeschia 
aethiopica, Chenopodium album, Kedrostis Africana, Acacia karroo, Emex australis, Pachycarpus 
concolor, Ranunculus multifidus, Capparis sepiaria and Pentanisia prunelloides. Time-dependent 
(irreversible) inhibition of CYP3A4/5 (KI = 296 µg/mL, kinact = 0.063 min
-1
) and delay in the 
production of midazolam metabolites in the human hepatocytes, leading to a 40% decreased 
midazolam upscaled in vivo clearance, was observed with Lessertia frutescens. Further, Lessertia 
frutescence inhibited the activity of P-gp (IC50 = 324.8 µg/mL), OATP1B1 (IC50 = 10.4 µg/mL) and 
OATP1B3 (IC50 = 6.6 µg/mL). Hypoxis hemerocallidea inhibited the activity of OATP1B1 (IC50 = 118.7 
µg/mL) and OATP1B3 (IC50 = 290.1 µg/mL) with no potent inhibitory effects on P-gp. None of the two 
inhibited the activity of BCRP within the tested concentrations. 
  
 
Conclusion  
The result indicates the potential for HDI between the selected medicinal herbs and the substrates of 
the enzymes investigated in this study, if sufficient in vivo concentrations are achieved. 
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Abstrak 
 
Inleiding 
Vroeëre studies het aangedui dat die gebruik van plantaardige produkte as tradisionele, aanvullende 
en alternatiewe medikasie baie gewild is.  Een van die grootste kliniese risiko‟s geassosieer met die 
gelyktydige gebruik van plantaardige produkte met voorskrifmedikasie is farmakokinetiese kruie-
geneesmiddel interaksies (HDI).  Hierdie interaksies word veroorsaak deur die vermoë van 
plantchemikalieë om die aktiwiteit van metaboliese ensieme en transportproteïene te inhibeer of te 
induseer.  Die doel van hierdie studie is om ondersoek in te stel na die moontlikheid van onsuiwer 
ekstrakte van gewilde Suid-Afrikaanse medisinale kruie om die belangrikste sitochroom P450 (CYP)-
ensieme en transportproteïene te inhibeer. Hierdie ondersoek sal plaasvind deur middel van in vitro-
studies. 
 
Metodes 
Medisinale kruie is verkry vanaf tradisionele genesers, waaruit ŉ totaal van 15 kruie geselekteer is vir 
gebruik tydens hierdie studie.  Die geselekteerde kruie is geëkstraheer en met menslike 
lewermikrosome geïnkubeer om die volgende reaksies as merkers vir die metaboliese aktiwiteit van 
die onderskeie CYP-ensieme te moniteer: fenasetien-O-deëtilasie (CYP1A2), diklofenak-4‟-
hidroksilasie (CYP2C9), S-mefenitoïen-4‟-hidroksilasie (CYP2C19) en testosteroon-6β-hidroksilasie 
(CYP3A4).  Afgesien van die voorafgaande, is ook die invloed van Lessertia frutescens en Hypoxis 
hemerocallidea op verskeie ander iso-ensieme ondersoek. Hierdie iso-ensieme is soos volg: 
koumarien-7-hidroksilasie (CYP2A6), bupropioonhidroksilasie (CYP2B6), paklitaksiel-6α-hidroksilasie 
(CYP2C8), bufuralol-1‟-hidroksilasie (CYP2D6), chloorsoksasoon-6-hidroksilasie (CYP2E1) en 
midasolaam-1‟- hidroksilasie (CYP3A4/5).  Die produksie van CYP-spesifieke substrate/metaboliete is 
gemoniteer en deur middel van LC-MS/MS-analises gekwantifiseer.  Die metaboliese opruiming van 
midasolaam deur middel van krio-gepreserveerde hepatosiete is gemoniteer in die teenwoordigheid 
van Lessertia frutescens en Hypoxis hemerocallidea.  Die moontlikheid van beide om menslike ATP-
bindingskasset (ABC)-transporteerderaktiwiteit te inhibeer is bepaal deur die gebruik van 
rekombinante MDCKII- en LLC-PK1-selle wat onderskeidelik menslike borskanker-weerstandige 
proteïen (BCRP) en menslike P-glikoproteïen (P-gp) potensieel.  Op ŉ soortgelyke wyse is die 
moontlikheid vir interaksies met menslike organiese anion-transportpolipeptiede (OATP1B1 en 
OATP1B3) bepaal deur rekombinante HEK293-selle te gebruik wat onderskeidelik OATP1B1 en 
OATP1B3 potensieel. 
 
Resultate 
Bowiea volubilis, Kedrostis Africana, Chenopodium album, Lessertia frutescens (metanol-ekstrak), 
Hypoxis hemerocallidea, Spirostachys africana en Lessertia frutescens (water-ekstrak), in 
toenemende potensie, het sterk inhibisie van CYP1A2-aktiwiteit (IC50 = 1-100 g/mL) getoon.  In 
ooreenstemming met die voorafgaande resultate het Emex australis, Alepidea amatymbica, 
Pachycarpus concolor, Lessertia frutescens, Capparis sepiaria, Kedrostis africana en Pentanisia 
prunelloides CYP2C9 met IC50–waardes van minder as 100 g/mL geïnhibeer.  Die volgende het 
sterk inhibisie van CYP2C19 met IC50-waardes van minder as 100 g/mL getoon: Acacia karroo, 
Capparis sepiaria, Chenopodium album, Pachycarpus concolor, Ranunculus multifidus, Lessertia 
frutescens en Zantedeschia aethiopica. CYP3A4 is deur Lessertia frutescens, Hypoxis 
hemerocallidea, Spirostachys Africana, Bowiea volubilis, Zantedeschia aethiopica, Chenopodium 
album, Kedrostis Africana, Acacia karroo, Emex australis, Pachycarpus concolor, Ranunculus 
multifidus, Capparis sepiaria en Pentanisia prunelloides geïnhibeer.  Tydafhanklike (onomkeerbare) 
inhibisie van CYP3A4/5 (KI = 296 µg/mL, kinact = 0.063 min
-1
) en vertraging in die produksie van 
midasolaammetaboliete in menslike hepatosiete wat aanleiding gee tot ŉ 40% afname in midasolaam 
bepaal in vivo opruiming, is waargeneem met Lessertia frutescens. Lessertia frutescens het ook die 
aktiwiteit van P-gp (IC50 = 324.8 µg/mL), OATP1B1 (IC50 = 10.4 µg/mL) en OATP1B3 (IC50 = 6.6 
µg/mL) geïnhibeer.  Hypoxis hemerocallidea het die aktiwiteit van OATP1B1 (IC50 = 118.7 µg/mL) en 
OATP1B3 (IC50 = 290.1 µg/mL) geïnhibeer met geen betekenisvolle effekte op P-gp nie.  Geen een 
van die twee het die aktiwiteit van BCRP geïnhibeer binne die konsentrasies waarin getoets is nie.  
 
Gevolgtrekking 
Die resultate van hierdie studie dui aan dat wanneer voldoende in vivo-konsentrasies bereik word, die 
moontlikheid vir kruie-geneesmiddel interaksies tussen die geselekteerde medisinale kruie en 
ensiemsubstrate ŉ werklikheid word.   
Stellenbosch University  http://scholar.sun.ac.za
v 
 
Dedication 
 
To 
Mrs Avosewhe Fasinu (Nee Avosegbo) 
The mother, who in the face of despair accepts the sole responsibility/single parenthood of 
the three-month old baby  
Stellenbosch University  http://scholar.sun.ac.za
vi 
 
Acknowledgements 
 
I will like to thank all those who have in one way or the other contributed to the success of 
this study. A complete list of such people is almost impossible. This is however, to say a big 
„thank you‟ to everyone, whose support I have enjoyed no matter how seemingly minor.  
Firstly, I sincerely acknowledge and appreciate the invaluable role of my supervisor, 
Professor Bernd Rosenkranz who has seen through the conceptualization of this study, and 
the realization of the findings. I am most grateful to him for his motivating and inspiring 
mentorship and guidance.  
I will also like to appreciate my co-supervisor, Prof Patrick Bouic whose ideas and 
contributions made this study a success. I am grateful for his thoroughness mixed with 
simplicity. It would have been impossible to conduct this study without his push. My sincere 
appreciation to the following members of staff of the Drug Metabolism and Pharmacokinetic 
Unit of Novartis Institute for Biomedical Research, Basel Switzerland, for their support: Gian 
Camenisch, Piet Swart, Heike Gutmann, Hilmar Schiller, Alexandra-David James,  Bertrand-
Luc Birlinger, Lisa Bijasson, Sylwia Faller and Cyrille Marvalin. I thank the Novartis Diversity 
and Inclusion Group, headed by Colin Pillai, for the opportunity to conduct part of this study 
in the Novartis facility in Basel. Much thank to Olivier Heudi and Marcelo Gutierrez for their 
input. 
My sincere appreciation to HOPE Cape Town and its staff for supporting this study 
financially and morally. I am grateful to Rev Fr Stefan Hippler, Pauline Jooste, Kerstin 
Behlau, Sonia Daniels and all the staff members of HOPE Cape Town who individually 
supported. I will like to acknowledge Mrs Nomsisi Stefans and Nombuso Keme who supplied 
me with the medicinal herbs and Dr Heiner Seifart who helped with his analytical expertise. I 
will also like to thank SURMEPI for providing me the bursary in the course of this study. 
I am indeed thankful to my immediate family – my lovely wife, Ebunoluwa Grace, I cannot 
quantify your immesurable support; Setonji, my son who is forced so early to get used to a 
nomadic father; Mrs Avosewhe Fasinu, my mother to whom I owe so much for bearing the 
pain and loneliness of my long absence; my siblings: Kunnuji, Medese and Felix, for 
believing in me and holding the forth while I sojourn. I thank you all for your selflessness and 
love. 
I will not forget the roles played by my supporting cousins – Dr Jendele Hungbo and Dr 
Senayon Olaoluwa. I thank you both for holding the torch while I follow. To colleagues and 
friends – Hilary Masenda, Anthony Adefuye (with Janet and Adeola), Adeniyi Ogunjale, 
Stellenbosch University  http://scholar.sun.ac.za
vii 
 
Ibukun Oyeyipo, Emmanuel Modebe, Ehigha Enabudoso (and the late wife – may her soul 
rest in peace), Samuel Mburu, the Egieyehs, Peter Kudenup (and family), Martins Kudenupo 
and family, Rev Frs Vincent Zannu and Moses Amune, and many others too numerous to 
mention. May God smoothen your paths. 
To the staff and students of the Division of Pharmacology – Lejandra Hanekom (thanks for 
enduring all the troubles), Prof van Zyl, Dr Kim Prescott, Carine Marks, Cherylynn Wium, Jan 
de Bruyn, John Lawrence, Henry Bester, Arina du Plessis, Dennis Francis, Alma van der 
Merwe and Gerald Fortuin, I am most grateful for your moral support and the friendly 
environment. And my colleagues – Brian Flepisi, Lizanne de Kock, Charles Awortwe and 
Lyne van Rensburg, thank you for the times we share and your constructive input. 
And finally, I adore the Almighty, whose promises are true, faithfulness real, mercies 
enduring and love eternal. 
  
Stellenbosch University  http://scholar.sun.ac.za
viii 
 
Research Output 
 
Publications from this thesis (Appendix A) 
1. Pius Fasinu, Patrick J Bouic and Bernd Rosenkranz (2012). Liver-based in vitro 
technologies for drug biotransformation studies – a review. Curr Drug Metab, 13:215-
224 (Abstract in Appendix A1). 
2. Pius Fasinu, Patrick J Bouic and Bernd Rosenkranz (2012). An overview of the 
evidence and mechanisms of herb–drug interactions Frontier in Pharmacol, 3:69. 
doi:10.3389/fphar.2012.00069 (Abstract in Appendix A2). 
3. Pius Fasinu, Heike Gutmann, Hilmar Schiller, Alexander-David James, Patrick J Bouic 
and Bernd Rosenkranz (2013). The potential of Sutherlandia frutescens for herb-drug 
interaction. Drug Metab Dispos, 41(2):488-97. (Abstract in Appendix A3). 
 
Conference proceedings and published abstracts from this thesis (Appendix B) 
4. Pius Fasinu, Heike Gutmann, Hilmar Schiller, Bertrand-Luc Birlinger, Lisa Bijasson, 
Sylwia Faller, Heiner Seifart, Patrick Bouic and Bernd Rosenkranz. Herb-drug 
interaction potential of popular South African medicinal herbs: an in vitro assessment. 
Proceedings of the Annual Congress of the South African Society for Basic and Clinical 
Pharmacology in association with the Department of Family Medicine, University of 
Pretoria) and Toxicology Society of South Africa, 29 September – 2 October 2012 
(Abstract in Appendix B1). 
5. Pius Fasinu, Heiner Seifart, Patrick Bouic and Bernd Rosenkranz. The potential of H. 
hemerocallidea and S. frutescens to induce herb-drug interaction with antiretroviral 
drugs. Proceedings of the 56th Annual Academic Day, 15-16th August 2012, Tygerberg 
Campus, University of Stellenbosch, South Africa; Page 70. Available online: 
http://sun025.sun.ac.za/portal/page/portal/Health_Sciences/English/Annual_Academic_
Day/AAD_Menu/Programme%20Book%20Akademiese%20Jaardag%202012.pdf 
(Abstract in Appendix B2). 
6. Pius Fasinu, Hilmar Schiller, Heike Gutmann, Alexandra-David James, Cyrille Marvalin, 
Bertreand-Luc Birlinger, Lisa Bijasson, Sylwia Faller, Majorie Simon, Patrick Bouic and 
Bernd Rosenkranz. Herb-drug Interaction Potential of Sutherlandia frutescens and 
Stellenbosch University  http://scholar.sun.ac.za
ix 
 
Hypoxis hemerocallidea. Annual Novartis Next Generation Scientist Research Day, 
Basel, Switzerland, August 2012. 
7. Pius Fasinu, Heiner Seifart, Patrick Bouic, and Bernd Rosenkranz. In vitro Investigation 
of the Effects of Commonly Used South African Medicinal Herbs on CYP1A2 activity 
Employing Human Liver Microsomes. Proceedings of the 6th International Conference 
on Pharmaceutical and Pharmacological Sciences, University of KwaZuluNatal, Durban 
South Africa, 25th – 27th September, 2011; Page 42. Available online: 
http://www.sapharmacol.co.za/CONGRESS_Site/html_pages/Docs/program.pdf 
(Abstract in Appendix B3). 
8. Pius Fasinu, Heiner Seifart, Patrick JD Bouic and Rosenkranz B. In vitro investigation 
of herb-drug interaction potential: the influence of 15 commonly used South African 
medicinal herbs on CYP1A2 activity. Proceedings of the 55th Annual Academic Day, 17-
18th August 2011, Tygerberg Campus, University of Stellenbosch, South Africa; Page 
57. Available online.  
http://sun025.sun.ac.za/portal/page/portal/Health_Sciences/English/Annual_Academic_
Day/Information/Programme%20Book%202011%20FINAL.pdf (Abstract in Appendix 
B4). 
 
Additional Outputs from Collaborative Research (Appendix C) 
Publications  
9. Pius Fasinu, Yahya E. Choonara, Riaz A. Khan, Lisa C. Du Toit, Pradeep Kumar, 
Valence M. K. Ndesendo, Viness Pillay (2012). Flavonoids and polymer derivatives as 
CYP3A4 inhibitors for improved oral drug bioavailability. Journal of Pharmaceutical 
Sciences 2012 Nov 27. doi: 10.1002/jps.23382 [Epub ahead of print] (Abstract in 
Appendix C1).. 
10. Pius Fasinu and Bernd Rosenkranz (2012). Drug-drug interactions in ageing HIV-
infected individuals. African Journal of Pharmacy and Pharmacology 6(38):2710-2723 
(Abstract in Appendix C2). 
11. Xolani W. Njovane, Pius Fasinu, Bernd Rosenkranz. Comparative evaluation of 
warfarin utilization in two primary health care clinics in the Cape Town area. 
Cardiovascular Journal of Africa 2012 Dec 3. [Epub ahead of print] (Abstract in 
Appendix C3). 
Stellenbosch University  http://scholar.sun.ac.za
x 
 
12. Pius Fasinu, Viness Pillay, Valence Ndesendo, Lisa du Toit and Yahya Choonara 
(2011). Diverse approaches for the enhancement of oral drug bioavailability. 
Biopharmaceutics and Drug Disposition; 32:185-209 (Abstract in Appendix C4). 
 
Conference Proceedings 
13. Pius Fasinu. Pharmacokinetic drug interaction as a route for improving oral drug 
bioavailability. Proceedings of the South African Congress for Pharmacology and 
Toxicology, Cape Town, 3rd – 6th October, 2010; Page 45; Available online: 
http://www.sapharmacol.co.za/CONGRESS_Site/html_pages/Docs/abstr2010.pdf 
(Abstract in Appendix C5). 
  
Stellenbosch University  http://scholar.sun.ac.za
xi 
 
List of abbreviations 
 
Abbreviation Description 
a Maximal transporter inhibition 
ABC ATP-binding cassette 
ABCB1 ATP-binding cassette, sub-family B, member 1 (P-glycoprotein) 
ABCG2 ATP-binding cassette sub-family G member 2 (also known as breast 
cancer resistant protein) 
ADME  Absorption, distribution, metabolism and excretion 
AIDS Acquired immunodeficiency syndrome 
ARV Antiretroviral drugs 
ATO Atorvastatin 
ATP Adenosine-5'-triphosphate 
AZT Azidothymidine (zidovudine) 
cat. no.  Catalog number 
CLh,b  Hepatic metabolic blood clearance 
CLint  Intrinsic clearance 
CYP   Cytochrome P450 
DDI   Drug- drug interactions 
DIG Digoxin 
DMEM Dulbecco‟s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
ESI(+) Electrospray ionization in positive ion mode  
ESI(-)  Electrospray ionization in negative ion mode 
FBS Fetal bovine serum 
FTC Fumitremorgin C 
fumic   Fraction of unbound test substance in microsomal incubations 
G418 Geneticin 
GIT Gastrointestinal tract 
GSH  Glutathione 
GST Glutathione S-transferase 
HBSS Hank‟s balanced salt solution 
HDI Herb-drug interaction 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human immunodeficiency virus 
HLM   Human liver microsomes 
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CHAPTER ONE 
INTRODUCTION TO STUDY 
 
 
1.1. Background of this Study 
Traditional healing is fast becoming an integral component of healthcare all over the world 
(Ernst, 2004). In South Africa where traditional health practitioners (THPs) (also called 
sangomas) are the most popular type of healers who practice with some governmental 
regulations, it is estimated that up to 85% populace use herbal remedies, usually in 
combinations of two or more (Van Wyk et al., 1997; Moagi, 2009). THPs often give their 
patients medications of plant and animal origin (Muti) for the treatment of physical and 
mental illness, social disharmony and spiritual difficulties (Puckree et al., 2002). The formal 
health sector in South Africa and other African countries have shown continued interest in 
the role of THPs and in the popularity of their traditional herbal remedies with the ultimate 
aim of total integration of traditional medicine into health care (Pretorius, 1991; Wreford, 
2005; Babb et al., 2007). 
While traditional medicine entails a wide range of practices, the use of medicinal herbs forms 
the bedrock of African traditional medical practices. Medicinal herbs contain phytochemicals 
which include potent pharmacologically active substances such as flavonoids, alkaloids, 
furanocoumarins, terpenoids, anthocyanins, phytoestrogens, hypericins, saponins and a 
host of others.  
For example, in South Africa, one of the well documented herbs employed in traditional 
healing is Callilepsis laureola. In a study conducted by Popat and co-workers (2001), the 
toxicity and the potential for pharmacodynamic drug interactions with this herb were 
reported. Although there are limited documented pharmacokinetic herb-drug interactions 
between common South African medicinal herbs and prescription drugs, Malangu (2008) 
reported that 9% of the interviewed HIV/AIDS patients who are on antiretroviral therapy 
consumed herbal medications. Such figures vary from study to study, depending on the 
region and the population group. A recent review on the use of African herbal medicines in 
the treatment of HIV and other chronic diseases by Mills and co-workers (2005a) concluded 
that more information about the potential for drug interactions of traditional medicines used 
by the THPs is required. This information will be important to assess the safety of the 
concomitant use of traditional herbal medicines in pharmacotherapy. The necessity of 
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polypharmacy in the management of most diseases further increases the risk of herb-drug 
interactions in patients who are on concomitant traditional medications.  
 
One of the major steps involved in the development of new drug candidates is the 
verification of their potential for interaction with other drugs (Veber et al., 2002; Umehara and 
Camenisch, 2011). Various in vitro liver-based methods have been developed for such 
purpose. In vitro investigations of drug metabolism provides information regarding the 
metabolic stability of the test drug, its potential for possible interactions with other 
compounds that have affinity for the same drug-metabolizing enzymes, and indication of its 
oral bioavailability and toxicological potential (White, 2000; Masimirembwa et al., 2001; 
Veber et al., 2002). One of the best characterized and validated models for such drug 
metabolism studies is the use of microsomes fractionated from the human liver subcellular 
organelles by differential ultracentrifugation (Wrighton et al., 1993; Ekins et al., 2000). A 
human liver microsomal fraction contains a full complement of cytochrome P450 (CYP) 
which makes it a suitable tool for studying CYP-catalyzed metabolite formation and inhibitory 
interactions. In addition to reliability and reproducibility of in vitro data generated from their 
use, human liver microsomes (HLM) are relatively easy to prepare, commercially available 
and stable on prolonged storage. This has made the application of liver microsomes the 
most widely used in metabolic and toxicological studies (Taavitsainen, 2001). Additionally, 
cryopreserved hepatocytes and transfected cell lines can be used to investigate drug 
metabolism and transport. 
Although there are various in vitro techniques to investigate drug metabolism, the desired 
clinically relevant information on drug interactions has been reliably obtained through the 
utilisation of HLM, cell lines and hepatocytes, the results of which provide indications of in 
vivo behaviour (Umehara and Camenisch, 2011). Such in vitro investigations are optimized 
by either measuring the rate of disappearance of substrates in incubation mixtures or the 
rate of formation of a specific metabolite.  
 
The current project addressed the drug interaction potential of selected medicinal herbs 
used by South African THP through in vitro liver-based techniques. 
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1.2. Rationale and Motivation for this Study 
There has been a high increase in the consumption of herbal remedies across South Africa 
despite the availability of orthodox medications. This traditional practice cuts across social 
classes. A large number of patients who are on ARVs, anti-tubercular drugs and other 
medications are also on concurrent traditional therapy. The likelihood of herb-drug 
interaction is believed to be higher than that of drug-drug interaction (Fugh-Berman, 2000). 
This is because most therapeutic agents contain single chemical entities whereas herbal 
medications are made of complex mixture of pharmacologically active chemical agents, even 
in single herbal products. In addition to the insufficient knowledge of the efficacy of traditional 
medicine, the risk of pharmacokinetic drug interaction poses two major extreme challenges – 
pharmacotoxicity and treatment failure. The former can result from the inhibition of the 
metabolic enzymes while the latter may be the consequence of enzymatic induction leading 
to faster drug metabolism.  
The human CYP enzyme family is responsible for the metabolism of a wide range of clinical 
drugs. For the determination of appropriate dosage regimens, the pharmacokinetic profiles 
of the individual drugs are taken into consideration including their metabolic clearance. Many 
drugs are prone to pharmacokinetic drug interactions in the presence of CYP inhibitors or 
inducers. It is therefore important to investigate the influence of commonly used medicinal 
herbs on the metabolic enzymes, especially CYP. Following satisfactory correlation between 
in vitro and in vivo animal and human studies, there is increasing acceptance of in vitro 
metabolic studies as alternative methods which can reduce, refine or replace the use of 
laboratory animals as advanced and promoted by the European Centre for the Validation of 
Alternative Methods (ECVAM) (Kenworthy et al., 1999; Casati et al., 2005; Nair et al., 2007). 
Information on the safety and HDI potential of popular western and Chinese herbal products 
is available in the literature (see Chapter 2). The novelty of this study is its intention to 
investigate the suitability of concomitant use of orthodox and traditional medicines in South 
Africa, the potential for herb-drug interactions and the possible influence on therapeutic 
efficacy or toxicity. Information in this field is currently sparse and is in great demand for 
regulatory policy designs and integral medical practice.  
The choice of medicinal herbs used in this study is dependent on the information obtained 
from THPs. This is because; they are the custodian of traditional medical practices. They 
enjoy patronage from a number of patients. Aqueous and methanolic extracts of the 
medicinal herbs were used because they represent what the patients are exposed to in real-
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life situations. This is necessary in order to make the findings of this study relevant to the 
society.  
 
1.3. Hypothesis 
The primary hypothesis to be tested in this research is that, due to the overlapping substrate 
specificity of CYP enzymes and transport proteins, herbal products may interact with them, 
thereby inhibiting their metabolic/transport activity. This effect can provide an indication of in 
vivo potential for HDI with co-administered drugs that are CYP and/or transport protein 
substrates.  
CYP and some transport proteins are richly expressed in the human intestines and the liver. 
CYP-mediated metabolism has significant influence on oral drug bioavailability and the 
systemic elimination of xenobiotics from the body. Alteration in CYP activities may lead to 
significant changes in the known pharmacokinetic profiles of drugs. 
It is hypothesized that components of the crude extracts of commonly used medicinal herbs 
in South Africa may inhibit the activity of CYP isozymes and transport proteins involved in 
the disposition of drugs. 
 
1.4. Aims and Objectives 
The overall aim of this study was to assess the inhibitory effect of selected traditional 
medications employed in the management of various diseases in South Africa on the 
metabolic activity of CYP isozymes responsible for the metabolic clearance of conventional 
drugs through in vitro metabolic techniques. The study also aimed to assess the inhibitory 
effect of selected herbal extracts on drug transporters.  
 
1.4.1. Specific Objectives 
1. To provide a literature overview of known herb-drug interactions; and the various liver-
based technologies for biotransformation studies. 
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2. To source from South African traditional healers, common herbal medications employed 
in the management of diseases, select such medicinal herbs with preference for those 
used in chronic diseases (in reflection of long-term use). 
3.  To prepare crude extraction of the selected herbs in close reflection of traditional use, 
for the in vitro interaction studies.  
4. To assess the inhibitory effect of the crude extracts of the identified herbs on drug 
metabolism employing pooled HLM which express various CYP isozymes especially 
CYP1A2, CYP2C9, CYP2C19 and CYP3A4. 
5. To perform a more extensive in vitro study with crude extracts of Lessertia frutescens 
(formerly Sutherlandia frutescens) and Hypoxis hemerocallidea (the two most popular 
medicinal herbs used by people living with HIV/AIDS in South Africa (Mills et al., 
2005a)). The study included the investigation of the inhibitory effect on CYP2A6, 
CYP2B6, CYP2C8, CYP2D6 and 2E1 in HLM.  
6. To investigate the inhibitory effects of the crude extracts of Lessertia and Hypoxis on 
CYP3A4-mediated metabolism of midazolam utilizing cryopreserved hepatocytes. 
7. To investigate the inhibitory effects of the crude extracts of Lessertia and Hypoxis on 
efflux and uptake proteins employing cell lines stably expressing these drug transport 
proteins.  
8. To analyse and interpret such influence as observed in 3, 4, 5 and 6 above, quantifying 
the influence on the metabolic/transport process in terms of concentrations (IC50) 
required to inhibit 50% of the substrate concentration; and to put such figures in 
medical/safety perspective. 
 
1.5. Potential Benefits of this Study 
The results of in vitro HDI studies are important to provide indications for in vivo activity and 
further studies. Test compounds lacking inhibitory activity on metabolic enzymes in vitro are 
not likely to inhibit metabolism in vivo. In vivo studies can be used to confirm in vitro findings. 
The knowledge of the herb-drug interaction in the management of chronic diseases such as 
HIV/AIDS and tuberculosis in South Africa will be important in policy designs and provide the 
basis to apply caution in herb-drug use advocacy. Such knowledge will provide warning 
signals to healthcare providers where necessary and may encourage warning against the 
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concomitant use of traditional medications and conventional drugs. The outcome of this 
study will add to the knowledge of the safety of the co-administration of traditional remedies 
and orthodox medications.  
 
1.6. Ethical Consideration 
This study was approved by the University of Stellenbosch Health Research Ethics 
Committee with Ethics Reference number N10/09/307 (Appendix D). 
 
1.6.1. Sourcing of medicinal herbs 
Material transfer agreement (MTA) guiding the collection and transfer of traditional medicinal 
product from traditional medical practitioners for research purposes was made and signed by 
both parties under the supervision of the legal advisory department of the University of 
Stellenbosch (Appendix E). Informed consent from the traditional medical practitioners who 
supplied the herbal specimens used in this study was obtained through the administration of 
approved semi-structured questionnaire (Appendix F). 
  
Stellenbosch University  http://scholar.sun.ac.za
7 
 
CHAPTER TWO 
AN OVERVIEW OF HERB-DRUG INTERACTIONS, THEIR MECHANISMS AND CLINICAL 
SIGNIFICANCE1 
 
2.0. Summary 
This chapter details the clinical implications of concurrent herb-drug use with respect to 
herb-drug interaction (HDI). While the potential for HDI for a number of herbal products is 
inferred from non-human studies, certain HDIs are well established through human studies 
and documented case reports. A general overview along with the significance of 
pharmacokinetic and pharmacodynamic HDI is provided, detailing basic mechanisms and 
nature of evidence available. An increased level of awareness of HDI is necessary among 
health professionals and drug discovery scientists. With the increasing interest in plant-
sourced drugs, the potential for HDI should be assessed in the non-clinical safety 
assessment phase of drug development process. More clinically relevant research is 
required in this area as current information on HDI is insufficient for clinical applications. 
 
  
                                               
1
 This Chapter is an updated version of Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and 
mechanisms of herb-drug interactions. mechanisms of herb-drug interactions. Front Pharmacol. 2012;3:69. Epub 
2012 Apr 30. 
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2.1. Introduction 
There is increasing consumption of medicinal herbs and herbal products globally, cutting 
across social and racial classes, as it is observed both in developing and developed 
countries (Hussin, 2001; Cheng et al., 2002; Bodeker, 2007; Mitra, 2007). Medicinal plants 
were the major agents for primary health care for many centuries before the advent of 
modern medicine (Sheeja et al., 2006). Their use however declined in most developed 
western countries during the last century‟s industrialization and urbanization (Ogbonnia et 
al., 2008). In the past two decades a new resurgence in medicinal plants consumption was 
observed. According to the WHO, about 70% of the world population currently uses 
medicinal herbs as complementary or alternative medicine (Wills et al., 2000). It is estimated 
that over 40% of the adult American population consume herbal products for one medical 
reason or the other (Tachjian et al., 2010). A recent study involving 2055 patients in the US 
revealed that the consumption pattern of traditional medications has no significant gender or 
social difference (Kessler et al., 2001). Consumption rate has been particularly high in 
Canada (Calixto, 2000), Australia (Bensoussan et al, 2004), as well as Europe where the 
highest sales of herbal products have been reported in Germany and France (Capasso et 
al., 2003). In Africa, there is continuous addition to the list of medicinal herbs, while 
consumption rate is also increasing.  
The indications for herbal remedies are diverse (Ernst, 2005). Studies have shown that 67% 
of women use herbs for perimenopausal symptoms, 45% use it in pregnancy and more than 
45% parents give herbal medications to their children for various medical conditions (Ernst, 
2004). Regulations in most countries do not require the demonstration of therapeutic 
efficacy, safety or quality on the part of herbal remedies, as most of them are promoted as 
natural and harmless (Homsy et al., 2004; Routledge, 2008). It is pertinent however, that 
herbs are not free from side effects as some have been shown to be toxic (Perharic et al., 
1993; Popat et al., 2001; Déciga-Campos et al., 2007; Patel et al., 2011). Habitual pattern of 
concomitant consumption of herbal and prescription medication has been reported. Kaufman 
and co-workers (2002) reported that 14-16% of American adult population consume herbal 
supplements often concomitantly with prescribed medications, while 49.4% of Israeli 
consumers of herbal remedies use them with prescription drugs (Giveon et al., 2004). This is 
significant bearing in mind that less than 40% of patients disclose their herbal supplement 
usage to their health care providers coupled with the fact that many physicians are unaware 
of the potential risks of herb-drug interactions (HDI) (Klepser et al., 2000). 
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HDI is one of the most important clinical concerns in the concomitant consumption of herbs 
and prescription drugs (Gouws et al., 2010; Tarirai et al., 2010; Müller and Kanfer, 2011). 
The necessity of polypharmacy in the management of most diseases further increases the 
risk of HDI in patients. The ability of intestinal and hepatic CYP to metabolize numerous 
structurally unrelated compounds, apart from being responsible for the poor oral 
bioavailability of numerous drugs is responsible for the large number of documented drug-
drug and drug-food interactions (Quintieri et al., 2008). This is more so, considering that oral 
drug delivery is the most employed in the management of most disease conditions in which 
case, drug interaction alters both bioavailability and pharmacokinetic disposition of the drug. 
This alteration and the resulting poor control of plasma drug concentrations would 
particularly be of concern for drugs that have a narrow therapeutic window or a precipitous 
dose-effect profile (Aungst, 2000; Perucca, 2006). The risk of pharmacokinetic drug 
interaction poses two major therapeutic challenges – pharmacotoxicity and treatment failure. 
The former can result from the inhibition of the metabolic enzymes responsible for the 
metabolism and clearance of the drugs, while the latter may be the consequence of 
enzymatic induction leading to faster drug metabolism. This is in addition to the intrinsic 
pharmacodynamic actions of the herbal products themselves which may include 
potentiating, additive, antagonistic or neutralization effects.  
Until recently, HDI was often unsuspected by physicians for several reasons. Most 
physicians lack adequate knowledge on herbal drugs and their potential for drug interactions 
(Suchard et al., 2004; Clement et al., 2005, Ozcakir et al., 2007; Fakeye and Onyemadu, 
2008); herbal products also vary considerably in composition depending on the source and 
package (Liang et al, 2004; Sousa et al., 2011); most patients do not consider it necessary 
to disclose their herbal consumptions to physicians who themselves hardly inquire such 
(Cassidy, 2003; Howell et al., 2006; Kennedy et al., 2008; Chao et al., 2008). Further 
challenges with herbal medications include scientific misidentification, product contamination 
and adulteration, mislabeling, active ingredient instability, variability in collection procedures 
and failure of disclosure on the part of patients (Boullata and Nace, 2000). A fairly recent 
systematic review by Izzo and Ernst (2009) on the interactions between medicinal herbs and 
prescribed medications provides some more details on these. 
Herbal products are made of complex mixtures   of pharmacologically active phytochemicals 
(Mok and Chau, 2006), most of which are secondary metabolites generated through the 
shikimate, acetate-malonate and acetate-mevalonate pathways. These constituents include 
phenolics, (such as tannins, lignins, quinolones and salicylates), phenolic glycosides (such 
as flavonoids, cyanogens and glucosinolates), terpenoids (such as sesquiterpenes, steroids, 
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carotenoids, saponins and iridoids), alkaloids, peptides, polysaccharides (such as gums and 
mucilages), resins and essential oils which often contain some of the aforementioned 
classes of phytochemicals (Wills et al., 2000; Wang et al., 2008). This complexity increases 
the risk of clinical drug interactions.  
 
2.2. Aim, Search Strategy and Selection Criteria 
The current review is aimed at providing an overview of known and recently reported HDI 
with interest in the evidence available and the mechanism thereof. The review was 
systematically conducted by searching the databases of MEDLINE, PUBMED, EMBASE and 
COCHRANE libraries for original researches, and case reports on HDI using the following 
search terms or combinations thereof: „drug-herb‟, „herb-drug‟, „interaction‟, „cytochrome 
P450‟, „plant‟, „extract‟, „medicinal‟ „concomitant administration‟, „herbal and orthodox 
medicines‟. Relevant search terms were employed to accommodate the various individual 
medicinal herbs employed in Africa, America, Asia, Europe and Australia. The reported 
interactions and their mechanisms, with orthodox medications were searched and collated. 
Searches were not limited by date or place of publications, but to publications available in 
English language. 
 
2.3. Results 
2.3.1. Clinical presentation of herb-drug interactions 
Clinical presentations of HDI vary widely depending on the herbs and the drugs concerned. 
Examples for relevant clinical presentations of HDI include the potentiation of the effects of 
oral corticosteroids in the presence of liquorice (Glycyrrhiza glabra) (Liao et al., 2010); 
potentiation of warfarin effects with resultant bleeding in the presence of garlic (Allium 
sativum) (Borrelli et al., 2007), dong quai (Angelica sinensis) (Page and Lawrence, 1999; 
Nutescu et al., 2006) or danshen (Salvia miltiorrhiza) (Chan, 2001); decreased blood levels 
of nevirapine, amitriptyline, nifedipine, statins, digoxin, theophyline, cyclosporine, midazolam 
and steroids in patients concurrently consuming St John‟s wort (SJW) (Hypericum 
perforatum) (De Maat et al., 2001; Henderson et al., 2002; Johne et al., 2002; Mannel, 2004; 
Borrelli and Izzo, et al., 2009), decreased oral bioavailability of prednisolone in the presence 
of the Chinese herbal product xiao-chai-hu tang (sho-saiko-to) (Fugh-Berman, 2000); 
ginseng (Panaz ginseng)-induced mania in patients on antidepressants (Engelberg et al., 
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2001); production of extrapyramidal effects as a result of the combination of neuroleptic 
drugs with betel nut (Areca catechu) (Huang et al., 2003; Coppola and Mondola, 2011); 
increased blood pressure induced by tricyclic antidepressant-yohimbine (Pausinystalia 
yohimbe) combination (Tam et al., 2001), increased phenytoin clearance and  frequent 
seizures when combined with Ayurvedic syrup shankhapushpi (Patsalos and Perucca, 
2003), among other clinical manifestations. These clinical presentations reflect the 
mechanism the HDI – inhibition or induction of drug metabolic and/or transport pathways. 
 
2.3.2. Evidence-based HDI studies and clinical relevance 
HDIs have been reported through various study techniques. While these reports usually give 
evidence of potential interactions, the level of evidence varies often failing to predict the 
magnitude or clinical significance of such HDI. Apart from the specific limitations attributable 
to study methods employed (Table 1), major draw-backs in deducting relevant conclusions 
from reported HDI include misidentification and poor characterization of specimen, presence 
and nature of adulterants (some of which may be allergens), variations in study 
methodologies including extraction procedures, source location of herbs involved, seasonal 
variation in the phytochemical composition of herbal materials, under-reporting and genetic 
factors involved in drug absorption, metabolism and dynamics. Table 1 provides some 
limitations of the methods commonly applied in drug metabolism studies. 
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Table 1: Comparison of study methods available for HDI  
Report/Study 
method 
Comments Advantages Limitations to clinical inferences 
In vitro studies Usually involves 
deliberate investigations 
employing metabolic 
enzymes, tissues or 
organs e.g. CYP-
transfected cell lines, 
hepatic subcellular 
fractions, liver slices, 
intestinal tissues 
Provides information on 
potential HDI, easy to 
perform, good for high 
throughput screenings; 
Compared to in vivo 
animal studies, results 
are closer to human if 
human liver-based 
technologies are 
employed 
Concentrations used in study may 
be at significant variance with 
clinical concentrations; other in vivo 
phenomena like protein binding and 
bioavailability are not accounted 
for; poor reproducibility of results; 
poor correlation to clinical situation 
Non-clinical in 
vivo studies 
Usually involves 
metabolic studies in 
animals, especially 
mammals 
Concentration and 
bioavailability of active 
components are taken 
into consideration 
Results are often difficult to 
interpret due to species variation; 
most results are from 
disproportionate and non-
physiologic dosages 
Case Reports Patients diagnosed with 
HDI after history taking 
Ideal in providing 
information on HDI 
Hardly discovered by physicians; 
infrequent and under-reporting; 
difficult to ascertain the identity of 
the herb responsible for HDI in 
multiple herbal use 
Human studies Involves the use of 
human subjects 
The ideal study, 
providing directly 
extrapolative data on 
interactions 
Generally costly with stringent 
ethical considerations; most 
subjects are healthy leaving out the 
effects of pathologies on drug 
metabolism; genetic variation in 
enzyme activity 
 
 
Recently, structured assessment procedures have been emerging in an attempt to provide 
levels of evidence for drug interactions. In addition to evidence of interaction, such 
assessments take into consideration the clinical relevance of the potential adverse event 
resulting from the interaction, the modification- and patient-specific risk factors, and disease 
conditions for which the interaction is important. Van Roon and co-workers (2005) developed 
a system of hierarchical evidence-based structured assessment procedure of drug-drug 
interaction. This can be applicable to HDI. This method particularly allows the extraction of 
HDIs that have been well established and those that are merely inferred from certain 
phytochemical characteristics. A modified form of this method as presented in Table 2 is 
applied in this literature review to provide the nature and level of evidence for the HDIs 
mentioned.  
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Table 2: Quality of HDI evidence for clinical risk assessment 
Level Description of evidence 
1 Published theoretical proof or expert opinion on the possibility of HDI due to 
certain factors including the presence of known interacting phytochemicals in 
the herbs, structure activity relationship  
2 Pharmacodynamic and/or pharmacokinetic animal studies; in vitro studies with 
a limited predictive value for human in vivo situation 
3 Well documented, published case reports with the absence of other explaining 
factors 
4 Controlled, published interaction studies in patients or healthy volunteers with 
surrogate or clinically relevant endpoint 
 
2.3.3. Mechanisms of herb-drug interactions 
The overlapping substrate specificity in the biotransformational pathways of the physiologic 
systems is seen as the major reason for drug-drug and HDI (Marchetti et al., 2007). The 
ability of different chemical moieties to interact with receptor sites and alter physiological 
environment can explain pharmacodynamic drug interactions, while pharmacokinetic 
interactions arise from altered absorption, interference in distribution pattern as well as 
changes and competition in the metabolic and excretory pathways (Izzo, 2005). The major 
underlying mechanism of pharmacokinetic HDI, like drug-drug interaction, is either the 
induction or inhibition of intestinal and hepatic metabolic enzymes particularly the CYP 
enzyme family. Additionally, similar effect on drug transporters and efflux proteins 
particularly the p-glycoproteins (P-gp) in the intestines is responsible in most other cases 
(Meijerman et al., 2006; Nowack, 2008; Farkas et al., 2010). The presystemic activity of CYP 
and efflux proteins often influence oral bioavailability, thus the modulating activity of co-
administered herbal products has been shown to result in pronounced reduction or increase 
in the blood levels of the affected drugs (Brown et al., 2008). 
Potential for in vivo drug interactions are often inferred from in vitro studies with liver 
enzymes. In vitro results of HDI studies have provided indications of in vivo occurrence, 
although, the extent of clinical significance is poorly inferable (Rostami-Hodjegan and 
Tucker, 2007; Iwamoto et al., 2008; Xu et al., 2009; Umehara and Camenisch, 2011). Thus 
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most of the well-established HDIs, as will be seen in subsequent sections, were initially 
demonstrated through in vitro studies and confirmed in vivo.  
The interaction of herbal products with hepatic enzymes can also result in hepatic toxicity 
(van den Bout-van den Beukel et al., 2008; Nivitabishekam et al., 2009; Dasgupta et al., 
2010; Asdaq and Inamdar, 2010; Kim et al., 2010a.) Specific liver injury inducible by 
phytochemical agents includes elevation in transaminases (Zhu et al., 2004; Saleem et al., 
2010), acute and chronic hepatitis (Stedman 2002; Pierard et al., 2009), liver failure (Durazo 
et al., 2004), veno-occlusive disorders (DeLeve et al., 2002), liver cirrhosis (Lewis et al., 
2006), fibrosis (Chitturi and Farrell, 2000), cholestasis (Chitturi and Farrell, 2008), zonal or 
diffusive hepatic necrosis (Savvidou et al., 2007), and steatosis (Wang et al., 2009). 
Mechanisms of liver injury include bioactivation of CYP, oxidative stress, mitochondrial injury 
and apoptosis (Cullen, 2005).  
 
2.3.3.1. Induction and Inhibition of metabolic enzymes 
The CYP superfamily is generally involved in oxidative, peroxidative and reductive 
biotransformation of xenobiotics and endogenous compounds (Nebert and Russell, 2002; 
Hiratsuka, 2011). It is conventionally divided into families and subfamilies based on 
nucleotide sequence homology (Omura and Sato, 1962; Fasinu et al., 2012). There is a high 
degree of substrate specificity among the various families. CYP belonging to the families 1, 2 
and 3 are principally involved in xenobiotic metabolism, while others play a major role in the 
formation and elimination of endogenous compounds such as hormones, bile acids and fatty 
acids (Norlin and Wikvall, 2007; Amacher, 2010). The most important CYP subfamilies 
responsible for drug metabolism in humans are 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 
3A4 and 3A5 (Ono et al., 1996; Wang and Chou, 2010).  
Induction is the increase in intestinal and hepatic enzyme activity as a result of increased 
mRNA transcription leading to protein levels higher than normal physiologic values 
(Amacher, 2010). When this happens, there is a corresponding increase in the rate of drug 
metabolism affecting both the oral bioavailability and the systemic disposition (Argikar et al., 
2009). In the formulation and dosage design of oral medications, allowance is often made for 
pre-systemic metabolism in order to achieve predictable systemic bioavailability. A disruption 
in this balance can result in significant changes in blood concentrations of the drugs. As 
shown in subsequent sections, some herbal products have been shown to be capable of 
inducing CYP. Concomitant administration of enzyme-inducing herbal products and 
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prescription drugs can therefore result in sub-therapeutic plasma levels of the latter with 
therapeutic failure as a possible clinical consequence.  
Apart from enzyme induction, herbal products can also inhibit enzyme activities. The 
inhibition of CYP and other metabolic enzymes is usually competitive with instantaneous and 
inhibitor concentration-dependent effects (Zhang and Wong, 2005). Most inhibitors are also 
substrates of CYP (Zhou, 2008). This phenomenon alters pharmacokinetic profiles of 
xenobiotics significantly. As a result of the suppression of the anticipated pre-systemic 
intestinal and hepatic metabolism, unusually high plasma levels of xenobiotics are observed. 
Toxic manifestation could be the ultimate effect of this observation. An equally clinically 
important consequence of enzyme inhibition is drug accumulation due to subdued hepatic 
clearance. These effects will be of particular concern in drugs with narrow therapeutic 
window or steep dose-response profiles. 
SJW is widely used for its antidepressant properties (Lawvere and Mahoney, 2005; Høyland, 
2011). It is a potent inducer of CYP3A4 and depending on the dose, duration and route of 
administration, it may induce or inhibit other CYP isozymes and P-gp (Markowitz et al., 
2003b; Roby et al., 2000; Tannergren et al., 2004; Komoroski et al., 2004; Madabushi et al., 
2006). Studies from case reports indicate that, due to its inducing effects on CYP3A4, it 
significantly reduces the plasma levels of CYP3A4 substrates including cyclosporine, 
simvastatin, indinavir, warfarin, amitriptyline, tacrolimus, oxycodone and nevirapine (Johne 
et al., 2002; Henderson et al., 2002; Nieminen et al., 2010; Vlachojannis et al., 2011). It has 
been reported that the alteration in the blood serum concentration of cyclosporine due to 
SJW has led to organ rejection in patients (Ernst, 2002; Murakami et al., 2006). Reports of 
breakthrough bleeding and unplanned pregnancies due to interaction between SJW and oral 
contraceptives have been documented (Hu et al., 2005). The group of drugs with a high 
potential for clinically significant pharmacokinetic drug interaction with SJW is the 
antidepressants as SJW itself is consumed by patients with depression. Its concomitant use 
with SSRIs like sertraline and paroxetine has been reported to result in symptoms of central 
serotonergic syndrome (Barbenel et al., 2000; Dannawi, 2002; Spinella and Eaton, 2002; 
Birmes et al., 2003; Bonetto et al., 2007). Amitriptyline is a substrate to both CYP3A4 and 
intestinal P-gp. The risk of therapeutic failure is thus high due to induction of CYP3A4-
dependent metabolism activities resulting in poor oral bioavailability. In a study by Johne and 
co-workers (2002), a 21% decrease in the area under the plasma concentration-time curve 
of amitriptyline was observed in 12 depressed patients who were concomitantly administered 
with extracts of SJW and amitriptyline for 2 weeks.  
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It has also been said to increase the incidence of hypoglycemia in patients on tolbutamide 
without apparent alteration in the pharmacokinetic profile of tolbutamide (Mannel, 2004). It 
also inhibits the production of SN-38, an active metabolite of irinotecan, in cancer patients 
(Caraci et al., 2011). 
Other CYP and P-gp substrates whose pharmacokinetic profile have been altered by SJW 
include anticoagulants like phenprocoumon and warfarin; antihistamines like fexofenadine; 
antiretroviral drugs including protease inhibitors and reverse transcriptase inhibitors; 
hypoglycemic agents such as tolbutamide; immunosuppressants like cyclosporine, 
tacrolimus and mycophenolic acid; anticonvulsants such as carbamazepine; anticancer like 
irinotecan; bronchodilators like theophylline; antitussives like dextromethorphan; 
cardiovascular drugs like statins, digoxin and dihydropyridine calcium channel blockers; oral 
contraceptives; opiates like methadone and loperamide; and benzodiazepines including 
alprazolam and midazolam (Greeson et al., 2001; Di et al., 2008; Hojo et al., 2011).  
Following a single dose administration of 300mg standardized extracts of SJW containing 
5% hyperforin to humans, a maximum plasma concentration of 0.17-0.5µM hyperforin was 
obtained. Compared with in vitro inductive concentrations, in vivo extrapolation suggests a 
high possibility of in vivo pharmacokinetic drug interaction (Agrosi et al., 2000). Bray and co-
workers (2002) confirmed through animal studies that SJW modulates various CYP 
enzymes. Dresser and co-workers (2007) demonstrated that SJW is capable of inducing 
CYP3A4 in healthy subjects through the observation of increased clearance of midazolam. 
Thus animal and human studies further confirm SJW as containing both inhibitory and 
inducing constituents on various CYP isozymes. These effects depend on dosage and 
duration of administration, and are species- and tissue-specific. While the individual 
phytochemical constituents of SJW have elicited varying effects on the metabolic activity of 
the CYP isozymes, whole extracts and major constituents especially hyperforin have been 
reported to induce the metabolic activities of CYP1A2, 2C9, 2C19, 2D6 and 3A4 as shown in 
in vitro studies and in vivo studies (Lee et al., 2006; Madabushi et al., 2006, Hokkanen et al., 
2011). 
Ginkgo biloba have been reported to induce CYP 2C19-dependent omeprazole metabolism 
in healthy human subjects (Yin et al., 2004). Piscitelli and co-workers in a garlic-saquinavir 
interaction study reported 51% decrease in saquinavir oral bioavailability caused by the 
presence of garlic and attributable to garlic-induced CYP3A4 induction (Pisciteli et al., 2002). 
Its effects on the pharmacokinetics of warfarin have been reported in animal models (Taki et 
al., 2011) 
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Although grapefruit juice is not consumed for medicinal purposes, the discovery of the 
inhibitory activity of its flavonoid contents on CYP has led to further researches in medicinal 
herbs which have revealed HDI potentials in flavonoid-containing herbal remedies (Choi and 
Burm, 2006; Palombo, 2006; Paine et al., 2008; Quintieri et al., 2008, Alvarez et al., 2010). A 
related CYP inhibitor is rotenone. By interfering with the electron transfer of the heme iron, 
rotenone, a naturally occurring phytochemical found in several plants such as the 
jicama vine plant is known to inhibit CYP activity (Sanderson et al., 2004). Resveratrol, a 
natural polymer, and tryptophan, an amino acid have been documented as potent CYP 
inhibitors (Rannug et al., 2006). Some herbal medications and their phytochemical 
constituents capable of interacting with CYP are presented in Table 3. A more detailed 
involvement of CYP in HDI is detailed in some recently published reviews (Delgoda and 
Westlake, 2004; Pal and Mitra, 2006; Cordia and Steenkamp, 2011; Liu et al., 2011). 
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Table 3: Some herbal products known to interact with CYP and efflux proteins 
 
Medicinal Plant 
and parts used  
Scientific 
name 
Major 
constituents 
Mechanism of drug 
interactions 
Candidates for interactions LE
1
 References 
       
Cranberry 
(fruit extract)  
Vaccinium 
macrocarpon 
Anthocyanins, 
flavonoids 
Inhibition of CYP enzymes 
and P-gp 
Warfarin, CYP1A2, 2C9 and 
3A4 substrates 
4
2
 Uesawa and Mohri, 2006; 
Lilja et al., 2007; Li et al., 2009; Kim 
et al., 2010b; Roberts and 
Flanagan, 2011; Hamann et al., 
2011 
Dong quai 
(root) 
 
Angelica 
sinensis 
Flavonoids, 
coumarins 
Inhibition of CYP1A2, 3A4 
and P-gp 
CYP substrates 3 Page and Lawrence, 1999; Scott 
and Elmer, 2002; Tang et al., 2006; 
Sevior et al., 2010 
Gan cao 
(root) 
Glycyrrhiza 
uralensis 
Glycyrrhizin CYP2C9 and 3A4 induction Warfarin, lidocaine, CYP2C9 
and 3A4 substrates 
2 Mu et al., 2006; Tang et al., 2009 
Garlic  
(bulb) 
Allium sativum Allicin, phytoncide CYP 3A4 and P-gp induction Saquinavir, warfarin, 
CYP2D6 and 3A4 substrates 
4
3
 Piscitelli et al., 2002; Markowitz et 
al., 2003a; Cox et al., 2006; Berginc 
and Kristl, 2012 
Germander 
(leaves) 
Teucrium 
chamaedrys 
Saponins, 
flavonoids, 
diterpenoids 
Production of toxic CYP3A4-
induced metabolites  
CYP3A4 inducers like 
phenobarbital, rifampicin 
3 De Berardinis, et al., 2000; 
Savvidou et al., 2007 
Ginseng 
(root)  
Panax ginseng Ginsenosides Inhibition and induction of 
CYP2C9, 2C19, 2D6 and 
3A4 activity 
Imatinib, CYP2E1 and 2D6 
substrates 
4
4
 Gurley et al., 2005a; Bilgi et al., 
2010; Malati et al., 2011 
Grape seed 
(seed oil) 
Vitis vinifera Proanthocyanidin, 
resveratrol 
Decreased CYP2C19, 2D6 
and 3A4 activity 
CYP2C19, 2D6 and 3A4 
substrates 
4
5
 Nishikawa et al., 2004 
Kava kava 
(root) 
Piper methysti
cum 
Kavalactones Decreased CYP1A2, 2D6, 
2E1 and 3A4 activity 
CYP substrates 4
6
 Gurley et al., 2005b; Teschke, 
2010; Sarris et al., 2011 
Liquorice 
(root) 
Glycyrrhizia 
glabra 
Glycyrrhizic acid Inhibition of CYP2B6, 2C9 
and 3A4 
CYP2B6, 2C9 and 3A4 
substrates 
4
7
 Kent et al., 2002; Al-Deeb et al., 
2010; Methlie et al., 2011 
St John‟s wort 
(aerial parts) 
Hypericum 
perforatum 
Hyperforin, 
hypericin, 
flavonoids 
Inhibition and induction of 
CYP and P-gp 
Orally administered CYP 
substrates 
4
8
 Johne et al., 2002; Komoroski et 
al., 2004 Hu et al., 2005; Hafner et 
al., 2009; Lau et al., 2011 
1
LE – Level of evidence; 
2
A daily consumption of 1 cup of cranberry juice for 3 days; 
3
Garlic extract (3x 600 mg twice daily of for 14 days); 
4Daily ingestion of Panax 
ginseng via energy drinks for the past 3 months; 
5
Continuous ingestion of grape seed over time; 
6
28-day administration; 
7
3-day administration; 
8
Single 300 mg dose 
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Phase II metabolic enzymes including uridine diphosphoglucuronosyl transferase (UGT), N-
acetyl transferase (NAT), glutathione S-transferase (GST) and sulfotransferase (ST) 
catalyse the attachment of polar and ionizable groups to phase I metabolites aiding their 
elimination. While cytochrome P450-mediated HDI have been extensively investigated in 
various studies, the effects of herbal extracts on phase II enzymes have not been 
adequately studied. However, there is sufficient evidence to suggest the potential of phase II 
enzymes to induce clinically significant HDI.  
In a study carried out in rat models by Sheweita and co-workers (2002), extracts of 
hypoglycemic herbs, Cymbopogon proximus, Zygophylum coccineum and Lipinus albus 
reduced the activity of GST and GSH. Curcumin, from Curcuma longa, an herbal antioxidant 
with anti-inflammatory and antitumor properties increased the activity of GST and quinone 
reductase in the ddY mice liver (Iqbal et al., 2003). Valerian, a herbal sleeping aid has 
demonstrated the potential of inducing HDI through the inhibition of UGT. Up to 87% of 
inhibition of UGT activity by valerian extract was reported in an in vitro study utilizing 
oestradiol and morphine as probe substrates (Alkharf and Frye, 2007). Kampo, a traditional 
Japanese medicine made of a mixture of several medicinal herbs has shown inhibitory 
effects on some phase II enzymes. In an in vitro study by Nakagawa and co-workers (2009), 
nine out of 51 components of kampo medicine elicited more than 50% inhibition of UGT2B7-
mediated morphine 3-glucuronidation. In the same study, extracts of kanzo (Glycyrrhizae 
radix), daio (Rhei rhizona) and keihi (Cinnamomi cortex) elicited more than 80% inhibition of 
morphine AZT glucuronidation. This result agrees with Katoh et al., (2009) who carried out 
similar studies on rhei, keihi and ogon (Scutellariae radix).  
Apart from the well-known effects of Ginkgo biloba on CYP enzymes as illustrated earlier 
(section 2.3.3.1), its extracts have demonstrated potent inhibition of mycophenolic acid 
glucuronidation investigated in human liver and intestinal microsomes (Mohamed and Frye, 
2010).  
In a study to investigate the influence of 18 herbal remedies on the activity of human 
recombinant sulfotransferase 1A3 employing dopamine and ritodrine as substrates, extracts 
of grape seed, milk thistle, gymnema, SJW, ginkgo leaf, banaba, rafuma and peanut seed 
coat showed potent inhibition with IC50 values lower than putative gastrointestinal 
concentrations (Nagai et al., 2009). Similarly, Mohamed and Frye (2011a) reported the 
inhibition of UGT1A4 by green tea derived epigallocathechin gallate; of UGT 1A6 and 
UGT1A9 by milk thistle; of UGT1A6 by saw palmetto; and of UGT 1A9 by cranberry. A 
recent publication presents evidence of potential HDI mediated by UGT (Mohamed and 
Frye, 2011b). 
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Certain phytochemicals including coumarin, limettin, auraptene, angelicin, bergamottin, 
imperatorin and isopimpinellin have been reported to be capable of inducing hepatic GST 
activities (Kleiner et al., 2008). While the clinical significance of these findings is yet to be 
determined, it is noteworthy that phase II metabolic enzymes may play significant roles in 
HDIs. 
 
2.3.3.2. Inhibition and induction of transport and efflux proteins 
The ATP-binding cassette (ABC) family of drug transporters plays significant roles in the 
absorption, distribution and elimination of drugs. P-gp, the most studied member of this 
family is a 170-kDa plasma glycoprotein encoded by the human MDR1 gene (also known as 
ATP-binding cassette, sub-family B, member 1 (ABCB1)). It is constitutively expressed in a 
number of body tissues and concentrated on the apical epithelial surfaces of the bile 
canaliculi of the liver, the proximal tubules of the kidneys, the pancreatic ductal cells, the 
columnar mucosal cells of the small intestine, colon and the adrenal glands (Marzolini et al., 
2004; Degorter et al., 2011). It is actively involved in drug absorption, distribution and 
elimination from the intestines the liver, kidneys and the brain. Specifically these proteins are 
involved in the processes of hepatobiliary, direct intestinal and urinary excretion of drugs and 
their metabolites (Szakács et al., 2008). Thus, the modulation of P-gp or competitive affinity 
as substrates for its binding sites by co-administered herbs presents a potential for alteration 
in the pharmacokinetic profile of the drug.  
Pharmacokinetic interaction occurs when herbal drugs inhibit or decrease the normal activity 
level of drug transporters through a competitive or non-competitive mechanism. Interactions 
can also occur through the induction of transport proteins via the increase of the mRNA of 
the relevant protein. Studies have identified a number of clinically important P-gp inhibitors 
including phytochemicals – flavonoids, furanocoumarins, reserpine, quinidine, yohimbine, 
vincristine, vinblastine among others (Krishna and Mayer, 2001; Zhou et al., 2004; 
Patanasethanont et al., 2007; Iwanaga et al., 2010; Eichhorn and Efferth, 2011; Yu et al., 
2011). Borrel and co-workers (1994) reported that mobile ionophores such as valinomycin, 
nonactin, nigericin, monencin, calcimycin, and lasalocid inhibit the efflux of anthracycline by 
P-gp whereas channel-forming ionophores such as gramicidin do not (Larsen et al., 2000). A 
number of herbal products which interact with CYP also have similar effects on transport 
proteins (Table 3). The transport proteins are actively involved in the pharmacokinetics of 
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anti-cancer drugs and account for one of the well-known mechanisms of multiple resistance 
of cancerous cells to chemotherapeutic agents (Bebawy and Sze, 2008; Bosch, 2008; He et 
al., 2011). The influence of some herbs on transport proteins with respect to anti-cancer 
drugs is presented in Table 4. Clinically relevant interactions between herbal medicine and 
chemotherapeutic agents are detailed in a recent review by Yap and co-workers (2010). 
 
Table 4: Influence of herbal products on transport proteins 
Drug 
transporter 
Anti-cancer substrates Interacting herbal 
products 
LE* References 
     
P-glycoprotein 
(ABCB-1, 
MDR-1) 
Actinomycin D, daunorubicin, 
docetaxel, doxorubicin, etoposide, 
irinotecan, mitoxantrone, paclitaxel, 
teniposide, topotecan, vinblastine, 
vincristine, tamoxifen, mitomycin C, 
tipifarnib, epirubicin, bisantrene 
Rosmarinus officinalis 2 Oluwatuyi et al., 
2004; Nabekura et 
al., 2010 
MRP-1 
(ABCC-1) 
Etoposide, teniposide, vincritine, 
vinblastine, doxorubicin, 
daunorubicin, epirubicin, idarubicin, 
topotecan, irinotecan, mitoxantrone, 
chlorambucil, methotrexate, 
melphalan 
Curcuma longa 2 Shukla et al., 2009 
MRP-2 
(ABCC-2) 
SN-38G (metabolite of irinotecan), 
methotrexate, sulfinpyrazone, 
vinblastine 
Inchin-ko-to 2 Okada et al, 2007 
BCRP (ABCG-
2, MXR) 
9-aminocamptothecin, 
daunorubicin, epirubicin, etoposide, 
lurtotecan, mitoxantrone, SN-38, 
topotecan 
Flavonoid-containing 
herbs such as Glycine 
max (soybean), 
Gymnema sylvestre and 
Cimicifuga racemosa 
(black cohosh)  
2 Merino et al., 2010; 
Tamaki et al., 2010 
*LE = Level of evidence 
ABC = ATP-binding cassette; BCRP = breast cancer resistance protein; MDR = multidrug resistance gene; MRP = multidrug 
resistance-associated protein; MXR = mitoxantrone resistance-associated protein 
 
 
2.3.3.3 Alteration of gastrointestinal functions 
Besides their influence on the intestinal metabolic enzymes and efflux proteins, herbal 
medications can alter the absorption of concomitantly administered medicines through a 
number of mechanisms. Changes in the gastrointestinal pH and other biochemical factors 
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can alter dissolution properties and the absorption of pH-dependent drugs such as 
ketoconazole and itraconazole. Complexation and chelation, leading to the formation of 
insoluble complexes and competition at the sites of absorption especially with site-specific 
formulations can greatly affect the absorption of medicines. Anthranoid-containing plants – 
cassia (Cassia senna), Cascara (Rhamnus purshiana), rhubarb (Rheum officinale) and 
soluble fibres including guar gum and psyllium can decrease drug absorption by decreasing 
GI transit time. They are known to increase GIT motility. During concomitant use with 
prescribed medication, significant alteration in the absorption of the latter has been reported 
due to decreased GI transit time (Fugh-Berman, 2000). 
Izzo and others (1997) demonstrated that anthranoids could be harmful to the gut epithelium 
by inhibiting Na+/K+ ATPase and by increasing the activity of nitric oxide synthase. This 
significantly increased intestinal transit due to the alteration in the intestinal water and salt 
absorption and the subsequent fluid accumulation. In a study conducted by Munday and 
Munday (1999), a garlic-derived compound was shown to increase the tissue activities of 
quinone reductase and glutathione transferase in the gastrointestinal tract of the rat. In view 
of their roles in metabolism, both enzymes are considered chemoprotective especially from 
chemical carcinogens. In addition to CYP and P-gp mediated mechanisms, ginseng may 
cause pharmacokinetic HDI through its inhibitory effects on gastric secretion (Suzuki et al., 
1991). The potential of rhein and danthron to increase the absorption of furosemide, a poorly 
water-soluble drug, has been demonstrated through in vitro studies (Laitinen et al., 2007). In 
a study carried out in mice, a Chinese herbal plant, Polygonum paleaceum, showed the 
potential to depress the motility of the gastrointestinal tract, inhibit defecation reflex and 
delay gastric emptying (Zhang, 2002). A similar study demonstrated the inhibitory effects of 
two Chinese traditional herbal prescriptions, Fructus aurantii immaturus and Radix paeoniae 
alba on gastrointestinal movement (Fang et al., 2009). 
The absorption of drugs such as phenoxymethylpenicillin, metformin, glibenclamide and 
lovastatin may be reduced by high-fiber herbal products through the sequestration of bile 
acids (Colalto, 2010). Mochiki and co-workers (2010) reported the ability of kampo, a 
traditional Japanese medicine, to stimulate elevated intestinal blood flow, and to induce 
increased secretion of gastrointestinal hormones including motilin, vasoactive intestinal 
peptide, and calcitonin gene-related peptide. Similarly, another traditional Japanese 
medicine has been shown to increase the intestinal secretion of ghrelin, a hunger-related 
hormone, leading to delayed gastric emptying (Tokita et al., 2007; Kawahara et al., 2009; 
Hattori, 2010; Matsumura et al., 2010). Also, Qi and co-workers (2007) demonstrated the 
capability of Da-Cheng-Qi-Tang, a traditional Chinese herbal formula, to increase plasma 
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motilin, enhance gastrointestinal motility, improve gastric dysrhythmia, and reduce 
gastroparesis after abdominal surgery. These effects have the potential of reducing the 
intestinal transit time of concurrently administered drug, with the risk of reduced absorption. 
 
2.3.3.4. Alteration in renal elimination 
This involves herbal products capable of interacting with renal function, leading to altered 
renal elimination of drugs. Such interaction can result from the inhibition of tubular secretion, 
tubular reabsorption or interference with glomerular filtration (Isnardd et al., 2004). In 
addition to this group of herbal products are those products consumed as diuretics. The 
mechanism of herbal diuresis is complex and non-uniform. Certain herbs increase the 
glomerular filtration rate but do not stimulate electrolyte secretion while some others act as 
direct tubular irritants (Crosby et al., 2001; Al-Ali et al., 2003; Musabayane et al., 2005). 
Some herbs capable of interacting with renal function and drug elimination are presented in 
Table 5. 
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Table 5: Some herbal remedies capable of interacting with other drugs via alteration in renal functions 
Medicinal plants Brief description Mechanism LE References 
     
Aristolochia fangchi A Chinese weight loss/slimming herbal remedy  It contains aristolochic acid which forms DNA 
adducts in renal tissues leading to extensive loss 
of cortical tubules 
4
1
 Martinez et al., 
2002; Lai et al., 
2010 
Djenkol bean (Pithecellobium lobatum) A pungent smelling edible fruit, used for medicinal 
purposes in Africa 
It contains djenkolic acid which is known to be 
nephrotoxic 
3 Luyckx and Naicker, 
2008; Markell, 2010 
Impila (Callilepis laureola) A South African herb whose root is used in traditional 
medicine 
Its consumption has been shown to cause 
damage to the proximal convoluted tubules and 
the loop of henle, shown to be hepatotoxic 
3 Steenkamp and 
Stewart, 2005 
 Licorice root (Glycyrrhiza glabra) A herbaceous and leguminous plant native to Europe 
and parts of Asia, whose root and extracts are used in 
chronic hepatitis and other ailments 
Glycyrrhizic acid in licorice root is hydrolyzed to 
glycyrrhetenic acid which is an inhibitor of renal 
11-hydroxysteroid dehydrogenase leading to a 
pseudoaldosterone- like effect. The resulting 
accumulation of cortisol in the kidney stimulates 
the aldosterone receptors in cells of the cortical 
leading to increased BP, sodium retention and 
hypokalaemia. This may potentiate the action of 
drugs such as digoxin 
4
1
 Isbrucker and 
Burdock 2006; 
Kataya et al., 2011 
Noni fruit (Morinda citrifolia), alfalfa 
(Medicago sativa), Dandelion (Taraxacum 
officinale), horsetail (Equisetum arvense), 
stinging nettle (Urtica dioica) 
These plants and their extracts are used variously in 
traditional medicine, and have been shown to contain 
very high potassium levels 
Hyperkalemic, hepatotoxic 3 Mueller et al., 2000; 
Saxena and 
Panbotra, 2003; 
Stadlbauer et al., 
2005; Jha, 2010 
Rhubarb (Rheum officinale) Used as laxative 
 
High oxalic acid content may precipitate renal 
stone formation and other renal disorders 
1 Bihl and Meyers, 
2001 
Star fruit (Averrhoa carambola) A tree popular in Southeast Asia and South America 
employed traditionally as antioxidant and antimicrobial 
Oxalate nephropathy  Chen et al., 2001; 
Wu et al., 2011 
Uva ursi (Arctostaphylos uva ursi), goldenrod 
(Solidago virgaurea), dandelion (Taraxacum 
officinale), juniper berry (Juniperus 
communis), horsetail (Equisetum arvense), 
lovage root (Levisticum officinale), parsley 
(Petroselinum crispum), asparagus root 
(Asparagus officinalis), stinging nettle leaf 
(Urtica dioica), alfalfa (Medicago sativa) 
Various plants used as diuretics. Plants have diuretic properties* and may 
increase the renal elimination of other drugs 
1 Dearing et al., 2001; 
Wojcikowski et al., 
2009 
Wild mushrooms Some species of widely consumed  wild mushroom 
especially Cortinarius have been shown to be 
nephrotoxic 
Contain orellanine shown to be nephrotoxic 3 Mount et al., 2002; 
Wolf-Hall, 2010 
*Some of these herbs exert their diuretic effects via extra-renal mechanisms with no direct effects on the kidneys (see Dearing et al., 2001); 1Long-term use;  
LE = Level of evidence 
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2.3.3.5. Pharmacodynamic synergy, addition and antagonism 
HDI can occur through the synergistic or additive actions of herbal products with 
conventional medications as a result of affinities for common receptor sites (Ma et al., 2009). 
This can precipitate pharmacodynamic toxicity or antagonistic effects (Table 6). Like most 
other herbs, SJW contains complex mixture of phytochemicals including phenylpropanes, 
naphthodanthrones, acylphloglucinols, flavonoids, flavanol glycosides and biflavones. 
Hyperforin is known to inhibit the reuptake of neurotransmitters (dopamine, serotonin, and 
noradrenalin) and is believed to be the main bioactive moiety responsible for the 
antidepressant activity of SJW. 
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Table 6: Examples of pharmacodynamic interactions between herbal products and conventional drugs 
Medicinal plant Major active ingredients Indications Mechanism of action Drug candidates for  
potential interactions 
LE References 
Adonis vernalis 
(pheasant's eye, red 
chamomile) 
Adoniside Cardiotonic Cardiostimulant Cardiovascular drugs 1 Lange, 2000 
Allium sativum (Garlic) Allins Hypercholesterolemia, 
prevention of 
arteriosclerosis 
Antihypertensive, 
antidiabetic, 
antiplatelet, 
antilipidemic 
Propranolol, 
antihypertensives, 
hypoglycemic agents, 
anticoagulants 
3 Bernajee and 
Maulik, 
2002;Asdaq et 
al., 2009; Asdaq 
and Inamdar, 
2011 
Anabasis sphylla Anabesine Skeletal muscle relaxant Nicotinic 
receptor agonist which 
at high doses 
produces 
a depolarizing block of 
nerve transmission 
Muscle relaxants 1 Taylor, 2000 
Angelica sinensis 
(Dong quai) 
Phytoestrogens, 
flavonoids, coumarins 
Gynecological and 
circulation disorders 
Estrogenic, 
vasorelaxant, anti-
inflammatory 
Contraceptives, 
vasodilators, 
anticoagulants, 
antiplatelets 
3 Goh and Loh, 
2001; Circosta 
et al., 2006 
Anisodus tanguticus Anisodine , Anisodamine Used in treating acute 
circulatory shock in China 
Anticholinergic Cholinomimetics 1 Fabricant and 
Farnsworth, 
2001 
Areca catechu (Betel 
nut) 
Arecoline Muscular relaxant Direct acting 
cholinergic agonist 
Cholinergic agents, CNS 
drugs 
4 Boucher and 
Mannan, 2002 
Aspilia Africana Alkaloids, tannins Malaria Antagonism Artemisinin, chloroquine 1 Waako et al., 
2005, Abii and 
Onuoah, 2011 
Atropa belladonna 
(Deadly nightshade) 
Atropine Motion sickness, GIT 
disorders 
Anticholinergic Cholinergic drugs 1 Ulbricht et al., 
2008 
Black henbane, 
stinking nightshade, 
henpin 
Hyoscyamine GIT disorders Anticholinergic Cholinergic drugs 3 Gilani et al, 
2008 
Calabar bean Physostigmine  Cholinesterase 
inhibitor 
Cholinergic drugs 3 Hsieh et al., 
2008 
Callilepsis laureola Atractyloside GIT disorders, fertility, Hepatotoxicity Liver-dependent 3 Stewart et al., 
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Medicinal plant Major active ingredients Indications Mechanism of action Drug candidates for  
potential interactions 
LE References 
(Impila) cough, worm infestations metabolism 2002 
Camellia sinensis 
(Green tea) 
Polyphenols, caffeine Cardiovascular diseases, 
prevention of cancer 
Antioxidants, CNS 
stimulants, 
antilipidemic 
Sedatives, hypnotics 
and anxiolytics 
1 Ferrara et al., 
2001 
Camellia sinensis, 
Theobroma cacao, 
Thea species 
Caffeine CNS stimulant CNS stimulant CNS drugs 1 Ashihara and 
Crozier 2001 
Carica papaya 
(Papaya) 
Papain GIT disorders Alteration in platelet 
functions 
Anticoagulants, 
antihypertensives 
2 Ono et al., 2000 
Catha edulis (Khat) Catinone Loss of energy CNS stimulant, indirect 
sympathomimetic 
Antihypertensives, 
antiarrhythmic, 
vasodilators 
1 Al-Habori, 2005 
Chelidonium majus 
(Greater celandine) 
Alkaloids Gallstones, dyspepsia Hepatotoxicity Liver-dependent 
metabolism 
3 Crijns et al., 
2002; Gilca et 
al., 2010 
Cissampelos pareira 
(Velvet)  
Cissampeline Skeletal muscle relaxant Muscle relaxants Muscle relaxants 2 Bafna and 
Mishra, 2010 
Convallaria majalis 
(Lily-of-the-valley) 
Convallatoxin Cardiotonic Cardiostimulant Cardiovascular drugs 3 Knight and 
Walter, 2002 
Cyamopsis 
tetragonolobus (Guar 
gum) 
Galactomannan, lipids, 
saponin 
Diabetes, obesity, 
hypercholesterolemia 
Hypoglycemic, 
antilipidaemic 
Hypoglycemic agents 2 Mukhtar et al., 
2006 
Digitalis lanata 
(Grecian foxglove, 
woolly foxglove)  
Acetyldigoxin, digitalin, 
digoxin, digitoxin, gitalin, 
lanatosides 
Cardiotonic Positive ionotrope Cardiovascular drugs 1 Wood et al., 
2003 
Echinacea species Alkamides, phenols, 
polysaccharides 
Upper respiratory tract 
infections 
Immunostimulants Immunosuppressants 3 Barnes et al., 
2005 
Eleutherococcus 
senticosus (Siberian 
ginseng) 
Eleutherosides Loss of energy and 
memory, stress, male 
sexual dysfunction 
Immunomodulatory, 
anti-inflammatory, 
antitumor 
Immunosuppressants 4 Szołomicki et 
al., 2000 
Ephedra species (Ma-
huang) 
Ephedrine Weight loss Hepatotoxicity CNS drugs 3 Shekelle et al., 
2003 
Ginko biloba (Ginko) Flavonoids, ginkgolides, 
ginkgolic acid 
Cardioprotection, dementia, 
antioxidant 
Alteration in platelet 
function 
Anticoagulants, 
antiplatelets 
3 Yagmur et al., 
2005 
Glycine max (Soya) Phytoestrogens Menopausal symptoms, 
prevention of heart 
diseases and cancer 
Hepatoprotective, anti-
osteoporosis 
Contraceptives 4 Albert et al., 
2002 
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Medicinal plant Major active ingredients Indications Mechanism of action Drug candidates for  
potential interactions 
LE References 
Glycyrrhiza glabra 
(Liquorice) 
Glycyrrhizinic acid Gastric ulcer, catarrhs, 
inflammation 
Antiulcer, aldosterone-
like effects, 
(mineralocorticoid 
actions) expectorant, 
anti-inflammatory 
Diuretics, 
antihypertensives,  
3 Armanini et al., 
2002 
Harpagophytum 
procumbes (Devils 
claw) 
Harpagophy cumbens Musculoskeletal and 
arthritic pain 
Anti-inflammatory, 
anti-arrhythmic, 
positive inotropic 
Anti-arrhythmic 3 Galindez et al., 
2002 
Heliotropium species, 
senecio species, 
symphytum crotalaria 
(Pyrrolizidines) 
Pyrrolizidine alkaloids Herbal teas and enemas  Hepatotoxicity Liver-metabolized drugs 2 Huxtable and 
Cooper, 2000 
Jaborandi, Indian 
hemp 
Pilocarpine Purgative Parasympathomimetic Cholinergic drugs 3 Agra et al., 2007 
Jimsonweed Scopolamine Sedative Sedative Cardiovascular drugs 2 Ayuba and 
Ofojekwu, 2005 
Khetin Kheltin Asthma Bronchodilator Anti-asthma drugs 1 Ziment and 
Tashkin, 2000 
Larrea tridentata 
(Chaparral) 
Lignans, flavonoids, 
volatile oils, amino acids 
RTI, chicken pox, TB, STI,  
pain, TB, weight loss 
Estrogenic activity, 
hepatotoxicity 
Steroids 3 Arteaga et al., 
2005) 
Lyceum barbarum 
(Chinese wolfberry) 
Glycoproteins, 
polysaccharides, vitamin 
C 
Energy replenishing agent, 
Diabetes, liver and kidney 
diseases 
Hypoglycemic, 
immunostimulants 
Hypoglycemic agents, 
immunosuppressants 
3 He and Liu, 
2005 
Lycopodium serratum 
(Jin Bu huan) 
Tetrahydropalmatine Sedative, analgesic Hepatotoxicity CNS drugs 3 Emma, 2008 
Mentha pulegium 
(Pennyroyal) 
Pulgenone Abortifacient, herbal tonic Hepatotoxicity Most drugs 2 Sztajnkrycer et 
al., 2008 
Octea glaziovii Glasiovine Antidepressant Antidepressant CNS drugs 3 Maridass and 
De Britto, 2008 
Ouabain tree Ouabain Cardiotonic Cardiostimulant Cardiovascular drugs 1 Schoner, 2000 
Panax ginseng 
(Ginseng) 
Triterpene saponins 
(ginsenosides) 
Loss of energy and 
memory, stress, male 
sexual dysfunction 
Immunomodulatory, 
hypoglycemic 
Immunosuppressants, 
hypoglycemic agents 
3 Wilasrusmee et 
al., 2002; Ni et 
al., 2010 
Peumus boldus 
(Boldo) 
Boldine Indigestion, constipation, 
hepatic disorders 
Diuretic, choleretic, 
cholagogue 
Diuretics, laxatives 2 De Almeida et 
al., 2000 
Piper methysticum 
(Kava) 
Kavapyrones Anxiety, insomnia Anxiolytic, anesthetic, 
muscle relaxants 
Sedative/hypnotic/anxiol
ytics 
2 Feltenstein et 
al., 2003 
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Medicinal plant Major active ingredients Indications Mechanism of action Drug candidates for  
potential interactions 
LE References 
Rauwolfia canescens; 
Rauwolfia serpentina 
Deserpidine, reserpine Antihypertensive, 
tranquilizer 
Antihypertensive Cardiovascular drugs 3 Emilio et al., 
1998 
Rhamnus purshiana 
(Cascara) 
Anthracene glycosides laxative Increasing GIT motility Orally administered 
drugs 
1 Fugh-Berman, 
2000 
Salvia miltiorriza 
(Danshen) 
Tanshinones, phenolic 
compounds 
Cardiovascular diseases Vasorelaxants, anti-
platelets 
Warfarin, vasodilators, 
anticoagulants 
3 Shi et al., 2005; 
Wu and Yeung, 
2010 
Squill Scillarin A Cardiotonic Sedative Cardiovascular drugs 1 Marx et al., 
2005 
Tamarindus indica 
(Tamarind) 
Saponins, flavonoids, 
sesquiterpenes, tannins 
Stomach disorder, jaundice Alteration in platelet 
functions 
Anticoagulants 3 Scott et al., 
2005 
Tanacetum 
parthenium (Feverfew) 
Parthenolide, tanetin Headache, fever, arthritis Inhibition of serotonin 
and prostaglandin 
release, thus altering 
platelet function 
Antiplatelets, 
anticoagulants 
2 Rogers et al., 
2000 
Ternstroemia pringlei Essential oils: 
monoterpenes 
Sedative Sedative synergy Sedatives, hypnotics  2 Balderas et al., 
2008 
Trigonella foenum-
graecum (Fenugreek) 
Alkaloids, flavonoids, 
saponins 
Diabetes, 
hypercholesterolemia 
Antilipidemic, 
hypoglycemic, 
cholagogue 
Oral hypoglycemic 
agents 
2 Vats et al., 
2002; Tripathi 
and Chandra, 
2010; Moorthy 
et al., 2010; 
Baquer et al., 
2011 
Vaccinium 
macrocarpon 
Anthocyanins, flavonoids Antioxidant VKORC1* genotype 
dependent interaction 
Warfarin 4 Mohammed et 
al., 2008 
White false hellebore Protoveratrines A, B Antihypertensives Antihypertensive Cardiovascular drugs 3 Gaillard and 
Pepin, 2001 
Yohimbe Yohimbine Aphrodisiac Vasodilatory Cardiovascular drugs 2 Ajayi et al., 2003 
Zingiber officinale 
(Ginger) 
Zingerone, gingerols Nausea, dyspepsia Antiemetic, 
antiplatelet, antiulcer, 
anti-inflammatory 
Diclofenac, 
anticoagulants 
3 Thomsom et al., 
2002; Lala et al., 
2004; Young et 
al., 2006 
*VKORC1 = Vitamin K epoxide reductase complex subunit 1; LE = Level of evidence 
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2.4. Conclusion 
Concomitant use of herbs and conventional drugs may present with untoward events. 
Available evidence indicates various mechanisms through which this can occur. By 
interacting with conventional medication, herbal remedies may precipitate manifestations of 
toxicity or in the other extreme, therapeutic failure. A good knowledge of the potential of 
commonly consumed herbal medicines to interact with prescription medicines, irrespective of 
the nature of evidence available, will equip health professionals in their practice. Apart from 
those demonstrated in significant numbers in human subjects, not all reported HDIs are 
clinically significant. As such, more clinically relevant research in this area is necessary. 
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CHAPTER THREE 
AN UPDATE ON LIVER-BASED IN VITRO TECHNOLOGIES FOR DRUG 
BIOTRANSFORMATION STUDIES2 
 
3.0. Summary 
Although various other body organs are involved in drug biotransformation, the liver is the 
predominant organ of metabolism for a wide range of endogenous compounds and 
xenobiotics. The enzymes contained in the cytochrome P450 superfamily present 
predominantly in the liver have been identified as the single most important catalyst of drug 
metabolism and have formed the bedrock of most matured technologies for in vitro drug 
biotransformation studies. With the development of a number of liver-based technologies, in 
vitro metabolism has gained significant popularity in the past three decades. This has come 
in response to several demanding factors including the waning relevance of data from 
animal studies; the high cost and stringent regulatory and ethical requirements, as well as 
safety issues involved with studies using human subjects; and the need for high throughput 
due to the wide range of chemical entities for routine tests. In vitro liver-based metabolic 
technologies have found ready application in generating the desired information on the 
substrate and inhibitor specificity of most metabolic enzymes. The technologies available 
vary from whole liver to subcellular fractions. These include isolated fresh liver; liver slices; 
primary, cultured and cryopreserved hepatocytes; microsomes; cytosolic fractions; and 
purified or heterologously expressed drug-metabolizing enzymes. The choice of a particular 
method depends on the metabolic questions to be answered. The determining factors for 
such choices could be drug interaction studies, metabolic profiling and metabolite 
identification, sequential and/or parallel oxidative and conjugative biotransformation in the 
same system among others. A common advantage to all the in vitro technologies is the 
reduced complexity of the study system. In this review, the general principles of in vitro 
enzyme kinetics are discussed. The review also discusses the major features, advantages 
and disadvantages of the various liver-based in vitro methodologies for drug metabolism 
study. 
  
                                               
2
 This Chapter is an updated version of Fasinu P, Bouic PJ, Rosenkranz B. Liver-based in vitro technologies for 
drug biotransformation studies - a review. Curr Drug Metab. 2012 Feb;13(2):215-24. 
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3.1. Introduction 
Drug biotransformation study is an integral part of preclinical screening for new drug 
candidates (Pelkonen and Raunio, 2005). This assessment usually involves both in vitro and 
in vivo models in animal species where the main pharmacokinetic, pharmacodynamic and 
toxicological profiles are investigated (Singh 2006). Biotransformation involves the 
physiologic conversion of nonpolar, lipophilic and pharmacologically active drugs into polar, 
hydrophilic, inactive or nontoxic molecules. In certain instances as with prodrugs like 
tamoxifen, enalapril, levodopa among others, products of biotransformation can be bioactive, 
and further routes of disposition are responsible for their clearance. The liver is responsible 
for the biotransformation of the majority of drugs. Other organs including the kidneys, skin, 
lungs and intestine contribute significantly to the biotransformation of xenobiotics (Krishna 
and Klotz, 1994; De Kanter et al., 2002).  
The biotransformation pathway of a drug could be mediated by any or combination of phase 
I (hydrolysis, oxidation and reduction), phase II (conjugations) and phase III (further 
modification, efflux transport, excretion) reactions (Xu et al., 2005). Phase I 
biotransformation is mediated predominantly by the cytochrome P450 (CYP) enzyme 
superfamily present in the liver, intestines, kidney, lung and other organs. This superfamily of 
hemoproteins is expressed throughout the phylogenic spectrum and is responsible for 
catalytic metabolism of a wide range of endogenous and foreign chemicals. Initially thought 
to be hepatic, CYP has been found to be significantly expressed in other body organs 
including the intestines, spleen and the kidneys (Ingelman-Sundberg, 2004). Phase II 
enzymes including uridine diphosphoglucuronosyl transferase (UGT), N-acetyl transferase 
(NAT), glutathione S-transferase (GST) and sulfotransferase (ST) mediate the attachment of 
polar and ionizable groups to phase I metabolites aiding their elimination while drug 
transporters (phase III) exert their influence on the absorption, distribution and elimination of 
drugs (Petzinger and Geyer, 2006). 
The use of human subjects for comprehensive clinical pharmacology studies seems to be 
ideal. However, the risks involved, and the stringent regulatory demands make this 
practically challenging with attendant high cost and long time duration. Results from animal 
studies pose challenges regarding their clinical significance. Current guidelines for drug 
development encourage the use of in vitro systems for qualitative and supportive 
assessments. In general, in vivo studies are deemed necessary only after positive in vitro 
results. The European Centre for the Validation of Alternative Methods (ECVAM) promotes 
the scientific and regulatory acceptance of alternative methods which reduce, refine or 
replace the use of laboratory animals (Eric et al., 2001). 
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Several in vitro absorption, distribution, metabolism and excretion (ADME) models utilized in 
studying hepatic drug biotransformation were developed in the 80s and 90s and have since 
gained prominence in the drug discovery process towards a „‟fail early, fail cheaply‟‟ 
philosophy (Ekins et al., 2000; Brandon et al., 2003). Such models which range from whole 
cell systems (intact perfused liver, human hepatocytes cultures, hepatic and transfected cell 
lines) to enzyme preparations (liver microsomes and isolated enzymes cultures) are now 
increasingly applied for quantitative and qualitative assessment in preclinical drug 
development, post-approval routine checks, identification of metabolic determinant factors 
and prediction of drug-drug, herb-drug and food-drug interactions. Apart from helping 
researchers and drug discovery scientists extract important information on chemical and 
metabolic characteristics from early screening in the drug discovery phase, results from in 
vitro investigations are relevant determinants for clinical trials of new drugs. Results have 
been utilized for physiology-based pharmacokinetic modeling (Baneyx et al., 2012; 
Heikkinen et al., 2012). In addition, they help to predict drug-drug interactions at metabolic 
levels. One of the most important features of in vitro drug biotransformation research is how 
to make reliable extrapolations relevant to clinical practice (Wrighton et al., 1995; Obach et 
al., 1997; Hewitt et al., 2001).  This has been achieved with a number of the liver-based 
technologies. 
Each in vitro model presents with its own peculiar advantages and limitations. The choice of 
method however is determined mainly by the goal of evaluation. Factors to be considered in 
the choice of an in vitro model include in vivo resemblance, ethical considerations, cost and 
availability. Further, the choice of a particular method depends on the research question to 
be answered: the metabolites formed, the enzymes involved, the enzyme-substrate 
specificity, presence of active metabolites and/or intermediate substrate, influence of test 
drugs on enzyme activity and the relevance to man (Eddershaw and Dickins, 1999; Gosal et 
al., 2003; Gomez-Lechon, 2004; Walsky and Obach, 2004).  
The aim of the current review is to provide an update on the various in vitro liver-based 
models currently utilized in drug biotransformation studies. The major features of each in 
vitro technology are highlighted.  
 
3.2. Principles of in vitro metabolism 
Depending on the throughput demand, biotransformation assays in most in vitro models can 
be conducted manually or robotically. Some of the in vitro models require exogenous supply 
of cofactors for activity. These include primary hepatocytes, cell lines, liver slices and 
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isolated perfused liver. The cofactors employed consists of NADP-regenerating system 
(NRS) (phase I) or uridine-5‟-diphospho-α-D-glucuronic acid (UDPGA) (phase II 
glucuronidation). NADPH is required for the measurement of oxidase activity catalyzed by 
CYP, flavin-containing monooxygenases, NADPH-CYP reductase and many other oxidase 
enzymes. The choice of incubation conditions is believed to have significant influence on the 
outcome of in vitro metabolism (Venkatakrishnan et al., 2001; Kalvas et al., 2001; Bjornsson 
et al., 2003; Pelkonen et al., 2010). The in vivo physicochemical environment can be 
mimicked by incubating at pH values similar to the in vivo conditions. For insoluble test 
compounds and substrates, care should be taken in the choice of lipophilic solvents. Studies 
have demonstrated that beyond certain concentrations, organic solvents such as ethanol, 
dimethyl sulfoxide, isopropanol, methanol, acetonitrile, dimethyl formamide, acetone and 
polyethylene glycol can greatly interfere with the metabolic activities of in vitro enzymes 
(Tang et al., 2000; Mountfield et al., 2000; Easterbrook et al., 2001; Uchaipichat et al., 2004). 
Thus solvent effects are often part of the optimization process for in vitro metabolism. It is 
generally recommended that organic solvents should not exceed 1% of total incubation 
mixture (Yan and Caldwell, 2005).  
The metabolic activities of in vitro models are assessed through the rate of metabolite 
formation or substrate depletion (Jones and Houston, 2004). Most single-substrate 
enzymatic reactions follow the Michaelis-Menten principle. The initial rate of enzymatic 
reactions is usually linearly proportional to the substrate concentration. The initial reaction 
rate, V0 depends on the position of the substrate-binding equilibrium and the rate of 
metabolite formation (Kou et al., 2005). Beyond the substrate concentration where reaction 
rate is maximal (Vmax), there is loss of linearity between the rate of metabolite formation and 
substrate concentration [S]. The substrate concentration corresponding to half the Vmax is 
referred to as the Michaelis-Menten constant (Km) (Hsu et al., 2001). The Michaelis-Menten 
equation as expressed in Equation 3.1 is the basis of most single-substrate (one enzyme 
model) enzyme kinetics. V is measured in nmole/hr/mg or nmole/min/mg protein for HLM or 
nmole/hr/nmole CYP when activities of CYP isoforms are involved. 
 
 
   
       
      
                 Equation 3.1 
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Where V0  is the initial rate of metabolism; Vmax, the maximum rate of metabolism; [S], the 
substrate concentration and Km, the Michaelis-Menten constant. 
 
The rate of product formation depends on both the enzyme and substrate concentrations 
reaching its peak at equilibrium where the saturation of the enzyme binding site yields the 
highest rate of product formation. A typical Michaelis-Menten curve is therefore non-linear 
and various attempts have been made to modify it in a way that enzyme kinetic parameters 
can be estimated at a linear glance. One of the most common linearized modifications to the 
Michaelis-Menten curve is the Hanes-Woolf Plot. It is based on the rearrangement of 
Michaelis-Menten equation as depicted in Equation 3.2. 
 
   
 
 
   
    
 
  
    
           Equation 3.2 
 
As presented in Equation 3.2, a plot of the ratio of the initial substrate concentration to the 
reaction velocity ([S]/V) against [S] will yield a linear graph with 1/Vmax as the slope, a y-
intercept of Km/Vmax and an x-intercept of –Km. The Hanes-Woolf Plot has been used for 
rapid and easy determination of major kinetic parameters such as the Km and the Vmax. 
 
When 2 or more CYP isoforms with distinct affinities are involved in catalyzing a given 
metabolic pathway, a biphasic model is used as expressed in equation 3.3.  
 
    
        
       
  
        
       
         Equation 3.3 
where Km1 and Km2 are affinity constants. 
Softwares are now available for easier and more accurate determination of enzyme kinetic 
parameters. An example is the SigmaPlot® Enzyme Kinetic Software (SigmaPlot: Enzyme 
Kinetic Module, Systat Software Inc., Chicago, IL, USA) which determines Michaelis Menten 
kinetics through its non-linear and linearized plots including Lineweaver-Burk, Eadie-
Hofstee, Scatchard, Hill and Hanes-Woolf. 
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The influence of test chemical inhibitors is assessed in the drug metabolism incubation 
mixture by co-incubating the enzyme-expressed in vitro system with test compound in the 
presence of various CYP-isoform-specific inhibitors. IC50 and Ki values are then determined. 
The IC50 is defined as the inhibitor concentration that causes 50% inhibition of substrate 
metabolism. It is calculated as shown in equation 3.4 below. 
 
  
  
   
   
    
  
         Equation 3.4 
 
Where Vo is the uninhibited velocity; V, the observed velocity; [I], the inhibitor concentration 
and S, the slope factor (Bloomer et al., 1994). Non-linear regression equations can also be 
generated by profiling the inhibitor concentration against observed inhibition. Such equation 
can be used to determine the IC50.  
Ki is a measure of the affinity of the compound to the enzyme determined graphically. The 
values of IC50 and Ki are determined by taking the concentration of marker substrates 
around their corresponding Km values and about 0.5-4-fold of their corresponding Km values 
respectively. Enzyme inhibition can also be expressed as percentage of control (Wang et al., 
2010). 
The use of in vitro technologies in drug biotransformation studies has thus evolved with 
standard procedures. The specific CYP and UGT activity can be measured with various 
substrate models as shown in Tables 7 and 8. 
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Table 7: A summary of recommended test substrates and inhibitors for various CYP 
isozymes (Brandon et al., 2003; Yan and Caldwell, 2005; Hariparsad et al., 2006) 
Isoform Occurrence Acceptable test 
substrates 
Metabolic reaction Inhibitor inducer 
1A1 Mainly 
extrahepatic 
Ethoxyresorufin 7-ethoxyresorufin O-
deethylation 
α-Naphtoflavone Polycyclic 
hydrocarbons, 
Rifampicin, 3-
methyl-
cholanthrene 
1A2 Liver Phenacetin 
Caffeine 
Phenacetin O-
deethylation 
Caffeine N3-
demethylation 
Furafylline  
2A6 Liver Coumarin Coumarin C7-
hydroxylation 
Sulfaphenazole Pyrazole 
Barbiturates 
2B1/2 Liver Pentoxyresorufin Pentoxyresorufin O-
dealkylation 
  
2B6 Liver Mephenytoin 
Bupropion 
(S)-mephenytoin N-
desmethylation 
Bupropion hydroxylation 
Sertraline  
2C8 Liver, 
intestine 
Paclitaxel Paclitaxel C6-α-
hydroxylation 
Glitazones Rifampicin 
Phenobarbital 
2C9 Liver, 
intestine 
Warfarin 
Diclofenac 
Tolbutamide 
(S)-warfarin C6-, C7 
hydroxylation 
Diclofenac 4‟-
hydroxylation 
Tolbutamide p-CH3-
hydroxylation 
Sulfaphenazole Rifampicin 
Phenobarbital 
2C18/19 Liver Mephenytoin (S)-mephenytoin C4‟-
hydroxylation 
Ticlopidine 
Ketoconazole 
Rifampicin 
Carbamazepine 
2D6 Liver, 
intestine, 
kidney 
Bufuralol 
Dextromorphan 
Codeine 
Bufuralol C1‟-
hydroxylation 
Dextromorphan O-
demethylation 
Codeine O-
demethylation 
Quinidine 
Haloperidol 
 
2E1 Liver, 
intestine, 
leukocytes 
Chlorzoxazone 
Lauric acid 
Chlorzoxazone C6-
hydroxylation 
Lauric acid C (ω1)-
hydroxylation 
Diethyl-
dithiocarbamate 
Ethanol 
3A4 Liver, GI 
tract, 
Midazolam 
Testosterone 
Dihydropyridines 
Midazolam C1‟-
hydroxylation 
Testosterone C6-β-
hydroxylation 
Hydroxylation 
Ketoconazole 
Furanocoumarin
s 
Grapfruit juice 
Flavonoids 
Rifampicin 
Barbiturates 
4A11 Liver, kidney Lauric acid Lauric acid ω-
hydroxylation 
17-Octadecynoic 
acid 
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Table 8: Suggested isoform-selective in vitro probe substrates for hepatic UGTs 
UGT Isoforms Probe substrates References 
 
UGT1A1 
 
Bilirubin 
Estradiol 
Etoposide 
 
Levesque et al., 2007 
Mano et al., 2007 
Burchell et al., 2005 
UGT1A3 R-Lorazepam 
26, 26, 26, 27, 27, 27-hexafluoro-
1α, 25-dihydroxyvitamin D3, 
Court, 2005 
Kasai et al., 2005 
UGT1A4 Trifluoperazine, 
Imipramine 
Lamotrigine 
Tamoxifen 
Uchaipichat et al., 2006 
Qian et al., 2004 
Argikar et al., 2009 
Kaku et al., 2004 
UGT1A6 Serotonin Krishnaswamy et al., 2004 
UGT1A9 Propofol 
7-hydroxy-mycophenolic acid 
Su et al., 2010 
Girard et al., 2006 
UGT2B4 Codeine 
Hyodeoxycholic acid 
Hanioka et al., 2008 
Barre et al., 2007 
UGT2B7 Zidovudine 
Morphine 
Epirubicin 
Uchaipichat et al., 2008 
Stone et al., 2003 
Innocenti et al., 2001 
UGT2B15 Androstanediol 
S-oxazepam 
Tamoxifen 
Rofecoxib 
Soars et al., 2003 
He et al., 2009 
Oleson and Court, 2008 
Court, 2006 
UGT2B17 Dihydrotestosterone Setlur et al., 2010 
 
 
3.3. Various technologies for liver based in vitro metabolism 
3.3.1. Isolated Perfused Liver 
The isolated perfused liver is considered theoretically as the most similar to the in vivo 
situation. However, only animal liver in small scale has been employed. The model usually 
involves the perfusion of isolated liver with Krebs-Henseleit buffer as perfusate (Lafranconi 
and Huxtable 1984; Jia and Liu, 2007). The three-dimensional cytoarchitecture, the 
presence of non-hepatic cells and transporters make this model the closest in similarity to 
the in vivo environment. The presence of functional bile canaliculi also makes this model 
suitable for bile collection and analysis (Groneberg et al., 2002). However this model is 
difficult to handle, has very short viable period of three hours due to the poor perfusion of the 
cells by oxygen and nutrients, poor reproducibility and low throughput. In addition, human 
liver is difficult to source (Brandon et al., 2003). 
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3.3.2. Liver slices 
Liver tissue slices have been widely used for biotransformation studies. First developed in 
1920s by Otto Heinrich Warburg, its use and reliability have further been improved by the 
development of high-precision tissue slicers (De Kanter et al., 1999; Edwards et al., 2003; 
Olinga et al., 1997, 2008). Unlike in perfused liver, the preparation of liver slices does not 
require harmful proteases (Seglen, 1973). This model offer intact cellular interaction, normal 
spatial arrangement and the possibility of morphological studies. Like the perfused liver, it 
has functional drug metabolizing enzymes, transporters and bile canaliculi. It has reasonably 
higher throughput than perfused liver. However, some of the disadvantages with this model 
include: lack of optimal cryopreservation procedure making it unavailable commercially, 
considerable decrease in CYP expression (>50%) within 24 hours of preparation, loss of 
hepatic function after 10 days, inadequate tissue penetration of the test medium, damaged 
cells on the outer layer and the necessity of expensive equipment (Lerche-Langrand and 
Toutain, 2000). In addition, viable cell enrichment is not possible with liver slices, the liver 
slices are not inducible by CYP inducers, biles collection for analysis may not be possible as 
in perfused liver and the presence of necrotic cells may affect drug transport studies (Olinga 
et al., 2001; Pan et al., 2002). 
 
3.3.3. Hepatocytes 
3.3.3.1. Primary hepatocytes  
In vitro models of the liver employing isolated primary hepatocytes have been popularized 
for various screening purposes. In addition to their application in drug biotransformation and 
toxicity studies, they are important tools for studying drug efficacy, hepatic proliferation and 
as supportive tools in other bioartificial studies (Wang et al., 2004). Primary hepatocytes 
have strong resemblance of in vivo situation with metabolic results closely correlated to in 
vivo yields. They reflect the heterogeneity of CYP-expression in human liver and are thus 
popularly employed for in vitro drug biotransformation studies (Hewitt et al., 2007). Different 
methods have been developed to obtain hepatocytes for drug biotransformation (Guguen-
Guillou et al., 1982; Smedsrod and Pertoft, 1985; Baccarani et al., 2003; McGinnity et al., 
2004). An important feature of primary hepatocytes is the preservation of drug metabolizing 
enzymes at in vivo levels. Further advantage is the relative ease to use and reasonably 
higher throughput (Wang et al., 2002). However, lack of cell polarity, cell-cell and cell-matrix 
contacts limits the in vivo resemblance of isolated hepatocytes in drug biotransformation 
research. Isolated hepatocytes also have limited viability (2-4hrs) (Bi et al., 2006).  
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3.3.3.2. Cultured hepatocytes 
Isolated hepatocytes can be maintained in monolayer cultures for a maximum of four weeks. 
This offers the advantage of longer viability compared to primary hepatocytes (Guillouzo et 
al., 1990; Wang et al., 2008). This longer viability period with the prolonged functional 
regulatory pathways enables the utilization of this model for assessing 
upregulation/downregulation of metabolic enzymes. Cultured hepatocytes gradually lose 
viability and liver-specific functions including decreased CYP expression with time (Luttringer 
et al., 2002). Another major challenge with the use of hepatocyte is the dependence of its 
availability on the handiness of fresh liver tissue. This makes it impossible to perform studies 
on demand, or to repeat studies with hepatocytes from same donor. To solve these 
challenges, cryopreservation procedures have been developed for hepatocytes, retaining the 
activity of most phase I and phase II enzymes (Zaleski et al., 1993; Ostrowska et al., 2009). 
This has made the commercial availability of human hepatocytes possible and accessibility 
independent of fresh liver tissue availability. The hepatocytes preserved in this form are a 
potential tool for chronic toxicity and drug-drug interaction studies (Hewitt et al., 2001).  
Hepatocyte cultures may require special supplements in media and, depending on the 
technology used to preserve the tissue function, cultured hepatocytes may maintain 
differentiated function and possess a functional bile canaliculi (LeCluyse et al., 2000). One of 
the major challenges with the use of human hepatocytes is the considerable inter-individual 
variation carried over from the source of the liver. This can be overcome by using mixtures of 
heptocytes from multiple donors (Hewitt et al., 2007). Human hepatocytes do not reflect 
completely the in vivo environment as non-hepatic cells like Kupffer cells which may be 
necessary for cofactor supply are absent. Although hepatocytes often give better in vitro–in 
vivo correlations than cell lines and subcellular fractions, perfused cell lines and liver slices 
are considered better in this regard (Boess et al., 2003). 
 
3.3.4. Liver cell lines 
Liver cell lines are often used as in vitro models for drug metabolism study but they are not 
as popular as other models. Their cellular characteristics are de-differentiated and they lack 
complete expression of all families of metabolic enzymes (Hoekstra and Chamuleau, 2002; 
Strick-Marchand and Weiss, 2002). They can be obtained as isolated cells from primary 
tumors of the liver parenchyma seen after chronic hepatitis or cirrhosis (Knasmuller et al., 
2004). Commercially available cell lines include Hep G2, Hep 3B, C3A, PLC/PRF/5, SNU-
398, SNU-449, SNU-182, SNU-475 and SK-Hep-1 among others. Each of these cell lines 
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expresses various metabolic enzymes to different degrees. The most widely used and best 
characterized liver cell line is the hepatoma cell line Hep G2 (Brandon et al., 2003). 
The metabolic activity of liver cell lines is generally low compared to freshly isolated human 
hepatocytes (Khetani and Bhatia, 2008). Liver cell lines require culture medium, the 
composition of which also greatly influences the metabolic activity (Xu et al., 2005). The 
main advantages of liver cell lines compared to other in vitro models are their ease to culture 
and their possession of relatively stable enzyme concentration (Khalil et al., 2001). On the 
other hand, the absence or low expression of most phase I and phase II enzymes is a major 
disadvantage. Metabolites are not easily detected and the activities of individual CYP and 
other enzymes are difficult to investigate. These factors limit the application of liver cell lines 
in drug biotransformation studies (Mersch-Sundermann et al., 2004). 
 
3.3.5. Human liver S9 fractions 
The liver S9 fractions are obtained after the centrifugation (9000g) of the supernatant yielded 
from an initial centrifuged (1000g) liver homogenates. They contain both microsomal and 
cytosolic fractions expressing a wide range of metabolic enzymes – CYP, flavin-
monooxygenases, carboxylesterases, epoxide hydrolase, UDP-glucuronosyl transferases, 
sulfotransferases, methyltransferases, acetyltransferases, glutathione S-transferases, 
among others. They have been widely employed for metabolic, toxicity and mutagenicity 
studies mainly in combination with the Ames test (Hakura et al., 2001; Slaughter et al., 2003; 
Chalbot and Morfin, 2005). For in vitro activity, an exogenous supply of a NADPH-
regenerating system or NADPH solution is required to provide the energy demand of the 
CYP enzymes. Similarly, for phase II reactions, uridine diphosphoglucuronic acid (UDPGA) 
and alamethicin for UGT; acetyl coenzyme A (acetyl CoA), dithiothreitol (DTT) and acetyl 
CoA regenerating system for NAT; adenosine-3‟-phosphate 5‟-phosphosulphate (PAPS) for 
ST; and glutathione for GST are necessary (Hakura et al., 2003). 
S9 fractions offer a more complete representation of the metabolic profile compared to 
microsomes and cytosol, as they contain both phase I and phase II activity. The major 
disadvantage is the lower enzyme activity in the S9 fraction compared to microsomes or 
cytosol which may leave some metabolites unnoticed (Hakura et al., 1999). 
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3.3.6. Human liver cytosolic fractions 
The human liver cytosol is obtained by differential centrifugation of whole liver homogenate, 
like microsomes or from the cytosolic (soluble) fraction of insect cells infected with 
recombinant baculovirus. It expresses the soluble phase II enzymes like N-acetyl 
transferase, glutathione S-transferase, sulfotransferase, carboxylesterases, soluble epoxide 
hydrolases, diamine oxidases, xanthine oxidases and alcohol dehydrogenase.  
Human liver cytosolic fractions are used often in drug biotransformation research for 
enzyme-specific studies (Maser et al., 2000; Walsh et al., 2002). Their use requires 
cofactors like acetyl coA, dithiothreitol and acetyl coA-regenerating system for NAT, 
adenosine-3‟-phosphate-5‟-phosphosulfate for ST, glutathione for GST activity and S-
adenosyl methionine (SAM) for thiopurine methyltransferase (TPMT). Human liver cytosol 
expressing the specific NAT isozymes in cytosol without the other soluble phase II enzymes 
is commercially available. This allows the study of the influence of both NAT1 and NAT2 
isozymes on the biotransformation pathways employing this model (Li et al., 2005). 
The most important advantage offered by this model is the presence of only few cystolic 
enzymes at concentrations higher than those in the liver S9 fraction. It allows individual 
study of the metabolic activity of NAT, ST and GST enzymes depending on the cofactors 
added. This limited enzyme expression also account for the main disadvantage, as other 
enzymes especially the UGT, which is located on the endoplasmic reticulum, are absent and 
cannot be investigated via this model (Li et al., 2005; Hariparsad et al., 2006). 
 
3.3.7. Human liver microsomes (HLM) 
HLM is the most popular model and is the most widely utilized in vitro model providing 
affordable tool for metabolic profiling and drug interaction studies (Buenz et al., 2007). 
Microsomes from the liver and small intestines are employed to investigate the potential for 
pre-systemic metabolism following oral drug administration while those from small intestine, 
kidney are often utilized to evaluate extrahepatic metabolism (Bu, 2006). Liver microsomes 
consist of vesicles of the hepatocyte endoplasmic reticulum prepared by differential 
centrifugation, and can be collected from liver preparations including fresh human liver, liver 
slices, liver cell lines and primary hepatocytes (Asha and Vidyavathi, 2010). They are used 
for the evaluation of phase I enzymes because of the rich expression of CYP, flavin 
monoxygenases, carboxyl esterases, epoxides, hydrolase and UDP glucuronyl transferases 
(Newton et al., 2005). The CYP retain their activity for many years in microsomes at low 
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temperatures (-80°C) (Pearce et al., 1996). HLM provides one of the most convenient ways 
to study CYP metabolism with high throughput. 
Typical HLM incubation mixture consists of test compound, NADPH-regenerating system 
(NRS) and buffers like potassium or sodium phosphate. The reaction is initiated by the 
addition of NRS, incubation at 30°C in a shaking water bath or shaking incubator. The 
metabolic reaction is terminated by the addition of a stop solution comprising ice-cold 
acetonitrile, trichloroacetic acid, ice-cold carbonate buffer, sodium hydroxide or hydrochloric 
acid, in order to precipitate the microsomal protein. The reaction mixture is then centrifuged 
and analyzed (Asha and Vidyavathi, 2010). Exogenous cofactors are required for in vitro 
microsomal activity, the choice of which depends on the desired enzyme activity. For UGT 
activity, a glucuronyl moiety donor usually UDPGA is required. For CYP monooxygenase 
reactions, NADPH-regenerating system consisting of β-NADP, glucose 6-phosphate and 
glucose 6-phosphate dehydrogenase is required. Alternatively, NADPH may be added 
directly to the incubation mixture to supply the required energy for metabolism. For UGT 
activity, pore-forming agents like alamethicin are often necessary to facilitate drug access to 
the UGTs (Yamazaki, 1997; Chen et al., 2007). HLM is employed in the drug discovery 
process for metabolite identification, comparison of metabolism by different species, 
prediction of in vivo clearance, reaction phenotyping and metabolic pathway identification 
(Bourrie et al., 1996; Li, 2001; Venkatakrishnan et al., 2001; Lu et al., 2003). The activity of 
HLMs can vary substantially between individuals. This problem however can be successfully 
solved by the application of microsomes pooled from a large bank of individual liver tissues 
while individual microsomes are used to study inter-individual variability in drug metabolism. 
Microsomes from single-sex sources are also available and are employed in the evaluation 
of gender-based discrepancies in drug metabolism (http://www.xenotechllc.com).  
The utilization of HLM offers major advantages including ease of application, affordability, 
well established procedure and the possibility of its use in studying inter-individual and 
population-based metabolic variation. It provides qualitative estimations of in vivo drug 
metabolism and is convenient tools for high throughput screening of compounds, lead 
optimization studies during drug development and drug interaction studies.  
The use of HLM is however limited in its quantitative clinical extrapolative relevance. Thus, 
results obtained from HLM cannot be used for quantitative estimations of in vivo human 
biotransformation (Brandon et al., 2003). This is because the microsomal fraction is enriched 
with CYPs and UGTs and there is no competition with other enzymes. This leads to 
relatively higher biotransformation rates in microsomes compared to the human in vivo 
situation, but also compared to primary hepatocytes and liver slices.The absence of other 
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enzymes like NAT, GST and ST, and cytosolic cofactors present in intact cells limits the 
metabolic reactions. This will necessarily lead to a reduction in the expected „metabolic 
competition‟ with limited number of metabolites. Secondly, the fraction of drug bound to 
plasma versus microsomal protein is an important determinant of extent of drug metabolism 
in vivo. The impact of this factor is difficult to assess in vitro. Also, the direct contact and 
accessibility of the drugs and their metabolites to the microsomal enzymes in the incubation 
mixture is not a true reflection of the in vivo situation (Asha and Vidyavathi, 2010). 
 
3.3.8. Recombinant human CYP and UGT enzymes 
3.3.8.1. Transgenic cell lines 
Transgenic cell lines are obtained by the recombinant expression of phase I and/or phase II 
enzymes in a cell line. They are enzyme-induced cells, often used in cytotoxic studies whose 
preparation involves the production of individual enzymes in the endoplasmic reticulum of an 
eukaryote host cell including yeast and mammalian cells (Donato et al., 2008). All human 
CYPs and UGTs have been expressed in this way to overcome the limitations of liver cell 
lines. Stable expression of human CYPs in a human cell line was first successfully 
performed in 1993 by Crespi and co-workers. Various other expression of liver enzymes in 
cell lines have been developed including the human lymphoblast stably expressing CYP1A2, 
CYP2A6, CYP2E1 and CYP 3A4 (Snawder et al., 1994; Sawada and Kamataki, 1998; Tiano 
et al., 2003; Zhuge et al., 2003; 2004). Cell lines may be transfected at high efficiency using 
protoplast fusion, centrifugation of lysozyme-treated bacteria bearing the desired vector with 
the parent cells in the presence of polyethylene glycol protoplast fusion (Crespi et al., 1997). 
The main advantages of transgenic cell lines are the ease of culturing, high expression of 
CYP and UGT enzymes and the possibility of single enzyme study as in supersomes. 
However, they are more expensive than most other enzyme-based technologies. They also 
do not completely reflect the in vivo situation (Ferro and Doyle, 2001). 
 
3.3.8.2. Non-mammalian cells containing expressed CYP and UGT enzymes 
CYP expression for this model includes bacterial expression in Escherichia coli and yeast 
cells. This model is the final and most focused „enzyme only‟ system in which the most 
popular is the baculovirus-based model allowing functional expression of recombinant 
proteins in insect cells (Guengerich et al., 1997). Insect cells lack endogenous CYP and 
uridine diphosphoglucuronosyl transferase activity. Microsomes from insect cells therefore 
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can be transfected with cDNA for human CYP and UGT. This has proven to be a useful tool 
in in vitro biotransformation studies (Miller et al., 2011). This model of baculovirus mediated 
microsomes of insect cells is sometimes referred to as baculosomes or supersomes 
(Gentest). 
Unlike in HLM where all CYPs and UGTs are present, specifically expressed human CYP 
and UGT in supersomes allows the assessment of individual metabolic enzymes and their 
contribution to the metabolic pathway of the test compound (Lavigne et al., 2002). Currently, 
all common human CYPs and UGTs co-expressed with NADPH-cytochrome P450 reductase 
are commercially available (Miller et al., 2011). A control experiment - incubation with 
nontransfected supersomes, must always be conducted. A NADPA-regenerating system 
(which consists of β-NADP, glucose 6-phosphate and glucose 6-phosphate dehydrogenase) 
or NADPH is required to supply the energy demand of the CYPs. For the UGT activity, 
uridine diphosphoglucuronic acid (UDPGA) has to be added as a cofactor (Invitrogen Life 
Technology, 2004). 
After the determination of the metabolic pathway using the HLM, the use of cDNA-expressed 
CYPs can be an excellent way to confirm results (Kurkela et al., 2003). Although studies with 
supersomes may lack quantitative in vivo relevance, they address very particular questions 
with respect to the role of specific CYP isozymes and their roles in the metabolic pathways 
of xenobiotics. Supersomes can be used to study not only isozyme-specific drug 
biotransformation but also drug-drug interactions (Wang et al., 2010). Because of the 
availability of different genotypes of the CYP isozymes (eg CYP2C9*1, CYP2C9*2 and 
CYP2C9*3), the influence of different polymorphisms on the drug biotransformation can also 
be studied employing the supersomes (Schwarz et al., 2001). However, in UGT 
supersomes, the UGT active site is shielded behind a hydrophobic barrier resulting in 
latency of glucuronidations. This disadvantage can be overcome by using a pore-forming 
agent like alamethicin (Brandon et al., 2003). The various technologies are compared in 
Table 9. 
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Table 9: A relative comparison of the features of the various liver-based in vitro drug 
metabolism technologies 
 In vivo 
correlation 
Throughput Technical 
simplicity 
Commercial 
availability 
Enzyme-
specific probe 
Viability 
period 
Reproducibility 
 
Perfused Liver 
 
+++ 
 
+ 
 
+ 
 
- 
 
+ 
 
+ 
 
+ 
Liver slices +++ + + - + + + 
Primary 
Hepatocytes 
++ ++ ++ - ++ + ++ 
Cultured 
Hepatocytes 
++ ++ ++ - ++ + ++ 
Cryopreserved 
Hepatocytes 
++ ++ ++ ++ ++ ++ ++ 
Liver cell lines + +++ +++ +++ +++ +++ ++ 
Liver cytosolic 
fractions 
+ +++ +++ +++ +++ +++ ++ 
Liver 
microsomes 
+ +++ +++ +++ +++ +++ +++ 
Recombinant 
CYP/UGT 
enzymes 
+ +++ +++ +++ +++ +++ +++ 
 
3.4. Discussion of methods employed in this study 
In this review, the available liver-based in vitro methods for drug biotransformation studies 
have been discussed. These techniques have made major contributions towards the 
development of various therapeutic agents and are still the preferable tools for future 
studies. It has been pointed out that the methods vary with their ease of use and the 
conclusions that can be inferred from them. They also present with unique advantages and 
disadvantages. The choice of any of the methods will depend on the research question to be 
answered. However, in certain instances, a combination of different in vitro tools may be 
required for a reliable assessment.  
In this study, HLM was employed to investigate the HDI potential of selected medicinal 
herbs. This is because of its ease to use, commercial availability, long-time viability, ethical 
and technical simplicity and the ability for high throughput. HLM is the most often used in 
similar studies. Positive results from HLM can be confirmed through the use of hepatocytes 
or in vivo human studies. By standard practice, if there is no enzyme inhibition in HLM in 
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vitro, further studies are often not necessary. The disadvantage of the use of HLM as 
mentioned earlier, is poor quantitative extrapolation to human. 
In addition, cryopreserved hepatocytes were utilized to establish CYP3A4 inhibition by 
Lessertia frutescens. This is because hepatocytes represent a closer system to human liver 
than HLM, but require more technical and complex procedures in the sourcing and usage.  
The activities of the selected herbs in this study on drug transporters were investigated 
employing cell lines stably expressing the specific transporters.  
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CHAPTER FOUR 
 
SELECTED COMMONLY USED SOUTH AFRICA MEDICINAL HERBS – SELECTION 
AND PREPARATION FOR IN VITRO STUDIES 
 
 
4.0. Summary 
While consumers may purchase herbal products over-the-counter, many patients consult 
traditional health practitioners (THPs) who prescribe and dispense to them, various herbal 
products in accordance with their presenting complaints. This part of the study was 
conducted to identify medicinal herbs utilized by traditional health practitioners to manage 
various conditions. It involved the collection of samples and the administration of semi-
structured interview. In all, 15 plant species belonging to 14 families were collected and 
identified scientifically. The parts used, methods of preparation and administration, together 
with specific indications were documented. An overview of published studies on the 
identified was provided. The absence of information on HDI potential of the medicinal herbs 
was identified.  
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4.1. Introduction 
Traditional medicine especially the use of medicinal herbs is popular among South Africans 
where THPs are the first point of call for health services in most rural areas. There are three 
loose and often intertwined classifications of THP in South African. The inyanga is a 
traditional doctor or herbalist, typically male, who often uses medicinal herbs to treat various 
diseases. The isangoma is usually a woman who combines divination and herbalism, 
operating as a medium between the ancestors and the clients within religious/supernatural 
context. The faith healer integrates religious ritual and traditional practices (Freeman and 
Motsei, 1992). The reason for the persistent popularity of traditional healers across South 
Africa is rooted in traditional and cultural acceptance, relative affordability and accessibility. It 
is also believed that THPs adopt a more holistic health management approach appropriate 
for psychological and social components of chronic diseases including HIV/AIDS and 
tuberculosis in the various communities (Babb et al., 2007). There is therefore, an increasing 
acceptance of the need to incorporate THP into the mainstream health care (Mills et al., 
2005a). This is in agreement with WHO recommendations where the popularity and 
acceptance of THP can be employed in their communities to mobilize people for voluntary 
counselling and testing programs, acceptance and adherence to drug regimens, cooperating 
with orthodox health practitioners to improving the well-being and quality of life of people 
living with chronic diseases especially HIV/AIDS (WHO, 2005). This advocacy has grown 
despite the absence of sufficient data on the safety and efficacy of herbal medicines. 
Although the use of medicinal herbs predates the emergence of HIV/AIDS, the utilization of 
herbs as immune boosters and for symptomatic management of AIDS has been popularized 
in South Africa. The high burden of HIV/AIDS has attracted various policy designs to 
accommodate a holistic approach to manage the scourge. While the crux of the various 
HIV/AIDS policies has been the introduction of free antiretroviral drugs (ARV), it is believed 
that the past controversy over HIV/AIDS and the official promotion of herbal medicine for its 
management have contributed to the persistently high rate of consumption of medicinal 
herbs by people living with HIV/AIDS despite the availability and/or consumption of ARVs 
(Morris, 2002; MacPhail et al., 2002; Mills et al., 2005a; Malangu, 2005).  
Studies have shown that many South Africans consult THPs especially for the treatment of 
Sexually Transmitted Infections (STIs) such as gonorrhoea, syphilis, and assumed HIV/AIDS 
Peltzer, 2001; 2003). While some HIV/AIDS patients consume medicinal herbs ab initio, 
studies have shown that a number of them resort to herbal medicine in response to adverse 
reactions to ARVs (Peltzer and Mngqundaniso, 2008). The number of HIV/AIDS patients 
who consume herbal medicine alone or concomitantly with ARVs is often under-estimated. 
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This is because, although the South African National ARV Treatment Guidelines require 
patients to disclose intake of any other medication including traditional medicines, most 
patients do not (Department of Health, South Africa, 2004). In a cross-sectional study carried 
out by Peltzer and colleagues (2008), up to 90% of respondents who were taking herbal 
therapies for HIV did not disclose this to their health care providers. This therefore calls for 
more research to establish the identities, therapeutic benefit and safety of the use of 
medicinal herbs in HIV/AIDS. This becomes very important because of the many 
documented cases of herbal toxicity, herb-drug interaction and therapy failure consequent 
upon concomitant use of herbs and prescription medicines. 
The long history of the use of medicinal herbs has impacted on the socio-cultural identities of 
indigenous Africans. There are research efforts globally to document the ethno-medical data 
of medicinal plants used in various communities. This becomes necessary because most 
THPs, who are seen as the custodian of the herbal knowledge, seldom keep records of their 
practice. Medical claims for the medicinal herbs are not well proven scientifically. 
 
4.2. Aim and Objectives 
The aim of this chapter was to identify and select medicinal plants for HDI studies. Further 
objective was to conduct a review of published studies on the identified plants, including data 
on HDI potential. 
 
4.3. Method 
The medicinal herbs to be investigated for HDI potential were sourced in collaboration with 
HOPE Cape Town who engages THPs for community mobilization for HIV/AIDS awareness 
and management programmes. Through this collaboration, two THPs, who practice in 
Mfuleni and Delft, two major Black3 communities in Cape Town, Western Cape Province, 
were recruited. They were registered with the traditional medicine council, had full-time 
practice in their communities, and had attended various HIV/AIDS training workshops. They 
were the major THP with patronage from neighbouring townships of Nyanga, Khayelitsha 
and Philippi. HIV/AIDS is endemic in these poor townships. Previous activity of HOPE Cape 
                                               
3
 The race classification was based on the national census categories and described as Black (Africans), 
Coloured, Indian and White 
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Town had exposed the THPs to health education including the necessity of encouraging and 
referring their patients suspected of HIV/AIDS for voluntary testing, counselling and ART.   
Mfuleni is a predominantly Black township about 40 kilometres from Cape Town, South 
Africa with a population of about 10,000 (according to 2001 census). Residents, like most 
Blacks in the Western Cape, claim origin from the Eastern Cape Province. The trado-cultural 
practices including traditional medicine are thus a reflection of the traditions of the Eastern 
Cape. Delft is a much bigger township about 34 kilometres North-East of Cape Town with a 
mixed population of Black and Coloured residents estimated in the year 2001 to be 92,000.   
The sourcing of the medicinal herbs involved three stages. Plant Material Transfer 
Agreements mutually agreeable to the THPs and the University of Stellenbosch were signed 
(Appendix E). Samples of herbal materials used for various chronic ailments were obtained 
from them. The herbal samples in their natural habitat were also obtained in Goso, near 
Ngcobo, in Eastern Cape Province (about 1400 kilometres away), and identified by their 
local (IsiXhosa) names with the assistance of the THPs.  
The collected plants were identified with the help of botanical experts in the Compton 
Herbarium, Cape Town and Voucher specimens were prepared and housed at the Division 
of Pharmacology, University of Stellenbosch. Information on the mode of use, dosage and 
indications were obtained and documented through semi-structured interview/questionnaire 
(Appendix F).  
Further, a literature search was conducted through the databases of Pubmed, Embase and 
Google Scholar to published studies on the identified plants. The scientific and local names 
of the respective plants were used as search terms.  
Ethic approval was obtained from the University of Stellenbosch Health Research Ethics 
Committee. Approval was obtained from the University of Stellenbosch legal department for 
the transfer of the plant materials. 
 
4.3.1. Administration of the semi-structured interview/questionnaire to the THPs 
The two THPs recruited for the purpose of sourcing the medicinal herbs used in this study 
were administered with a questionnaire (Appendix F). The content of the questionnaire was 
translated from English to IsiXhosa, the first language of the THPs, with the help of a fluent 
speaker of both languages. The THPs, having made to understand their roles in the 
research, consented by appending their signatures in the presence of witnesses. The major 
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roles of the THPs were the supply of the medicinal herbs for this study, and the provision of 
information on the traditional indications and mode of use. The intellectual property of the 
THPs was protected by the strict adherence to the national guidelines governing the 
interactions with THPs and other indigenous knowledge custodians. This included the 
notification of the department of Environmental Affairs of the Republic of South Africa of the 
intention to perform this research, and the filling of the Bioprospecting and Discovery 
Notification Form. These were done in collaboration with the Legal and Patent units of 
Stellenbosch University. 
 
4.3.2. Material transfer agreement 
In addition to the administered semi-structured questionnaires, a Material transfer 
Agreement (MTA) was mutually agreed upon, prepared and signed by both the researchers 
and the THPs. This was witnessed by the Legal and Patent units of Stellenbosch University. 
The content of the MTA ensured that the plant materials were the property of the THPs who 
had voluntarily made them available as a service to the research community. It also 
restricted the recipients to use the materials for research purposes only in which case, the 
materials are not transferable to any other person. The THPs allows the researchers to 
publish any findings therefrom and to acknowledge them. Further detail of the MTA is 
provided in Appendix G. 
 
4.4. Medicinal herbs collected 
This study identified 15 medicinal herbs commonly prescribed for patients by practicing 
THPs in Mfuleni, Delft and the adjoining Black communities. The identified plants belong to 
14 different families. The THPs visit the Eastern Cape regularly and seasonally to source for 
these plants. All the plants are administered as oral and/or topical infusions or decoctions. 
Various disorders managed with these herbal remedies include gastrointestinal, respiratory, 
skin and infectious diseases. The identities and use of the plants are summarized in Table 
10 and sample plant pictures are provided in Appendix G. Both THPs agreed on the 
information provided on the supplied medicinal herbs. 
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Table 10: Treatment practices and plant species used by THPs for HIV/AIDS patients 
Scientific name Family Vernacular4 names Part used/ 
extracted 
Preparation Uses 
Acacia karroo  Fabaceae Sweet thorn (E), 
UmNga 
Bark Crush and boil in water For cold, skin and eye 
infections, diarrhoea 
Alepidea amatymbica Eckl & 
Zeyh.  
 
Apiaceae Iqwili Rhizome Chewed or boiled, allowed 
to 
cool, and the infusion taken  
Respiratory problems 
- flu, coughs and 
chest complaints. 
Bowiea volubilis Harv. Ex 
Hook. F  
Hyacinthaceae Umagaqana Bulb Slice and boil in water, take 
cold 
Purgative, oedema, 
syphilis 
Capparis sepiaria L. var 
citrifolia (Lam) Toelken  
Capparidaceae Isihlo esimbovu Root  Crush and boil in water Respiratory disorders, 
rheumatism, gout, 
earache, allergy 
Chenopodium album L.  
 
Chenopodiaceae Fat hen (E), 
imbikicane 
embomvu 
Leaves  Crush in hot water to make 
infusion 
Anorexia, dysentery, 
diarrhoea, cough 
Emex australis  
 
Polygonaceae Devil‟s thorn (E), 
inkunzane 
Leaves Boil in water to make 
decoction 
Constipation, stomach 
cramps, appetite 
stimulation 
Hypoxis hemerocallidea Hypoxidaceae African Potato (E) 
Afrika patat (A), 
Inkomfe (Z), 
ilabatheka  
Corms Boil bulb, eat whole or take 
aqueous decoction 
Immune booster, skin 
rash 
Kedrostis africana L. Cogn. 
 
Cucurbitaceae uTuvana Leaves Crush and boil in water for 
oral use and topical wash 
Skin rash  
Pachycarpus concolor E. 
May.  
Asclepiadea Itshongwe Root  Infusion  Stomach ache, 
gastritis 
Pentanisia prunelloides  Rubiaceae Isicimamlilo, Root Crush and boil in water  Bacterial and viral 
                                               
4
Local names are in IsiXhosa except otherwise stated; A=Afrikaans; E=English; Z=Zulu 
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Scientific name Family Vernacular4 names Part used/ 
extracted 
Preparation Uses 
Itshamlilo infections, 
inflammation, skin 
rash 
Ranunculus multifidus Forssk  
 
Ranunculaceae Igangashane Root  Decoction (oral and 
enemas) 
STIs, genital sores, 
warts, haemorrhoid 
Spirostachys africana Sond.  
 
Euphorbiaceae Mthombothi Stem bark Crush and boil in water, 
take infusion while cold 
Diarhoea, dysentery 
Lessertia frutescens (formerly 
Sutherlandia frutescens) 
 
Fabaceae Cancer bush (E), 
Umnwele 
Leaves  Boil in water to make 
infusions, allow to cool; 
whole 
Rheumatism, stomach 
and liver problems, 
diarrhoea, cancer, 
immune boosting 
Tulbaghia violacea (Harv)  
 
Amaryllidaceae Wild garlic (E), 
wildenoflok (A), 
Isivumba,  
Bulb Crush, boil in water to make 
infusion 
Cold infusion to 
douche children; hot 
infusion  for  coughs, 
fever; as purgative 
Zantedeschia aethiopica L. 
Spreng.  
 
Araceae Inyibiba Leaves  Warm leaves as plasters, 
infusion for oral use 
Dressing for wounds, 
boils, sores and minor 
burns. Oral use to aid 
wound healing 
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4.5. Published studies on the selected plants 
A large number of studies have been conducted on the identified plants investigating their 
potential for therapeutic effects. Of the 15 plants identified in this study, Hypoxis 
hemerocallidea, Lessertia frutescens and Tulbaghia violacea are popular in the literature for 
the management of HIV/AIDS-related disorders.  
Hypoxoside, sterols and sterolins are important components of Hypoxis hemerocallidea that 
have been identified and thought to be responsible for pharmacological benefits (Albrecht et 
al., 1995). A geophyte with bright yellow flowers giving it its common name „yellow stars‟, H. 
hemerocallidea has found use traditionally in the treatment of benign prostatic hyperplasia in 
South Africa (Buck, 1996; Lowe and Ku, 1996; Marandola et al., 1997; Owira and Ojewole, 
2009); as purgative and delirium remedy among the Zulus of South Africa (Msonthi and 
Magombo, 1983); used to treat abdominal pain, fever, anorexia and vomiting by the Karanga 
people of Southern Africa (Watt and Breyer-Brandwijk, 1962; Mogatle et al., 2008); for 
uterine cancer in Swaziland (Amusan et al., 1995); and for sexual-related disorders in 
Mozambique (Banderia et al., 2001). Its major phytochemicals, hypoxoside and rooperol 
have been investigated for cancer therapy (Smit et al., 1995). Various other studies have 
suggested more therapeutic effects derivable from the corm African potato (Table 11). 
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Table 11: Published studies of the therapeutic effects of H. hemerocallidea 
Effects investigated Methodology Reference 
Anti-inflammatory effects Aqueous and methanolic extracts of the corm in rat 
model 
Ojewole, 2002 
Hypoglycaemic activity Aqueous extract of the corm in rat model Mahomed and 
Ojewole, 2003 
Antinociceptive, antidiabetic 
and anti-inflammatory effects 
Aqueous extract of the corm in mice and rat models Ojewole, 2006 
Hypotensive and 
cardiodepressant activity 
Corm extract isolated guinea pig cardiac muscle (in 
vitro) and on hypertensive rats (in vivo) 
Ojewole et al., 
2006 
Antioxidant activity In vitro investigation of hypoxoside, rooperol (both 
phytochemical constituent) and aqueous preparation 
on rat liver tissue  
Nair et al., 2007; 
Laporta et al., 
2007 
Anticonvulsant activity Aqueous extract of corm in rat model Ojewole, 2008 
Uterolytic effect Aqueous extract of corm on uterine horns isolated from 
rats and guinea pigs 
Nyinawumuntu 
et al., 2008 
Antidiarrheal activity Aqueous extract of corm in mice Ojewole, 2009 
Bronchorelaxant effect Aqueous extract of corm on tracheal smooth muscle 
isolated from guinea pig 
Ojewole et al., 
2009 
Prevention and treatment of 
inflammatory GIT disorders 
Methanolic extract in mice Liu et al., 2010
 
Antimicrobial activity Aqueous, ethanolic and petroleum ether extract of leaf 
and corm 
Ncube et al., 
2012
 
Effective in the treatment of 
benign prostatic hyperplasia 
Multicentric, placebo-controlled, double-blind clinical 
trials using beta-sitosterol, a bioactive component 
Berges et al., 
1995; Klippel et 
al., 1997 
Anti-cancer activity Human studies using hypoxoside Albrecht et al., 
1995
 
 
 
Widely known as cancer bush or kankerbos (Afrikaans) because of its traditional use in the 
management of cancer, Lessertia frutescens is one of the most reputable herbal remedies 
widely used among patients with HIV/AIDS to boost immunity (Prevoo et al., 2004; 2008). Its 
decoction is employed in the treatment of open wounds, fever, chicken pox, gastrointestinal 
cramps, rheumatism, heartburn, haemorrhoids, diabetes, inflammation and eye infections 
among indigenous South Africans (Van Wyk and Albrecht, 2008). It has been investigated for 
many of the anecdotal claims. Studies have suggested some possible anti-retroviral (Harnett 
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et al., 2005; Minocha et al., 2011), anti-cancer (Stander et al., 2007; 2009; Skerman et al., 
2011), anti-diabetic (Chadwick et al., 2006; Mackenzie et al., 2009; 2012; anti-inflammatory 
(Ojewole, 2004), anti-infective (Katerere and Eloff, 2005) anti-stress (Prevoo et al., 2004) and 
anti-convulsant effects (Ojewole, 2008).  
Tulbaghia violacea is traditionally used for the treatment of respiratory disorders including 
tuberculosis, asthma; gastrointestinal ailments, oesophageal cancer, fungal infection, fever 
and colds (Van den Heever et al., 2008). The close association between HIV/AIDS and 
tuberculosis has made it popular among people living with HIV/AIDS in South Africa. It 
contains a C–S lyase, cysteine and tetrathiaoctane derivatives (Kubeca et al., 2002). It 
inhibits angiotensin converting enzyme (ACE) supporting its use in hypertension (Duncan et 
al., 1999). Its extracts inhibited the growth of cancer cells and induced apoptosis in an in vitro 
study (Bungu et al., 2006). Other studies have suggested its anthelmintic (McGaw et al., 
2000) and antifungal activity especially against Candida albicans, a common cause of 
infection in HIV/AIDS patients (Motsei et al., 2003; Thamburan et al., 2006). 
Spirostachys africana is widely distributed in the vegetations of Southern Africa. A number of 
phytochemicals including stachenone, diosphenol and diterpenoid derivatives have been 
isolated and identified as active constituents (Duri et al., 1992). The latex is traditionally used 
in South Africa and Zimbabwe as purgative, to stimulate emesis, and manage infective 
diarrhoea and dysentery (Gelfand et al., 1995); as antimalarial in Tanzania and Mozambique 
and as topical anti-infective in South Africa (Munkombwe et al., 1997; 1998). It is used in 
South Africa, especially among the IsiXhosa-speaking people for the topical treatment of 
infantile cradle cap known locally as ishimca (Beach et al., 2010). In vitro studies have shown 
antimicrobial activity of isolated compounds against Escherichia coli, Salmonella typhi, 
Shigella dysentery, Staphylococcus aureus and Vibrio cholera (Mathabe et al., 2006; 2008). 
A clinical study of the antimalarial preparation from S. africana conducted in Mozambique 
reported significant reduction in parasitaemia (Jurg et al., 1991). 
Bowiea volubilis is known variously as climbing onion, ugibisisila or iguleni (isiZulu), 
umgaqana (IsiXhosa), gibizisila (IsiSwati) and Knolklimop (Afrikaans). It is widely sought after 
by indigenous South Africans for numerous medical conditions including dermatological 
disorders, sore eyes, urinary complications, infertility, facilitation and induction of 
abortion/abortion (Steenkamp, 2003). Some studies have claimed that its extracts 
demonstrated moderate in vitro antibacterial and antifungal activity (Buwa et al., 2006; Van 
Vuuren and Naidoo, 2010). 
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The leaves of Zantedeschia aethiopica contain triterpenes, α-linolenic acid, galactolipids and 
sterols which possess activity against algae (Greca et al., 1998). Kee and co-workers (2008) 
reported that its extracts inhibited inhibition of thrombin-induced clotting in an in vitro study. 
Chemopodium album is a popular edible herb known locally as Imbikilicane (IsiZulu). It is 
consumed nutritionally and for gastrointestinal complaints. In vitro antioxidant and anti-
inflammatory activity of its extracts has been reported (Lindsey et al., 2002).  
Alepidea amatymbica is one of the popular medicinal plants used for the treatment of 
abdominal disorders, constipation, respiratory tract infections and cold. Mulaudzi and co-
workers (2009) reported that its extracts demonstrated in vitro antibacterial and anti-
inflammatory activity.  
The leaves and bark of Acacia karroo contain proanthocyanidin and flavonols which possess 
antioxidant analgesic and membrane-stabilizing properties (Malan and Swartz, 1995; 
Adedapo et al., 2008).  
Emex australis is a common weed in South Africa used traditionally for gastrointestinal 
disorders. It possesses anti-inflammatory properties (Akula and Odhav, 2008). 
Capparis sepiaria contains α, β-amyrin, erythrodiol, taraxasterol, triterpin alcohol, betulin, β-
sitosterol, n-octacosanol, glycosides, alkaloids and amino acids (Rajesh et al., 2010). It is 
used in the treatment of oral ulcers (Hebbar et al., 2004). A study in animals has reported 
glucose-lowering activity in extracts from its leaves (Selvamani et al., 2008). 
Pentanisia prunelloides is used traditionally among the Zulus to facilitate labour. It has been 
shown to exhibit direct smooth muscle activity on rat uterus and ileum preparations (Kaido et 
al., 1997). Its extract was reported to inhibit the activitity of cyclooxygenasein an in vitro 
study; demonstrate antibacterial activity against Bacillus subtilis, Staphylococcus aureus, 
Escherichia coli and Klebsiella pneumoniae; and inhibit viral replication of influenza A virus 
(Yff et al., 2002).  
 
4.6. Discussion 
Apart from the identified medicinal herbs commonly used by the THP, the traditional health 
practices of the THPs demonstrated persistence of culture and tradition despite changes in 
location. This is because the THPs source their medicinal herbs from Eastern Cape on 
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regular and seasonal basis. Thus strong popularity of traditional health practices in Eastern 
Cape is carried through to these Black communities.  
H. hemerocallidea, S. frutescens and T. violacea are generally associated with the traditional 
management of HIV/AIDS in South Africa. Besides these three, most of the other plants 
identified in this study are often administered for other conditions. Due to the presence of co-
morbidities in HIV/AIDS patients, especially opportunistic infections, people living with 
HIV/AIDS consume them due to the various anecdotal reports of therapeutic benefit. In 
traditional health practice, precise instruction for medicinal herb use is therefore important. 
Phytochemical studies usually show significant variation in the chemical constituents of the 
different plant parts. This may explain the anecdotal belief in different indications for different 
parts of the same plants. 
Infusions and decoctions are the most common herbal preparations used by the THPs. 
Infusions are made usually from leaves in hot water, left or shaken for about 30 minutes to 
few hours while decoction involves boiling usually harder plant parts like roots, bark and 
stem. All preparations are taken orally. In addition, decoction from Kedrostis africana is 
applied as topical wash for skin rash while extracts of Ranunculus multifidus are used as 
enemas. The involvement of multiple dosage routes for the same dosage formulation is a 
demonstration of the flexibility and sophistication of traditional medicine. All the traditional 
indications for the identified plants have well-established conventional drug treatment. 
However, there are insufficient data from relevant clinical studies to verify the effectiveness of 
the herbal preparations.  
The literature search has demonstrated the extent of studies conducted on these plants. 
Apart from Kedrostis Africana, the search for which yielded no relevant study to the 
therapeutic claims, the identified plants in this study have been studied to some extent. Such 
studies are limited to in vitro and limited animal studies. Safety data on the use of the 
medicinal herbs are still not available.  
Most importantly, the effect of the identified medicinal herbs on metabolic enzymes and drug 
transporters is unknown. In the event of concomitant use conventional standard drug therapy 
of the respective indications, pharmacokinetic herb-drug interaction is a source of clinical 
concern (see Chapter 2). This has been the basis for the selection of these medicinal herbs 
for HDI assessment in this study. 
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CHAPTER FIVE 
INVESTIGATION OF THE INHIBITORY EFFECT OF SELECTED MEDICINAL HERBS ON 
CYP1A2, CYP2C9, CYP2C19 AND CYP3A4 
5.0. Summary 
The potential of the crude extracts of the 15 selected medicinal herbs to inhibit CYP1A2, 
CYP2C9, CYP2C19 and CYP3A4 was assessed using phenacetin O-dealkylation diclofenac 
4‟-hydroxylation, S-mephenytoin 4‟-hydroxylation and testosterone 6β-hydroxylation 
respectively as probe reactions. The inhibitory effect, where observed, was quantified and 
expressed in IC50 (the concentration of extracts that caused 50% inhibition of CYP activity) as 
presented in Table 12. 
 
Table 12: Summary of the inhibitory effects of the medicinal herbs on CYP1A2, CYP2C9, 
CYP2C19 and CYP3A4 
Medicinal plant IC50 value (g/mL) 
CYP1A2 CYP2C9 CYP2C19 CYP3A4 
Lessertia frutescens 
(methanolic) 
35.3 ± 3.6 24.4 ± 2.2 42.1 ± 3.2 26.4 ± 2.0 
Lessertia frutescens (aqueous) 4.3 ± 0.3 5.9 ± 2.3 10.0 ± 0.8 32.6 ± 3.5 
Hypoxis hemerocallidea 29.0 ± 6.0 - 220.4 ± 15.2 20.4 ± 1.6 
Spirostachys africana  14.3 ± 0.6 - - 47.4 ± 2.4 
Bowiea volubilis  92.3 ± 5.5 - >1000 8.1 ± 0.6 
Zantedeschia aethiopica  >1000 327 ± 34.1 87.8 ± 10.1 11.7 ± 2.2 
Chenopodium album  84.8 ± 7.5 - 51.4 ± 4.3 230 ± 5.1 
Kedrostis africana  86.6 ± 2.6 16.6 ± 4.6 157.0 ± 8.8 1.3 ± 0.2 
Alepidea amatymbica  712.9 ± 71.3 96.3 ± 9.5 >1000 - 
Acacia karroo  120 ± 17 115 ± 11.3 32.9 ± 3.2 1.9 ± 0.3 
Emex australis  - 97.4 ± 8.1 >1000 7.2 ± 0.6 
Pachycarpus concolor  - 27.8 ± 5.7 35.6 ± 5.7 8.8 ± 1.1 
Ranunculus multifidus  226.4 ± 42.3 255 ± 21.6 20.3 ± 2.3 10.1 ± 1.8 
Capparis sepiaria  378 ± 45 19.3 ± 4.6 7.3 ± 1.4 3.1 ± 0.1 
Pentanisia prunelloides  - 6.8 ± 1.1 >1000 31.6 ± 2.8 
Tulbaghia violacea 767.4 ± 10.8 921 ± 15.3 >1000 >1000 
(-) indicates the absence of inhibition 
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5.1. Introduction 
5.1.1. Cytochrome P450 1A2 
The CYP1 family is made up of three subfamilies CYP1A1, CYP1A2 and CYP1B1. All three 
are transcriptionally controlled by the aryl hydrocarbon receptor-aryl hydrocarbon receptor 
nuclear translocator (AHR-ARNT) and inducible by polycyclic aromatic hydrocarbons (PAH) 
and smoking (Schmidt and Bradfield, 1996; Zevin and Benowitz, 1999). The expression of 
CYP1A1 in humans is generally low, with extrahepatic expressions in the lungs, 
lymphocytes, mammary gland, and placenta (Raunio et al., 1999). There is very little 
involvement of CYP1A1 in drug metabolism. It is however significant in its roles as activators 
of procarcinogens, thus playing important role in chemically-induced carcinogenesis (Ji et al., 
2012). Like CYP1A1, the expression of CYP1B1 is mainly extrahepatic mainly in kidney, 
prostate, mammary gland, and ovary with little involvement in the metabolism of xenobiotics 
(Tang et al., 1999). 
CYP1A2 has been shown to be exclusively expressed in the liver constituting about 13-15% 
of the total hepatic CYP content (Shimada et al., 1994; Martignoni et al., 2006). It is the 
primary enzyme responsible for the phase I metabolism of a number of drugs including 
tacrine, theophylline, and clozapine. Inducers of CYP1A2 include cigarette smoke, indole-3-
carbinol-containing vegetables, charbroiled meat, rifampicin and phenytoin.   
Phenacetin, as well as caffeine and theophylline are the most widely used in vitro and in vivo 
probe substrates for evaluating the activity of CYP1A2 (Faber et al., 2005). Phenacetin is a 
prodrug and was a popular analgesic drug in the 70s and 80s (Sanerkin, 1971; Clissold, 
1986). Following oral absorption, phenacetin is completely absorbed but undergoes pre-
systemic metabolism in the liver. Its first metabolic step is CYP1A2-catalyzed O-deethylation 
to form the active acetaminophen (paracetamol). This makes phenacetin a suitable probe 
substrate for CYP1A2 metabolic activity. Further metabolism of phenacetin usually includes 
phase two reactions of metabolite conjugation with glucuronide, sulfate or glutathione to form 
soluble complexes that are ultimately excreted in the urine. 
 
5.1.2. Cytochrome P450 2C9 
The human CYP2 family, made of A, B, C, D, E, F and J subfamilies is a heterogeneous 
group of enzymes. Those of important interest in the metabolism of xenobiotics are 
CYP2A6/7, CYP2B6, 2C9, 2C19, CYP2D6 and CYP2E1. CYP2C (mainly 8, 9, 18 and 19) 
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accounts for about 20% of the total human hepatic CYP (Gerbal-Chaloin et al., 2001; 
Martignoni et al., 2006). 
The subfamily 2C is the second most abundant CYP after 3A representing over 20% of the 
total CYP present in the human liver. It comprises three active members: 2C8, 2C9 and 2C19 
all of which are involved in the metabolism of some endogenous compounds including retinol 
and retinoic acid (Lewis, 2004) 
CYP2C9 is the most abundantly expressed CYP2C isozyme (Rettie and Jones, 2005). 
Losartan, phenytoin, tolbutamide, and S-warfarin are some of the drugs metabolized 
primarily by CYP2C9. It is induced by rifampicin while amiodarone, fluconazole, and 
sulphaphenazole are known inhibitors. 
The gene coding for the CYP2C9 enzyme has been shown to be polymorphic displaying 
significant functional variants. Thus, poor metabolizers, as a result of low CYP2C9 
expression/activity are at  risk of adverse drug reaction due to the accumulation of CYP2C9 
substrates especially those with narrow therapeutic index such as phenytoin, S-warfarin, 
tolbutamide and glipizide (Pirmohamed and Park, 2003; Ninomiya et al., 2000). Other drugs 
metabolized by CYP2C9 are Irbesartan, losartan, cyclophosphamide, tamoxifen, fluvastatin, 
celecoxib, diclofenac, ibuprofen, lornoxicam, meloxicam, naproxen, glibenclamide, 
glimepiride, sulfonylurea, glipizide and tolbutamide, proton pump inhibitors (omeprazole, 
lansoprazole, pantoprazole, and rabeprazole), tricyclic antidepressants (imipramine, 
amitriptyline, and nortriptyline), selective serotonin reuptake inhibitors (citalopram, fluoxetine, 
and sertraline, moclobemide (an antidepressant), benzodiazepines (diazepam). 
One of the most well established in vitro CYP2C9-specific probe substrate is diclofenac 
(Konecný et al., 2007; Tai et al., 2008). CYP2C9 is responsible for the 4'-hydroxylation of 
diclofenac. The generation of 4'-hydroxydiclofenac in an in vitro CYP2C9 medium from 
diclofenac is a typical CYP2C9 probe. 
 
5.1.3. Cytochrome P450 2C19 
CYP2C19 is one of the important CYP in drug biotransformation. It catalyzed the phase I 
metabolism of approximately 10% of commonly used drugs (Gardiner and Begg, 2006). 
Important drugs metabolized by CYP2C19 include proton pump inhibitors (omeprazole, 
lansoprazole, pantoprazole, and rabeprazole), tricyclic antidepressants (amitriptyline, 
imipramine, and nortriptyline) and selective serotonin reuptake inhibitors (citalopram, 
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fluoxetine, and sertraline). Others are benzodiazepines (diazepam, flunitrazepam, 
quazepam, clobazam), barbiturates (hexobarbital, mephobarbital, phenobarbital), 
moclobemide, phenytoin, S-mephenytoin, bortezomib, voriconazole, selegiline, proguanil and 
nelfinavir (Zhou et al., 2009).  
S-mephenytoin has been established, and used extensively as an in vitro probe substrate for 
CYP2C19 metabolic activity (Goldstein et al., 1994; Lee and Kim, 2011). 
 
5.1.4. Cytochrome P450 3A4 
CYP3A is the only subfamily of the human CYP3 family and is made of CYP3A4, CYP3A5, 
CYP3A7, and CYP3A43 isoforms.  CYP3A4 is expressed in the liver and in extrahepatic 
tissues. CYP3A4/5 accounts for about 80% of intestinal CYP where it is responsible for 
presystemic drug metabolism while CYP3A7 is found in fetal liver (Paine et al., 2006).    
The CYP3A4 enzyme is the most important drug-metabolizing CYP accounting for about 
40% of the total hepatic CYP (although the levels may vary 40-fold among individuals), and 
50% of all CYP-mediated drug metabolism (Rendic, 2002; Ferguson and Tyndale, 2011; 
Singh et al., 2011). The inhibition of both intestinal and liver CYP3A4 has been shown to 
contribute to drug-drug interaction (Galetin et al., 2007). Examples of CYP3A4 substrates 
include the viral protease inhibitors, calcium channel blockers, statins, quinidine, 
erythromycin, cyclosporin, midazolam and triazolam. It is also responsible for the metabolism 
of endogenous substances such as testosterone, androstenedione and progesterone.  .  
About 40-fold inter-individual variation in the hepatic expression and metabolic function of 
human hepatic CYP3A4 has been reported (Lamba et al., 2002). It is therefore important to 
anticipate variation in the influence of the inhibition of CYP3A4 on the pharmacokinetics of 
administered substrates in different population groups. 
Midazolam, testosterone, erythromycin, nifedipine, and felodipine have been used as probes 
for CYP3A4 activity with overlapping substrate specificity with CYP3A5 (Table 13). 
Rifampicin, dexamethasone and phenobarbital are known inducers of CYP3A4 while 
ketoconazole is a typical inhibitor. Due to the importance of CYP3A4 in drug metabolism and 
the genetic polymorphism associated with its expression, it is a recommended practice to 
investigate it with two different substrates (Bjornsson et al., 2003). 
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Table 13: Some validated probes substrates of CYP3A4/5 (adapted and updated from 
Lakhman et al., 2009) 
Probe substrates Metabolized by 
 CYP3A4 CYP3A5 
Alfentanil Yes Yes 
Alprazolam No Yes 
Erythromycin Yes No 
Cortisol Yes Yes 
Midazolam Yes Yes 
Quinidine Yes No 
Tacrolimus No Yes 
Testosterone Yes  Yes  
Triazolam Yes Yes 
Vincristine No Yes 
 
 
5.2. Aims and objectives 
The aim of the present study was to assess the inhibitory activity of the crude extracts of the 
selected medicinal plants identified in Chapter Four on CYP1A2, CYP2C9, CYP2C19 and 
CYP3A4.  
Specific objectives were to 
1. optimize in vitro CYP-catalyzed reaction in HLM and using phenacetin and diclofenac as 
probe substrates 
2. determine the enzyme kinetic parameters from such optimized technique in 1 above 
3. apply the optimized methods to investigate the influence of the herbal extracts on 
CYP1A2, CYP2C9, CYP2C19 and CYP3A4 activity compared to furafylline, 
sulfaphenazole, ticlopidine and ketoconazole, the respective standard inhibitors of 
CYP1A2, CYP2C9, CYP2C19 and CYP3A4 
4. assess time-dependent inhibition of CYP3A4-catalyzed metabolism of midazolam by 
extracts of Lessertia frutescens. 
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5.3. Materials and Methods 
5.3.1. Materials 
5.3.1.1. Medicinal herbs 
Medicinal herbs employed for this study are those identified in Chapter 4 (Table 10). 
5.3.1.2. Chemical compounds 
The necessary chemical compounds were obtained as indicated: 1‟-hydroxybufuralol 
maleate, 1‟-hydroxymidazolam, 4‟-hydroxymephenytoin, 6β-hydroxytestosterone, bufuralol 
hydrochloride and midazolam from Ultrafine Chemicals (Pty) Ltd (Manchester, UK); 6-
hydroxychlorzoxazone, 7-hydroxycoumarin, acetaminophen, bupropion, chlorzoxazone, 
coumarin, furafylline, NADPH , estradiol-17β-D-glucuronide (sodium salt), paclitaxel, 
tranylcypromine, troleandomycin (TAO), warfarin, rifamycin, thioconazole, digoxin, 
cyclosporin A and testosterone from Sigma-Aldrich (Pty) Ltd (St. Louis, USA); 
dimethylsulfoxide (DMSO), di-potassium hydrogen phosphate (K2HPO4), acetonitrile, formic 
acid and methanol from Merck Chemicals (Pty) Ltd (Darmstadt, Germany); [13C6] 4‟ 
hydroxydiclofenac, [13C6] 7 hydroxycoumarin, [
2H3] 4‟-hydroxymephenytoin, diclofenac and 
paroxetine from Novartis Pharma AG (Basel, Switzerland); hydroxybupropion, [2H6] 
hydroxybupropion and [2H9] 1‟-hydroxybufuralol from BD Biosciences (Pty) Ltd (San Jose, 
USA); 6α-hydroxypaclitaxel from Gentest BD Biosciences (Woburn, USA); [2H3] 6β-
hydroxytestosterone, [2H4] 1‟-hydroxymidazolam from Cerilliant Chemicals (Pty) Ltd (Texas, 
USA); phenacetin,  magnesium chloride hexahydrate, ticlopidine hydrochloride and 
potassium dihydrogen phosphate (KH2PO4) from Fluka Chemicals (Pty) Ltd (Buchs, 
Switzerland); 4‟-hydroxydiclofenac from Calbiochem (Pty) Ltd (La Jolla, USA), (3S,6S,12aS)-
1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-
dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester (Ko143) 
from Tocris Bioscience (Pty) Ltd (Ellisville, MI); 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine-2 (PhIP) and its radio-labeled from (1.85 MBq/nmol, radiochemical purity >99%) 
from Toronto Research Chemicals (Pty) Ltd (North York, Canada); radio-labeled [3H]Digoxin 
(1.103 MBq/nmol, radiochemical purity >97%) and [3H]estradiol-17β-D-glucuronide (1.72 
MBq/nmol, radiochemical purity >97% from Perkin Elmer Radiochemicals (Pty) Ltd 
(Waltham, MA, USA); zosuquidar trihydrochloride (LY335979) from Chembiotek (Pty) Ltd 
(Kolkata, India). Other chemicals and reagents employed were of analytical grade. 
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5.3.1.3. Assay enzymes and cells 
Pooled mixed gender HLM prepared from 50 individual donors with total CYP and 
cytochrome b5 content of 290 pmol/mg protein and 790 pmol/mg protein respectively was 
obtained from Gentest BD Biosciences (Woburn, USA). The Catalytic activities of enzymes 
were provided by the manufacturer (Table 14).  
 
Table 14: Enzyme activities of human liver microsomes 
Enzyme Assay Activity  
(pmol/(mg protein • min)) 
CYP1A2 phenacetin O-deethylase 580 
CYP2A6 coumarin 7-hydroxylase 1100 
CYP2B6 (S)-mephenytoin N-demethylase 90 
CYP2C8 paclitaxel 6-hydroxylase 69 
CYP2D6 bufuralol 1'-hydroxylase 68 
CYP2E1 chlorzoxazone 6-hydroxylase 2500 
CYP3A4/5 testosterone 6β-hydroxylase 5800 
CYP4A11 lauric acid 12-hydroxylase 1700 
FMO methyl p-tolyl sulfide oxidase 1000 
UGT1A1 estradiol 3-glucuronidation 1200 
UGT1A4 trifluoperazine glucuronidation 740 
UGT1A9 propofol glucuronidation 5200 
P450 oxidoreductase cytochrome c reductase 340 
 
5.3.2. Methods 
5.3.2.1. Extraction of herbal products 
Based on the obtained information on method of use of the medicinal herbs identified in 
Chapter 4 (Table 10), the dried herbal materials were powdered and extracted with water. In 
addition, Lessertia was extracted with 60% methanol. 
Dried samples (leaves, corm, root, back or stem, as appropriate; Table 10) were powdered, 
weighed, and stirred in distilled water (50 mg/mL, 100ºC, 2 hr) and left to extract for 24 hr. 
The extracts were centrifuged, filtered through a 0.45 μm membrane filter system and freeze 
dried. Stock solutions of 20 mg/mL of dried extracts were made in water and stored at -20°C. 
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Lessertia is consumed both as aqueous decoction and often as whole leave (available in 
commercial capsule preparations of dried leaves). The air-dried and powdered leaves of 
Lessertia were extracted with water/methanol (40/60, 20 g/mL) in round bottom flask. After 
the initial constant stirring for 2 hr, the mixture was allowed to extract for 24 hr, decanted, and 
centrifuged (20,000 g, 5min). The supernatant was filtered (0.45 µL; Whatman International 
LTD, Maidstone, England) and dried using a vacuum rotary evaporator and freeze drying. 
The dried extract was reconstituted in methanol and stored at -20ºC for further use. 
 
5.3.2.2. Preparation of CYP substrates and microsomal dilutions for incubation 
Solutions of phenacetin, diclofenac, S-mephenytoin, testosterone and midazolam were 
prepared in 50% methanol over a range of 0.1-100 mM (0.1, 0.5, 1, 2, 4, 7.5 and 10 mM). 
Frozen (-80°C)  HLM (20 mg/mL) was thawed in water at room temperature (25°C) and 
appropriate volume was measured with a micropipette, diluted in 0.5 M phosphate buffer (pH 
7.4) to produce a final protein concentration of 0.4 mg/mL. This solution was kept on ice until 
further use. 
 
5.3.2.3. Optimization of in vitro metabolism 
Dilution of the test substance (phenacetin and diclofenac) stock solutions was done in 
methanol. Incubations were conducted in a 96-well plate format at 37°C using an IS89 96-
well plate incubator (Wesbart, Leimuiden, The Netherlands). The final methanol 
concentration in the incubations was <1% (v/v). The wells were filled with 250µL of the 
prepared HLM mixture. 5µL of each concentration of prepared phenacetin and diclofenac 
solutions was pre-incubated with 250µL HLM mixture. This was followed by the initiation of 
metabolic reaction through the addition of 245µL NADPH solution. The total volume of the 
incubation was 500µL with the final substrate concentration of 1, 5, 10, 20, 40, 75 and 100 
µM. Samples were incubated for 20 min at 37°C. Metabolic reactions were terminated by the 
addition of 10 µL 50% formic acid. By general standard, samples were tested in duplicates 
and repeated at a different day. The intra-plate, and inter-day variations were always less 
that 10% (which is the acceptable standard (Bjornsson et al., 2003). The composition and 
conditions of the incubation mixtures are summarized in Table 15. 
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Table 15: Microsomal incubation conditions for CYP1A2, CYP2C9, CYP2C19 and CYP3A4-
catalyzed reactions 
Parameters Values 
Concentration of potassium phosphate buffer, pH 7.4 in incubation mixture  50 mM 
Concentration of magnesium chloride in incubation mixture 5 mM 
Incubation pH 7.4 
Final graded concentration of herbal extracts 0 – 100 µg/mL 
Concentration of DMSO/methanol in incubation mixture 0.5%(
v
/v)  
Final concentration of NADPH in the incubation mixture 1 mM  
Incubation time 20 min 
CYP1A2 
CYP1A2-specific metabolite Acetaminophen    
HLM Concentration 0.2mg protein/mL 
Positive control Furafylline 
Initial phenacetin concentration  10 µM 
Literature Km values 14
a
, 31
b
, 54
c
 
 
CYP2C9  
CYP2C9-specific metabolite 4‟-hydroxydiclofenac  
HLM Concentration 0.1mg protein/mL  
Positive control Sulfaphenazole  
Initial diclofenac concentration  5 µM  
Literature Km values 9.0 µM
d
  
 
CYP2C19  
CYP2C19-specific metabolite 4'-hydroxy-mephenytoin  
HLM Concentration 0.5 mg protein/mL  
Positive control Ticlopidine   
Initial S-mephenytoinl concentration  30 µM  
Literature Km values 51
e
, 42
f
, 31
g
  
 
CYP3A4 
CYP3A4-specific metabolite 6-hydroxy-testosterone,  
1-hydroxymidazolam 
 
HLM Concentration (mg protein/mL) 0.2 (testosterone), 0.1 (midazolam)  
Positive control Ketoconazole  
Initial substrate concentration (µM) 30 (testosterone), 1 (midazolam)  
Literature Km values 50-60
h
, 51
i
 (testosterone), 3.3
j
, 2.5-
5.6
k
 (midazolam) 
 
 
a
Brøsen et al., 1993; 
b
Venkatakrishnan et al., 1998a; 
c
Rodrigues et al., 1997; 
d
Bort et al., 1999; 
e
Coller 
et al., 1999; 
f
Venkatakrishnan et al., 1998b; 
g
Schmider et al., 1996; 
h
Draper et al., 1998; 
i
Kenworthy et 
al., 2001; 
j
von Moltke et al., 1996; 
k
Ghosal et al., 1996 
 
5.3.2.4. Incubations with herbal extracts for IC50 determination 
Graded concentrations of the herbal extracts were prepared in water (or methanol, as 
appropriate) such that the addition of 5 µL to the 500 µL incubation mixtures yielded a final 
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crude extract concentration ranging from 1 – 100 µg/mL respectively. CYP substrate solution 
was added and the mixture pre-incubated at 37°C for 10 minutes using an IS89 96-well plate 
incubator (Wesbart, Leimuiden, The Netherlands). Metabolic reactions were initiated by 
adding NADPH solution and terminated after 20 minutes through the addition of formic acid 
(10 µL; 50%). All incubations were performed in duplicate. Positive control incubations (with 
CYP-specific inhibitors (as specified in Table 15) were performed alongside. Negative control 
incubations were conducted without inhibitors or herbal extracts (0 µg/mL extract 
concentration). Reactions terminated at time 0 (T0; terminated before the addition of NADP 
solution) were used as independent controls to ascertain the absence of metabolism before 
initiation. Herbal samples were tested in duplicates and repeated at a different day. The intra-
plate, and inter-day variations were always less that 10% (which is the acceptable standard 
(see Bjornsson et al., 2003). The final methanol concentration in the incubations was <1% 
(v/v). The concentrations of CYP substrates used were less than the determined or published 
Km values (Table 15). 
 
5.3.2.5. Post Incubation and quantitative analysis  
LC-MS methods were developed to analyze CYP substrates/metabolites. Total separation 
and elution of the analytes were achieved within 10 minutes run time. Reproducibility of the 
quantitative analysis was assessed through repeat injections at different times. Intra-day and 
inter-day variations were insignificant (less than 5%). LC/MS conditions are summarized in 
Table 16.  
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Table 16: Summary of the LC/MS analytical conditions for the quantitative determination of the metabolites 
Conditions Acetaminophen 4‟-hydroxy-
diclofenac 
4'-hydroxy-
mephenytoin 
6-hydroxy-
testosterone 
1-hydroxy-
midazolam 
Mobile phase (plus 0.1% 
formic acid) 
A: Water 
B: Acetonitrile 
Gradient of mobile phase: 
 
Time 
range 
A 
(%) 
B 
(%) 
0.0-1.0 65 35 
1.0-1.1 1.0 99 
1.1-5.5 1.0 99 
5.5-5.6 65 35 
5.6-10 65 35 
 
Time 
range 
A 
(%) 
B 
(%) 
0.0-1.0 50 50 
1.0-2.0 5 95 
2.0-8.0 5 95 
8.0-8.1 50 50 
8.1-11. 50 50 
 
Time 
range 
A 
(%) 
B 
(%) 
0.0 - 0.5 85 15 
0.5 - 2.0 55 15 
2.0 - 4.0 5 95 
4.0 - 4.2 5 95 
4.2 - 8.0 85 15 
8.0 85 15 
 
Isocratic 70% A and 30% B 
Injection volume (L) 2.5  2 
Flow speed (L / min) 300 60 
Column type Luna Phenyl-Hexyl 3 µm, inner dimensions 50 x 1 mm (Phenomenex, Torrance, USA) 
Column temperature 40°C 30°C 
Nebulizing temperature 375°C 
Mode Positive Negative Positive 
Quantifier transition (m/z) 180.2 / 110.1 293.88/249.00 169.4/102.3 289.2/96.8 326/291 
Qualifier transition(s) 
(m/z) 
180.2 / 138.1 No qualifier with a suitable intensity 342/203 
Dwell time (msec) 400  300  200  
Retention time (min) 3.35  6.65  6.65  3.2  
Total run time (min) 10  11  8  5  
Lower limit of detection 0.1 M 0.1 M 0.1 M 0.05 M 0.01 M 
Internal standard Thiacetazone (Retention time- 3.4 min; Quantifier transitions - 293.88/249.00) [2H4] 1-
hydroxymidazolam 
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Before chromatographic analysis, samples were subjected to solid-phase extraction using 
OASIS HLB 96-well plate 30 µm (30 mg) Elution plate (Waters, Milford, USA). This was 
performed by sequential washing with 1 mL each of water and water-methanol (95/5; v/v) 
followed by two elutions with 1 mL methanol. The elutes were dried employing the 96-well 
Micro-DS96 evaporator (Porvair Sciences Ltd., Shepperton, UK) at 37°C and reconstituted in 
100 µL of 10% acetonitrile containing 0.1% formic acid for LC-MS analysis.  
Enzyme activity was measured in terms of substrate depletion/metabolite formation. The rate 
of substrate metabolism was profiled against substrate concentrations employing the 
SigmaPlot® Enzyme Kinetic Software (SigmaPlot: Enzyme Kinetic Module, Systat Software 
Inc., Chicago, IL, USA) from where the enzyme kinetic parameters (Km and Vmax) were 
determined. 
 
5.3.2.6. Determination of IC50 of Extracts 
All absolute activities were converted into relative activities by defining the enzymatic 
activity without addition of inhibitor as 100% and recalculating the other activities relative 
to this number. The enzyme inhibition parameter (IC50) was calculated by employing the 
kinetic equation for sigmoid curves (Equation 5.1) where x = concentration; y = relative 
enzyme activity; and s = slope factor using the SigmaPlot® enzyme kinetic software. 
      Equation 5.1 
 
5.3.2.7. Incubations in HLM for the assessment of time-dependent inhibition 
Following the inhibitory effects of some of the extracts on various CYP isozymes, methanolic 
extracts of Lessertia frutescens was assessed for time-dependent inhibition of CYP3A4 
activity. For this procedure, all incubation steps were performed in a 96-well plate format at 
37°C using a liquid handling workstation epMotion 5075VAC (Eppendorf, Hamburg, 
Germany). LT (3.13, 6.25, 12.5, 25, 50 and 100 µg/mL) and positive control (5 µM 
troleandomycin) were added to phosphate buffer. After the addition of HLM (0.5mg/mL 
protein) and 10 min thermal equilibration, the reactions were initiated by adding NADPH 
(1mM). The samples were preincubated for 0, 4, 8, 16, 32 and 48 min respectively. All 
s
IC
x
y








50
1
%100
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incubations were done in duplicate. After the preincubation period, 20 µL of the microsomal 
incubations (corresponding to 0.025 mg/mL protein) were diluted 20-fold with buffer 
containing the probe substrate and NADPH (in order to minimize competitive inhibition by the 
test compounds) and incubated with midazolam (20µM) for 6 minutes at 37°C. Potassium 
phosphate buffer (1mM) was used as negative control. Reactions were terminated by the 
addition of 20 µL formic acid (50%). 
 
5.3.2.8. Calculation of kinetic parameters for time-dependent inhibition 
The enzyme activity in the presence of each inhibitor concentration was determined relative 
to activity at time t = 0. The resulting data pairs of relative enzyme activities and 
preincubation times were fitted with an Excel template in a least square approach to the 
exponential function (Equation 5.2) where y = relative activity; x = preincubation time; a = 
optimal starting value for relative activity; b = optimal negative rate of inactivation for a given 
inhibitor concentration 
 
       Equation 5.2 
 
The rate of CYP3A4 inactivation in the absence of test substance was subtracted from all 
other inactivation rates. The resulting values along with the corresponding inhibitor 
concentrations were used in a second least square fit to calculate kinetic parameters by 
linear regression to the Michaelis-Menten–like equation (Equation 5.3) where y = inactivation 
rate constant; x = inhibitor concentration; KI = inhibitor concentration that produces half 
maximal inhibition; kinact = maximal inactivation rate constant. 
 
xKI
xkinact
y



       Equation 5.3 
 
xbeay 
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5.3.2.9. Statistical analysis 
The percentage inhibition observed for the test extracts is defined in absolute terms.  The 
absolute values were obtained by comparing the metabolite production in the presence of 
test extracts, to metabolite production in the absence of any inhibitor (test extract or known 
inhibitors) (Bjornsson et al., 2003). The nonlinear-regression was generated by profiling the 
extract concentration against observed enzyme activity. The kinetic parameters were 
determined from the generated plot from the SigmaPlot® software with R2 > 0.9 and p < 0.05 
as the minimum level of significance. 
Positive controls are used in in vitro drug metabolism studies for qualitative purposes only. 
The positive controls (known CYP inhibitors) only provide indications that the enzymes can 
be inhibited in the experimental set up. By general standard, the use of HLM is for qualitative 
determination of the ability/potential of chemical substances to inhibit CYP enzymes 
(Brandon et al., 2003). The results obtained may not be linearly related to in vivo situation.  
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5.4. Results 
5.4.1. Extraction yield of the medicinal products 
The product of the crude extraction as weighed was documented, and the yield calculated 
(Table 17) 
 
Table 17: Extraction yield of the medicinal products 
Scientific name Yield (% w/w) 
Hypoxis hemerocallidea 12.6 
Lessertia frutescens  
 
Methanolic: 28.5 
aqueous: 20 
Spirostachys africana  18.1 
Bowiea volubilis  15.6 
Zantedeschia aethiopica  15.2 
Chenopodium album  17.7 
Kedrostis africana  20.6 
Alepidea amatymbica  14.5 
Acacia karroo  15.3 
Emex australis  19.0 
Pachycarpus concolor  16.5 
Ranunculus multifidus  14.1 
Capparis sepiaria  17.3 
Pentanisia prunelloides  19.2 
Tulbaghia violacea  
 
16.4 
 
5.4.2. Optimization of CYP1A2 and CYP2C9 activity 
The rate of phenacetin and diclofenac metabolism was profiled against the initial phenacetin 
and diclofenac concentrations using both the Michaelis-Menten and Hill enzyme kinetic plot 
of the SigmaPlot® EK software. The Km and Vmax of phenacetin metabolism was determined 
to be 34.3 µM and 4.9 nmol/min/mg respectively; while those of diclofenac were 7.5 µM and 
1.3 nmol/min/mg respectively (Figures 1 – 4). 
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Figure 1: Michaelis-Menten plot of the CYP1A2-catalyzed phenacetin metabolism (R2 = 
0.99) 
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Figure 2: Hill plot of the CYP1A2-catalyzed phenacetin metabolism (R2 = 0.99) 
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Figure 3: Michaelis-Menten plot of the CYP2C9-catalyzed diclofenac metabolism (R2 = 0.99) 
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Figure 4: Hill plot of the CYP2C9-catalyzed diclofenac metabolism (R2 = 0.99) 
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5.4.3. Influence of the herbal extracts on CYP activity. 
The effect of the graded concentrations of the herbal extracts and the positive control (Post 
Ctrl) were estimated. Results represent the mean of intra-day and inter-day duplicates. Intra-
day and inter-day variations were less than 10%. Figures 5 - 8 provide sample bar charts 
showing the reproducibility and the activity of control incubations. 
 
All the results were profiled in each enzyme group employing the SigmaPlot® Enzyme Kinetic 
software based on Equation 5.1.from where the IC50 values were estimated (Figures 9 - 73).  
 
 
 
 
Figure 5: The influence of graded concentrations of crude methanolic extracts of Lessertia 
frutescens on the CYP1A2-catalyzed metabolism of phenacetin 
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Figure 6: The influence of graded concentrations of crude aqueous extracts of Spirostachys 
africana on the CYP2C9-catalyzed metabolism of diclofenac 
 
 
 
Figure 7: The influence of graded concentrations of crude aqueous extracts of Chenopodium 
album on the CYP2C19-catalyzed metabolism of S-mephenytoin 
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Figure 8: The influence of graded concentrations of crude aqueous extracts of Pentanisia 
prunelloides on the CYP3A4-catalyzed metabolism of testosterone 
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5.4.3.1. Influence of the herbal extracts on CYP1A2 activity.
Lessertia frutescens (M)
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Figure 9: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 10: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Lessertia frutescens (R2 = 0.99)  
Hypoxis hemerocallidea
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Figure 11: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 
0.99)  
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Figure 12: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Spirostachys africana (R2 = 0.99) 
 
 
IC50 = 35.3 ± 3.6 g/mL IC50 = 29.0 ± 6.0 g/mL 
IC50 = 4.3 ± 0.3 g/mL 
IC50 = 14.3 ± 0.6 g/mL 
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Bowiea volubilis
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Figure 13: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Bowiea volubilis (R2 = 0.99) 
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Figure 14: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Zantedeschia aethiopica (R2 = 
0.99) 
Chenopodium album
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Figure 15: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Chenopodium album (R2 = 0.99) 
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Figure 16: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Kedrostis africana (R2 = 0.99)  
IC50 = 92.3 ± 5.5 g/mL IC50 = 84.8 ± 7.5 g/mL 
IC50 = 8378 ± 55.9 g/mL IC50 = 86.6 ± 2.6 g/mL 
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Alepidea amatymbica
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Figure 17: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Alepidea amatymbica (R2 = 0.99)  
 
Acacia karroo
Extract Concentration (µg/mL)
1 10 100
R
e
la
ti
v
e
 C
Y
P
1
A
2
 A
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
 
Figure 18: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Acacia karroo (R2 = 0.99)  
Emex australis
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Figure 19: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Emex australis (R2 = 0.99)  
 
Pachycarpus concolor
Extract Concentration (µg/mL)
1 10 100
R
e
la
ti
v
e
 C
Y
P
1
A
2
 A
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
 
Figure 20: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Pachycarpus concolor (R2 = 0.99)  
IC50 = 712.9 ± 71.3 g/mL IC50: No inhibition observed 
IC50 = 120 ± 17 g/mL 
IC50: No inhibition observed 
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Ranunculus multifidus
Extract Concentration (µg/mL)
1 10 100
R
e
la
ti
v
e
 C
Y
P
1
A
2
 A
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
 
Figure 21: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Ranunculus multifidus (R2 = 0.99) 
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Figure 22: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Capparis sepiaria (R2 = 0.99) 
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Figure 23: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Pentanisia prunelloides (R2 = 0.98)   
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Figure 24: The profile of CYP1A2-catalyzed 
metabolism of phenacetin in the presence of 
graded concentrations of crude aqueous 
extracts of Tulbaghia violacea (R2 = 0.99)  
 
 
  
IC50: No major inhibition observed  IC50 = 226.4 ± 42.3 g/mL 
IC50 = 378 ± 45 g/mL IC50 = 767.4 ± 10.8 g/mL 
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5.4.3.2. Influence of the herbal extracts on CYP2C9 activity. 
Lessertia frutescens (M)
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Figure 25: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 26: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Lessertia frutescens (R2 = 0.99) 
Hypoxis hemerocallidea
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Figure 27: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 0.99) 
 
Spirostachys africana
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Figure 28: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Spirostachys africana (R2 = 0.99)  
IC50 = 5.9 ± 2.3 g/mL IC50: No inhibition observed 
IC50 = 24.4 ± 2.2 g/mL IC50 = No inhibition observed 
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Bowiea volubilis
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Figure 29: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Bowiea volubilis (R2 = 0.99)  
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Figure 30: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Zantedeschia aethiopica (R2 = 0.99)  
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Figure 31: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Chenopodium album (R2 = 0.99)  
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Figure 32: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Kedrostis africana (R2 = 0.99) 
IC50: No inhibition observed IC50: No inbition observed 
IC50 = 327 ± 34.1 g/mL 
IC50 = 16.6 ± 4.6 g/mL 
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Alepidea amatymbica
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Figure 33: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Alepidea amatymbica (R2 = 0.99) 
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Figure 34: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Acacia karroo (R2 = 0.99)  
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Figure 35: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Emex australis (R2 = 0.99)  
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Figure 36: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Pachycarpus concolor (R2 = 0.99)  
 
 
IC50 = 96.3 ± 9.5 g/mL IC50 = 97.4 ± 8.1 g/mL 
IC50 = 115 ± 11.3 g/mL IC50 = 27.8 ± 5.7 g/mL 
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Ranunculus multifidus
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Figure 37: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Ranunculus multifidus (R2 = 0.99)  
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Figure 38: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Capparis sepiaria (R2 = 0.99) 
Pentanisia prunelloides
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Figure 39: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Pentanisia prunelloides (R2 = 0.99)  
 
Tulbaghia violacea
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Figure 40: The profile of CYP2C9-catalyzed 
metabolism of diclofenac in the presence of 
graded concentrations of crude aqueous 
extracts of Tulbaghia violacea (R2 = 0.99)   
  
  
IC50 = 255 ± 21.6 g/mL IC50 = 6.8 ± 1.1 g/mL 
IC50 = 921 ± 15.3 g/mL IC50 = 19.3 ± 4.6 g/mL 
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5.4.3.3. Influence of the herbal extracts on CYP2C19 activity
Lessertia frutescens (W)
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Figure 41: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 42: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 43: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 0.99) 
 
Spirostachys africana
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Figure 44: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Spirostachys africana (R2 = 0.99) 
 
IC50 = 42.1 ± 3.2 g/mL IC50 = 220.4 ± 15.2 g/mL 
IC50 = 10.0 ± 0.8 g/mL IC50: No inhibition observed 
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Bowiea volubilis
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Figure 45: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Bowiea volubilis (R2 = 0.99)  
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Figure 46: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Zantedeschia aethiopica (R2 = 0.99) 
 
Chenopodium album
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Figure 47: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Chenopodium album (R2 = 0.99) 
 
Kedrostis africana
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Figure 48: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Kedrostis africana (R2 = 0.99) 
 
IC50 = 87.8 ± 10.1 g/mL 
IC50 = 157.0 ± 8.8 g/mL 
IC50 = >1000 g/mL IC50 = 51.4 ± 4.3 g/mL 
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Alepidea amatymbica
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Figure 49: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Alepidea amatymbica (R2 = 0.99)  
 
Acacia karroo
Extract Concentration (µg/mL)
1 10 100
R
e
la
ti
v
e
 C
Y
P
2
C
1
9
 A
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
 
Figure 50: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Acacia karroo (R2 = 0.99)  
Emex australis
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Figure 51: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Emex australis (R2 = 0.99) 
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Figure 52: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Pachycarpus concolor (R2 = 0.99) 
 
IC50 = >1000 g/mL 
IC50 = 32.9 ± 3.2 g/mL 
IC50 = 35.6 ± 5.7 g/mL 
IC50 = >1000 g/mL 
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Ranunculus multifidus
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Figure 53: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Ranunculus multifidus (R2 = 0.99)  
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Figure 54: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Capparis sepiaria (R2 = 0.99)  
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Figure 55: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Pentanisia prunelloides (R2 = 0.99) 
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Figure 56: The profile of CYP2C19-catalyzed 
metabolism of S-mephenytoin in the presence of 
graded concentrations of crude aqueous 
extracts of Tulbaghia violacea (R2 = 0.99)
IC50 = 7.3 ± 1.4 g/mL 
IC50 = >1000 g/mL IC50 = 20.3 ± 2.3 g/mL 
IC50 = >1000 g/mL 
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5.4.3.4. Influence of the herbal extracts on CYP3A4 activity
Lessertia frutescens
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Figure 57: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99)  
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Figure 58: The profile of CYP3A4-catalyzed 
metabolism of midazolam in the presence of 
graded concentrations of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99)  
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Figure 59: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 60: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 0.99) 
 
IC50 = 32.6 ± 3.5 g/mL IC50 = 26.4 ± 2.0 g/mL 
IC50 = 28.1 ± 2.1 g/mL IC50 = 20.4 ± 1.6 g/mL 
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Spirostachys africana 
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Figure 61: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Spirostachys africana (R2 = 0.99)  
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Figure 62: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Bowiea volubilis (R2 = 0.99)  
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Figure 63: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Zantedeschia aethiopica (R2 = 0.99) 
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Figure 64: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Chenopodium album (R2 = 0.99) 
 
 
IC50 = 8.1 ± 0.6 g/mL IC50 = 230 ± 5.1 g/mL 
IC50 = 47.4 ± 2.4 g/mL IC50 = 11.7 ± 2.2 g/mL 
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Kedrostis africana
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Figure 65: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Kedrostis africana (R2 = 0.99)  
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Figure 66: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Alepidea amatymbica (R2 = 0.99) 
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Figure 67: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Acacia karroo (R2 = 0.99) 
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Figure 68: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Emex australis (R2 = 0.99) 
 
 
IC50 = 1.9 ± 0.3 g/mL IC50 = 1.3 ± 0.2 g/mL 
IC50: No inhibition observed IC50 = 7.2 ± 0.6 g/mL 
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Pachycarpus concolor
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Figure 69: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Pachycarpus concolor (R2 = 0.99) 
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Figure 70: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Ranunculus multifidus (R2 = 0.99) 
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Figure 71: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Capparis sepiaria (R2 = 0.99)  
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Figure 72: The profile of CYP3A4-catalyzed 
metabolism of testosterone in the presence of 
graded concentrations of crude aqueous 
extracts of Pentanisia prunelloides (R2 = 0.99) 
 
 
IC50 = 3.1 ± 0.1 g/mL IC50 = 8.8 ± 1.1 g/mL 
IC50 = 10.1 ± 1.8 g/mL IC50 = 31.6 ± 2.8 g/mL 
Stellenbosch University  http://scholar.sun.ac.za
96 
 
Tulbaghia violacea
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Figure 73: The profile of CYP3A4-catalyzed metabolism of testosterone in the presence of 
graded concentrations of crude aqueous extracts of Tulbaghia violacea (R2 = 0.99)  
 
 
5.4.4. Lessertia-induced time-dependent inhibition of CYP3A4 
Time-dependent (irreversible) inhibition of CYP3A4/5 by graded concentration of Lessertia 
frutescens (LT) was observed with a KI = 296 µg/mL and kinact = 0.063 min-1) under the 
conditions of this study. The influence of preincubation time, LT concentration and the 
positive control troleandomycin (TAO) on the enzymatic activity of CYP3A4/5 is illustrated in 
Figure 74. 
 
 
IC50 = >1000 g/mL 
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Figure 74: Effect of preincubation time and Lessertia extracts on the enzymatic activity of 
CYP3A4. 
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5.5. Discussion 
From the information gathered from the THPs, all the medicinal herbs are water-extracted for 
traditional use. Thus, in order to make the findings of this HDI assessment more relevant to 
immediate needs, water extraction was performed, and the yields were noted. Modern 
consumption of popular herbal products such as St John‟s wort, ginseng and ginkgo has 
taken the form of compressed tablets or whole-part capsules. This exposes consumers to 
more phytochemical constituents which are extracted in the GIT. Studies on such herbs tend 
to use organic extracts - toluene, methanol, ethanol etc – in order to obtain as much 
phytoconstituents as possible. In this study, in order to reflect what the consumers are 
exposed to, the choice of water-extraction was considered more appropriate. The advantage 
of this choice is that, only water-solube constituents as consumed by the patients are 
investigated, providing a truer reflection. On the other hand, the method of extraction 
including the filtration process which may exclude certain phytoconstituents, may provide 
variations between what is taken by consumers and what is available for HDI investigation 
after extraction.  
 
Formulations of the dried leaves of Lessertia frutescens are now commercially available in 
South Africa. It is also known that whole leaves are consumed. This exposes consumers to 
most of its constituents. In order to reflect this, a water-methanol (40:60) extraction of 
Lessertia frutescens was performed.  
The enzyme kinetic parameters especially the Km obtained from the optimization procedure 
for CYP1A2 (34.3 µM) and CYP2C9 (7.5 µM) compare satisfactorily with literature values 
(Table 15).   
There was a potent inhibition of CYP1A2 activity by a number of the herbal extracts. Apart 
from Emex australis, Pachycarpus concolor and Pentanisia prunelloides which demonstrated 
no inhibitory effects, the other herbal extracts inhibited CYP1A2 to varying degrees. A 
relative comparison (using an arbitrary IC50 value of 100 g/mL) (see Budzinski et al., 2000; 
Obach, 2000; Liu et al., 2006) showed that Alepidea amatymbica, Acacia karroo, Capparis 
sepiaria, Ranunculus multifidus, Tulbaghia violacea and Zantedeschia aethiopica are very 
weak inhibitors of CYP1A2 (IC50 > 100 g/mL). 
On the other hand, Bowiea volubilis, Kedrostis Africana, Chenopodium album, Lessertia 
frutescens (methanolic), Hypoxis hemerocallidea, Spirostachys africana and Lessertia 
frutescens (aqueous), in ascending order of potency demonstrated strong inhibition of 
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CYP1A2 activity (IC50 = 1-100 g/mL). It is also interesting to note the variation in the 
inhibitory activity of aqueous and methanolic extracts of Lessertia.  This is an indication of the 
differences in the phytochemical composition of the two extracts which reflects the variation 
in solubility. It suggests that the inhibitory phytochemical would be available in vivo to 
patients who consume either of whole leaves capsules or aqueous decoctions, as is the 
practice. 
CYP1A2 is responsible for the primary metabolism of a wide range of clinical drugs (Table 
18). For similar in vivo inhibitory effects on CYP1A2 activity, similar concentrations of 
phytoconstituents must be achieved after herbal intake. While information on the absorption 
of the herbal products is not available, the influence of the herbs on the drug metabolizing 
enzymes of the GIT may affect the absorption of concomitantly administered drugs. This may 
not be very important for CYP1A2 substrates because CYP1A2 is mainly expressed in the 
liver. If significant phytochemical constituents are absorbed however, with the potential of 
reaching blood levels comparable to the estimated in vitro IC50 values, a wide range of 
clinical drugs will be susceptible to herb-induced accumulation as a result of CYP1A2 
inhibition. 
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Table 18: Some examples of CYP1A2 substrates (adapted from Zou et al., 2009) 
Drug  Drug class  Metabolic pathway (s) Estimated contribution 
by CYP1A2 (%) 
R-Acenocoumarol Oral anticoagulant 6-Hydroxylation 10-20 
Acetaminophen Analgesic Oxidation 10-15 
Albendazole Benzimidazole anthelmintic 4-hydroxylation 5-10 
Almotriptan Selective 5-HT1B/1D agonist (for 
treating migraine) 
N-demethylation 5-10 
Alosetron Selective 5-HT3 antagonist (for 
irritable bowel syndrome) 
N-dealkylation and 
hydroxylation 
10-20 
Amiodarone Antiarrhythmic N-deethylation 5-10 
Aminoflavone Anticancer 3-hydroxylation 10-20 
Aminopyrine Analgesic N-demethylation 40-50 
Amitriptyline Tricyclic antidepressant 10-Hydroxylation 5-10 
Antipyrine Analgesic N-demethylation and 3- and 
4-hydroxylation 
10-25 
Azelastine Antihistamine N-demethylation 5-10 
Bortezomib Proteasome inhibitor (for 
treatment of multiple myeloma) 
Deboronation and 
dehydrogenation 
10-25 
Bufuralol β-Blocker 1′-Hydroxylation 5-10 
Caffeine CNS stimulant N-demethylation 95 
Carbamazepine 2- and  Anticonvulsant 3-Hydroxylation 5–10 
Carvedilol  β-Blocker 8-Hydroxylation and O-
demethylation 
5–10 
Cinnarizine   Antihistamine N-dealkylation 5–10 
Clomipramine  Tricyclic antidepressant N-demethylation 5–10 
Clozapine  Antipsychotic  N-demethylation and N-
oxidation 
40–55 
Coumarin  Anticancer 7-Hydroxylation 5–10 
Cyclobenzaprine  Tricyclic antidepressant N-demethylation 5–10 
5,6-
Dimethylxanthenone-4 
acetic acid  
Anticancer 6-Methyl hydroxylation 10–20 
Diphenhydramine  Antidepressant  N-demethylation 5–10 
Duloxetine Antihistamine  4-, 5-, and 6-Hydroxylation 30–40 
Efavirenz  
 
Non-nucleoside reverse 
transcriptase inhibitor 
7- and 8-Hydroxylation 5–10 
Erlotinib Epidermal growth factor 
receptor tyrosine 
kinase inhibitor (for cancer 
treatment) 
O-demethylation  
 
5–10 
Estradiol Steroid in oral contraceptives 2- and 4-hydroxylation 5–10 
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Flunarizine  Antihistamine N-dealkylation 5–10 
Flutamide Non-steroidal antiandrogen for 
prostate cancer treatment 
2-Hydroxylation 10–25 
 
Fluvoxamine SSRI O-demethylation 5–10 
Furafylline Antiasthmatic   10–20 
Guanabenz  α2-Adrenoreceptor agonist 
(antihypertensive) 
N-hydroxylation 5–10 
Haloperidol Antipsychotic  N-dealkylation  5–10 
Imatinib Bcr-Abl tyrosine kinase 
inhibitor (as anticancer agent) 
O-demethylation  
Indiplon Hypnotic drug N-demethylation 5–10 
 
Imipramine Tricyclic antidepressant N-demethylation  10–20 
KR-62980  
 
 
Selective peroxisome 
proliferator-activated 
receptor-γ modulator 
Hydroxylation 5–10 
 
KR-63198  
 
Selective peroxisome 
proliferator-activated 
receptor-γ modulator 
Hydroxylation 5–15 
 
Leflunomide  
 
Disease-modifying anti-
inflammatory agent 
N―O bond cleavage 40–55 
Lidocaine  
 
Antiarrhythmic and local 
anesthetic drug 
N-deethylation and 3-
hydroxylation 
10–20 
Maprotiline  Antidepressant  5–10 
Melatonin  
 
Pineal hormone 6-Hydroxylation and O-
demethylation 
40–60 
Mexiletine  
 
Antiarrhythmic drug Para- and 2-hydroxylation 10–20 
Mianserin  Antidepressant N-oxidation and N-
demethylation 
5–10 
Mirtazapine  
 
Antidepressant N-oxidation, 8-
hydroxylation, and N-
demethylation 
5–15 
Naproxen  NSAID O-demethylation 5–10 
Nabumetone  NSAID Aliphatic hydroxylation 30 
Nicotine  Agent for treating nicotine 
dependence 
N-hydroxylation and C-
oxidation 
5–10 
Nortriptyline  Tricyclic antidepressant 10-Hydroxylation 5–10 
Olanzapine  Atypical antipsychotic drug N-demethylation, and 4- 
and 7-hydroxylation 
30–40 
Ondansetron  Selective serotonin 5-HT3 
receptor antagonist 
7- and 8-Hydroxylation 5–10 
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(antiemetic) 
Paraxanthine  CNS stimulant 8-Hydroxylation 80 
Pentoxifylline  A drug used to treat 
intermittent claudication 
Xanthine 7-demethylation 10–20 
Phenacetin  Analgesic drug O-deethylation 86 
Promazine  
 
Antipsychotic drug N-demethylation and 5-
sulfoxidation 
30–45 
Propafenone  Antiarrhythmic drug 5-Hydroxylation and N-
desalkylation 
10–25 
Propofol  Sedative agent 4-Hydroxylation 10–25 
Propranolol  β-Blocker N-desisopropylation 30–50 
Riluzole  Antiglutamate agent for 
treatment of ALS 
N-hydroxylation, and 
possibly 4-, 
5-hydroxylation and O-
dealkylation 
75–80 
Rofecoxib  
 
Selective COX-2 inhibitor 
(withdrawn 
from the market) 
5-Hydroxylation  
 
5–10 
Ropinirole  
 
Non-ergoline dopamine 
agonist 
(for treatment of Parkinson‟s 
disease) 
N-deethylation 30–40 
 
Ropivacaine  Local anesthetic drug 3-Hydroxylation 50–65 
Selegiline  
 
Selective irreversible MAO-B 
inhibitor 
(for treatment of Parkinson‟s 
disease) 
N-demethylation 5–15 
 
Tacrine  
 
 
Centrally acting cholinesterase 
inhibitor 
(for treatment of Alzheimer‟s 
disease) 
1-, 2-, 4-, and 7-
hydroxylation  
50–65 
Tegafur 
(tetrahydrofuranyl- 5-
fluorouracil) 
Anticancer drug (a prodrug) N-dealkylation 10–20 
Terbinafine  
 
Antifungal agent N-demethylation and side 
chain oxidation 
10–25 
Thalidomide  Antiangiogenic agent (for 
treatment 
of multiple myeloma) 
5′-, 5-, and 6-hydroxylation  
 
5–10 
Theophylline  Bronchodilator N-demethylation 90–95 
Thioridazine  
 
Antipsychotic drug 5-Sulfoxidation and N-
demethylation 
35–45 
Tizanidine  Muscle relaxant  80–95 
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Trazodone  
 
Antidepressant Hydroxylation, dealkylation, 
and N-oxidation  
15–20 
Triamterene  Potassium-sparing diuretic 4′-Hydroxylation 5–10 
Verapamil  Calcium channel blocker N-demethylation 20–30 
R-Warfarin  
 
Oral anticoagulant 6-, 8-, and 10-Hydroxylation  10–20 
WHI-P131 (JANEX-1)  Janus kinase-3 inhibitor 
(an anti-inflammatory agent) 
7-O-demethylation  
 
5–15 
Zileuton  
 
 
Specific inhibitor of 5-
lipoxygenase (for treatment of 
asthma) 
Ring hydroxylation  5–15 
Zolmitriptan  
 
Selective agonists of 5-HT1B/1D 
receptor (for treatment of 
migraine) 
N-demethylation and N-
oxidation  
 
30–40 
Zolpidem  Non-benzodiazepine hypnotic 
drug 
Ring hydroxylation 5–10 
Zotepine  Atypical antipsychotic drug 2- and 3-Hydroxylation 5–10 
Zoxazolamine Muscle relaxant 6-Hydroxylation  5–10 
Abbreviations: ALS - amyotrophic lateral sclerosis, CNS - central nervous system, COX - cyclooxygenase, MAO - 
monoamine oxidase, NSAID - non-steroid anti-inflammatory drug, SSRI - selective serotonin reuptake inhibitor 
 
Hypoxis hemerocallidea, Spirostachys africana, Bowiea volubilis, and Chenopodium album 
did not inhibit the activity of CYP2C9 in the presence of up to 100 g/mL of the extracts. It is 
reasonable to conclude that, in vivo inhibition of CYP2C9 by these herbs is unlikely 
especially within the tested concentration of the extracts. 
With IC50 values greater than 100g/mL, the inhibitory activity of Acacia karroo (IC50 = 115 ± 
11.3 g/mL), Ranunculus multifidus (IC50 = 255 ± 21.6 g/mL), Tulbaghia violacea (IC50 = 921 
± 15.3 g/mL) and Zantedeschia aethiopica (IC50 = 327 ± 34.1 g/mL) on CYP2C9 can be 
said to be weak. Depending on the achievable phytochemical concentration in vivo, this 
inhibition may not be relevant clinically. 
However, the following demonstrated strong inhibitory activity, in ascending order of potency, 
against CYP2C9 activity:  Emex australis (IC50 = 97.4 ± 8.1 g/mL), Alepidea amatymbica 
(IC50 = 96.3 ± 9.5 g/mL), Pachycarpus concolor (IC50 = ( 27.8 ± 5.7 g/mL), Lessertia 
frutescens (aqueous; IC50 = 24.4 ± 2.2 g/mL), Capparis sepiaria (IC50 = 19.3 ± 4.6 g/mL), 
Kedrostis africana (IC50 = 16.6 ± 4.6 g/mL), Pentanisia prunelloides (IC50 = 6.8 ± 1.1 g/mL) 
and Lessertia frutescens (methanolic; IC50 = 5.9 ± 2.3 g/mL).  
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CYP2C9 is responsible for the primary metabolism of a number of clinically important drugs 
(Table 19). Such drugs are susceptible to HDI induced by these herbs, if sufficient 
phytochemical concentrations are achieved in vivo.  
 
Table 19: Examples of clinically important drugs that are metabolized by CYP2C9 
Drugs  Medical Uses CYP2C9-mediated reaction References 
58C80 Antimalarial  t-butyl oxidation Weaver et al., 1995 
Amitriptyline Antidepressant Hydroxylation Yu et al., 2012 
Celecoxib Analgesic  Hydroxylation Gong et al., 2012 
Diclofenac Analgesic 4'-hydroxylation Konecný et al., 2007 
Fluoxetine  Antidepressant  Hydroxylation  Yu et al., 2012 
Glimepiride Oral hypoglycemic Hydroxylation Holstein et al., 2011 
Glipizide Oral hypoglycemic Hydroxylation  Tan et al., 2010 
Glyburide Oral hypoglycemic Hydroxylation Holstein et al., 2011 
Ibuprofen Analgesic  Isopropyl hydroxylation García-Martín et al., 
2004 
Irbesartan Antihypertensive Monohydroxylation  Bourrié et al., 1999 
Lornoxicam Analgesic  5'-hydroxylation Bonnabry et al., 1996 
Losartan Hypnotic  Hydroxylmethyl oxidation Bae et al., 2011 
Mefenamic acid Analgesic  3'-methyl hydroxylation Bonnabry et al., 1996 
Naproxen Analgesic  O-demethylation Bae et al., 2009 
Phenytoin Anticonvulsant  4-hydroxylation Ninomiya et al., 2000 
Piroxicam Analgesic  5'-hydroxylation Perini et al., 2006 
Rosiglitazone Oral hypoglycemic Hydroxylation Holstein et al., 2011 
S-Warfarin Anticoagulant 7-hydroxylation Liu et al., 2012 
Tamoxifen Anti-cancer Hydroxylation  Wiseman and Lewis, 
1996 
Tolbutamide Oral hypoglycemic 4-methyl hydroxylation Vestergren et al., 2012 
Torasemide  Diuretic  Hydroxylation  Vormfelde et al., 2008 
 
With CYP2C19, the following can be classified as relatively strong inhibitors: Acacia karroo 
(IC50 = 32.9 ± 3.2 g/mL), Capparis sepiaria (IC50 = (7.3 ± 1.4 g/mL), Chenopodium album 
(IC50 = 51.4 ± 4.3 g/mL), Pachycarpus concolor (IC50 = 35.6 ± 5.7 g/mL), Ranunculus 
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multifidus (IC50 = 20.3 ± 2.3 g/mL), Lessertia frutescens (aqueous: IC50 = 142.1 ± 3.2 g/mL; 
methanolic: IC50 = 10.0 ± 0.8 g/mL) and Zantedeschia aethiopica (IC50 = 87.8 ± 10.1 
g/mL).  
On the other hand, Hypoxis hemerocallidea  and Kedrostis africana with IC50 values of 220.4 
± 15.2 and 157.0 ± 8.8 g/mL respectively can be considered weak inhibitors of CYP2C19. A 
near-total absence of inhibition was observed with Spirostachys africana while Bowiea 
volubilis, Alepidea amatymbica, Emex australis, Pentanisia prunelloides and Tulbaghia 
violacea with IC50 values >1000 g/mL demonstrated relatively less potent CYP2C19 
inhibition. 
The inhibition of CYP2C19 will be clinically dangerous for CYP2C19 substrates like 
phenytoin and R-warfarin which have narrow safety margins. Such drugs as omeprazole, 
proguanil, diazepam, moclobemide, imipramine and other substrates of CYP2C19 are 
susceptible to HDI in the presence of these herbal CYP2C19 inhibitors.  
CYP3A4 is the most important CYP in drug metabolism. As noted earlier, the phase I 
metabolism of about half of all marketed drugs is CYP3A4-dependent. In the light of this fact, 
inhibition of CYP3A4 activity by herbal products portends a more likelihood for HDI with 
concurrently administered orthodox medicine. 
The result from this study showed that only 2 (Alepidea amatymbica and Tulbaghia violacea) 
out of the 15 herbs exerted no inhibitory effects on CYP3A4 activity. Of the remaining 13, 
only Chenopodium album (IC50 = 230 ± 5.1 µg/mL) can be considered a relatively weak 
CYP3A4 inhibitor. All the other 12 herbs inhibited CYP3A4 activity potently with IC50 values 
less than 100 µg/mL:  Lessertia frutescens (methanolic, IC50 = 26.4 ± 2.0 µg/mL; aqueous 
IC50 = 32.6 ± 3.5 µg/mL), Hypoxis hemerocallidea (IC50 = 20.4 ± 1.6 µg/mL), Spirostachys 
Africana (IC50 = 47.4 ± 2.4 µg/mL), Bowiea volubilis (IC50 = 8.1 ± 0.6 µg/mL), Zantedeschia 
aethiopica (IC50 = 11.7 ± 2.2 µg/mL), Kedrostis Africana (IC50 = 1.3 ± 0.2 µg/mL), Acacia 
karroo (IC50 = 1.9 ± 0.3), Emex australis (IC50 = 7.2 ± 0.6 µg/mL), Pachycarpus concolor (IC50 
= 8.8 ± 1.1 µg/mL), Ranunculus multifidus (IC50 = 10.1 ± 1.8 µg/mL), Capparis sepiaria (IC50 
= 3.1 ± 0.1 µg/mL) and Pentanisia prunelloides (IC50 = 31.6 ± 2.8 µg/mL). 
There was no major difference in the inhibitory activity of Lessertia on CYP3A4 activity when 
testosterone (IC50 = 26.4 ± 2.0 µg/mL) was substituted with midazolam (IC50 = 28.1 ± 2.1 
µg/mL) as probe substrate. Although the use of one CYP-specific substrate provides results 
that are generally acceptable for predictive purposes, the use of two substrates (especially 
with CYP3A4) can be beneficial to rule out variations in inhibitory effects due to substrate 
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choice (Bjornsson et al., 2003). Such results confirm cross-substrate effects, and a 
demonstration of the inhibitory effects to be on the enzyme and not on the substrate.  
Both the aqueous and methanolic extracts of Lessertia inhibited CYP3A4. This suggests that 
the consumption of either of whole leaf products and aqueous decoctions by patients may 
predispose to HDI. It is also important to note that the level of inhibition of the aqueous (32.6 
± 3.5 µg/mL) and methanolic (26.4 ± 2.0 µg/mL) extracts of Lessertia is similar. 
As shown with the time-dependent inhibition in Figure 74, inhibitory influence of Lessertia will 
be more potent on repeated consumption due to the suppression of enzyme viability/activity. 
In reality, herbal remedies are consumed repeatedly over a long period of time. With a 
possible continuous suppression of enzymatic activity, administered drugs may accumulate, 
and precipitate toxicity. 
A futher in vitro-in vivo estimation of the effects of the herbs is presented in Chapter 10. 
 
5.6. Conclusion 
The effect of the crude extracts of the 15 selected medicinal herbs (Chapter 4) on CYP1A2, 
CYP2C9, CYP2C19 and CYP3A4 activity was investigated. Extracts of the following inhibited 
the activity of CYP1A2 to varying degrees: Acacia karroo, Alepidea amatymbica, Bowiea 
volubilis, Capparis sepiaria, Chenopodium album, Kedrostis Africana, Hypoxis 
hemerocallidea, Ranunculus multifidus, Spirostachys Africana, Lessertia frutescens, 
Tulbaghia violacea and Zantedeschia aethiopica.  Extracts of Emex australis, Alepidea 
amatymbica, Pachycarpus concolor, Lessertia frutescens, Capparis sepiaria, Kedrostis 
africana and Pentanisia prunelloides potently inhibited CYP2C9 activity. The extracts of 
Acacia karroo, Capparis sepiaria, Chenopodium album, Pachycarpus concolor, Ranunculus 
multifidus, and Lessertia frutescens inhibited CYP2C19 activity to varying degrees. In 
excemption of Alepidea amatymbica and Tulbaghia violacea, the extracts of all the medicinal 
plants inhibited CYP3A4 activity to varying degrees. Lessertia demonstrated time-dependent 
inhibition of CYP3A4 activity suggesting a more potent inhibition on continous repetitive use. 
It is therefore concluded that there is the potential for HDI between these herbs and the 
substrates of the respective CYP, if sufficiently high in vivo concentrations of the 
phytoconstituents are achieved. 
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CHAPTER SIX 
THE ASSESSMENT OF THE INHIBITORY EFFECT OF LESSERTIA FRUTESCENS AND 
HYPOXIS HEMEROCALLIDEA ON CYP2A6, 2B6, 2C8, 2D6 AND 2E1 
 
6.0. Summary 
The influence of the crude extracts of Lessertia frutescens and Hypoxis hemerocallidea on 
the metabolic activity of CYP2A6, CYP2B6, CYP2C8, CYP2D6 and CYP2E1 was 
investigated using standard probe reactions in human liver microsomes. The inhibitory 
effects, where observed, was estimated in IC50 value terms and presented in Table 20.  
 
Table 20: Summary of the inhibitory effects of Lessertia frutescens and Hypoxis 
hemerocallidea on CYP2A6, 2B6, 2C8, 2D6 and 2E1 
 IC50 value (g/mL) for CYP inhibition 
CYP Lessertia frutescens Hypoxis hemerocallidea 
2A6 570 ± 28.8 210 ± 9.5 
2B6 19.7 ± 2.1 98.5 ± 4.5 
2C8 25.5 ± 1.9 125 ± 4.7 
2D6 714 ± 44.3 - 
2E1 >1000 - 
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6.1. Introduction 
This chapter presents the in vitro inhibitory effects of two of the most commonly used 
medicinal herbs among people living with HIV/AIDS (Mills et al., 2005b) in South Africa – 
Lessertia frutescens (Lessertia) and Hypoxis hemerocallidea (Hypoxis) on the other CYP 
isozymes - CYP2A6, 2B6, 2C8, 2D6 and 2E1. 50% methanolic extract of Lessertia was used 
to obtain most phytoconstituents. This reflects the usual consumption in which consumers 
take whole-leave Lessertia capsules where they are exposed to most phytoconstituents. 
Aqueous extract of Hypoxis was used to reflect the popular consumption of aqueous 
decoction in traditional use. 
CYP2A6 is found in the liver constituting about 4% of total CYP content (Yun et al., 1991). 
There is also evidence suggesting extrahepatic expression in the nasal mucosal (Gu et al., 
2000).  The discovery of the involvement of CYP2A6 as the catalytic enzyme responsible for 
the metabolism of nicotine and other tobacco-related nitrosamines has increased interest in 
CYP2A6 (Hecht et al., 2000). CYP2A6 is responsible for the metabolism of a number of 
clinically important drugs (Table 21). Phenobarbital and rifampicin are known inducers of 
CYP2A6 activity. Coumarin 7-hydroxylation is a standard probe marker reaction for 
measuring the in vitro and in vivo activity of CYP2A6 (Kim et al., 2005; Schlicht et al., 2007). 
Coumarin is a naturally occuring compound in plants and is present in tobacco products, 
alcoholic beverages, soaps, detergents, and cosmetic preparations where it serves as 
sweetener, fixative, or stabilizer. It has been used for the management of lymphedema 
(Farinola and Piller, 2007). CYP2A6 is the major enzyme responsible for the metabolism (70-
80%) of coumarin to 7-hydroxycoumarin in humans.  
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Table 21: Examples of drugs metabolized by CYP2A6-mediated reactions (Adapted and 
updated from Lewis, 2003) 
Drugs  Medical Uses CYP2A6-mediated reaction 
Coumarin Lymphedema 7-hydroxylation 
SM-12502 Anticoagulant  S-oxidation 
Nicotine Stimulant  5'-oxidation 
Losigamone Antiseizure  3-hydroxylation 
4-Nitroanisole - O-demethylation 
Paracetamol Analgesic  3-hydroxylation 
Quinoline Antimalarial  1-oxidation 
Halothane Anaesthetic Reduction 
Hexamethylphosphoramide - Demethylation 
Valproic acid  Anticonvulsant   
Cyclophosphamide  Anticancer  4-hydroxylation 
Ifosfamide  Anticancer 4-hydroxylation 
Pilocarpine Antiglaucoma 3-hydroxylation 
Tegafur Anticancer 5-fluorouracil formation 
Cisapride Anticancer  O-dealkylation 
Disulfiram  Alcohol withdrawal  Hydroxylation  
Methoxyflurane  Analgesic Reduction  
SM-12502 = (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one 
 
 
CYP2B6 accounts for 1-2% of total hepatic CYP. Until recently, the human expression and 
metabolic role of CYP2B6 has been thought to be negligible (Niu et al., 2011). Current 
studies have however indicated that the average relative contribution of CYP2B6 to total 
hepatic CYP content range from 2-10% (Chen et al., 2012). Cyclophosphamide is one of the 
important substrates of CYP2B6. Some other clinically important substrates of CYP2B6 
include ifosfamide, tamoxifen,  efavirenz, nevirapine, bupropion, mephobarbital, valproic acid, 
mexiletine, procainamide, artemisinin, tazofelone, aminopyrine, antipyrine, propofol, 
ketamine, pentobarbital, ropivacaine, lidocain, sevoflurane, methadone, pethidine, selegiline, 
diazepam, temazepam, clotizazepam, midazolam, estrone, testosterone (Wang et al., 2008). 
Like for other CYPs like CYP2D6, 2C9 and 2C19, studies have established genetic variations 
in CYP2B6 with potentially significant clinical significance (Gandhi et al., 2012; Huang et al., 
2012). CYP2B6 is induced by phenobarbital and rifampicin. Bupropion hydroxylation is a 
standard in vitro and in vivo probe reaction for CYP2B6. Some important substrates of 
CYP2B6 are listed in Table 22.  
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Table 22: Examples of CYP2B6-mediated drug metabolic reactions (Adapted and updated 
from Lewis, 2003) 
Drugs  Pharmacological uses CYP2B6-mediated 
reaction 
4-Trifluoromethyl 7-
ethoxycoumarin 
CYP2B6 biomarker substrate O-deethylation 
 
7-Benzyloxyresorufin CYP2B6 biomarker substrate O-debenzylation 
S-Mephenytoin Anticonvulsant  N-demethylation 
Benzphetamine Weight loss N-demethylation 
Testosterone Anabolic agent 16β-hydroxylation 
Bupropion Antidepressant  t-butyl oxidation 
PNU 249173 CYP2B6 biomarker substrate cyclopentyl hydroxylation 
Diazepam Sedative  N-demethylation 
7-Ethoxycoumarin Anticoagulant  O-deethylation 
4-Chloromethyl 7-
ethoxycoumarin 
Anticoagulant  O-deethylation 
3-Cyano-7-
ethoxycoumarin 
Anticoagulant  O-deethylation 
 
CYP2C8 represents about 7% of the total hepatic CYP.  Extrahepatic expression is found in 
the brain, kidney, adrenal gland, heart, ovary, uterus, mammary gland, and duodenum 
(Delozier et al., 2007). It is responsible for the primary metabolism of thiazolidinediones 
(rosiglitazone, pioglitazone and troglitazone); meglitinides (repaglinide); 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (cerivastatin); chemotherapeutic 
agents (paclitaxel and all-transretinoic acid); antimalarials (amodiaquine and chloroquine); 
antiarrhythmics (amiodarone) and retinoid derivatives (tazarotenic acid) (Delozier et al., 
2007). CYP2C8 plays some minor role in the metabolism of NSAIDs (ibuprofen, diclofenac 
and tenoxicam), fluvastatin, simvastatin acid, carbamazepine, cyclophosphamide, dapsone, 
diltiazem, ifosfamide, loperamide, methadone, morphine, torsemide, verapamil and zopiclone 
(Totah and Tettie, 2005). More important CYP2C8 substrates are shown in Table 23. 6α-
hydroxylation of paclitaxel is a standard probe reaction for CYP3C8 activity (See Chapter 3). 
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Table 23: Some CYP2C8 substrates and other CYP isoforms that contribute to their 
metabolism (adapted - with permission - and updated from Daily and Aquilante, 2009; see 
also Totah and Retie, 2005)  
Specific drugs Drug class Treatment indication 
 
Other CYP enzymes 
that play a role in 
metabolism 
Major contribution of CYP2C8 to metabolism 
 
All-trans-retinoic 
acid 
Vitamin A derivative Promyelocytic 
leukemia 
CYP2C9 
 
Amiodarone Class III 
antiarrhythmic 
Supraventricular and 
ventricular arrhythmias 
CYP3A4, CYP1A2, 
CYP2C19, CYP2D6 
 
Amodiaquine 4-aminoquinoline Malaria CYP3A4, CYP1A1, 
CYP1B1 
 
Cerivastatin* HMG-CoA reductase 
inhibitor 
Hyperlipidemia CYP3A4 
Chloroquine 4-aminoquinoline Malaria CYP3A4, CYP2D6 
 
Paclitaxel Taxane Solid malignant tumors 
(e.g., breast, ovarian, 
lung) 
 
CYP3A4, CYP3A5 
 
Repaglinide Meglitinide Type 2 diabetes CYP3A4 
 
Rosiglitazone, 
pioglitazone 
Thiazolidinedione Type 2 diabetes CYP2C9, CYP3A4, 
CYP1A1 
 
Tazarotenic acid Retinoid derivative Acne and psoriasis – 
 
Troglitazone* Thiazolidinedione Type 2 diabetes CYP3A4 
Intermediate or minor contribution of CYP2C8 to metabolism 
 
Carbamazepine Anticonvulsant Epilepsy CYP3A4 (major) 
Cyclophosphamide Nitrogen mustard 
alkylating agent 
Lymphoma, leukemia, 
solid tumors 
CYP2A6, CYP2B6, 
CYP2C9, CYP2C19, 
CYP3A 
Dapsone Antibacterial sulfone Leprosy and 
pneumocystis 
pneumonia 
CYP2C9 (major) 
 
Diclofenac NSAID Pain and inflammation CYP2C9 (major), 
CYP3A4, and 
CYP2C19 
Diltiazem Calcium channel 
blocker 
Hypertension, 
arrhythmias, angina 
CYP3A4, CYP2C9 
 
Fluvastatin HMG-CoA reductase 
inhibitor 
Hyperlipidemia CYP2C9 (major), 
CYP3A4 
Ibuprofen NSAID Pain and inflammation CYP2C9 
 
Ifosfamide Nitrogen mustard Various cancers CYP2A6, CYP2B6, 
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Specific drugs Drug class Treatment indication 
 
Other CYP enzymes 
that play a role in 
metabolism 
alkylating agent CYP2C9, CYP2C19, 
CYP3A 
Loperamide -opioid receptor 
agonist 
Antidiarrheal CYP2B6, CYP2D6, 
CYP3A4 
Methadone Opioid agonist Pain and addiction to 
opioids 
CYP3A4, CYP2D6, 
CYP2B6 
Morphine Opioid agonist Pain CYP3A4 
Simvastatin acid HMG-CoA reductase 
inhibitor 
Hyperlipidemia CYP3A4 (major) 
 
Tenoxicam NSAID Pain and inflammation CYP2C9 (major) 
 
Torasemide Loop diuretic Edema CYP2C9 (major) 
Verapamil Calcium channel 
blocker 
Hypertension, 
arrhythmias, angina 
CYP3A4 (major), 
CYP3A5 
 
*Withdrawn from the market. 
 
 
CYP2D6 is an important drug metabolizing enzyme responsible for the metabolism of 
haloperidol, metoprolol, propranolol, codeine, bufuralol, debrisoquine, imipramine, 
desipramine, nortriptyline, ondansetron and dextromethorphan. CYP2D6 is particularly 
important because of its display of genetic polymorphism leading to large inter-individual and 
inter-ethic/racial differences in CYP2D6-mediated drug metabolism. CYP2D6 is not inducible.  
Bufuralol 1'-hydroxylation is a probe reaction for CYP2D6 activity.  
CYP2E1, which constitutes about 7% of the hepatic CYP, is well known as the catalyst for 
the metabolism of ethanol. It is also known to activate chemical carcinogens. Drugs 
metabolized by CYP2E1 include paracetamol, enflurane, chlorzoxazone, salicylic acid and 
halothane. It is inhibited by disulfiram and induced by acetone, ethanol, pyridine, pyrazole, 
and isoniazid. 6-hydroxylation of chlorzoxazone is a CYP2D6-specific reaction, used to probe 
its activity. 
 
6.2. Aims and objectives 
The aim of this chapter was to investigate the inhibitory influence of a 50% methanolic extract 
of Lessertia, and the aqueous extracts of Hypoxis on the metabolic activity of CYP2A6, 2B6, 
2C8, 2D6 and 2E1. Further objective was to quantify the inhibitory effects, where observed, 
in IC50 terms. 
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6.3. Materials and Methods 
6.3.1. Materials 
The sourcing, selection and preparation of the medicinal herbs, the chemical compounds and 
the HLM used in this study are as described in earlier chapters (Chapter 4 and 5). In addition, 
1‟-hydroxybufuralol maleate, and bufuralol hydrochloride were purchased from Ultrafine 
Chemicals (Pty) Ltd (Manchester, UK); 6-hydroxychlorzoxazone, 7-hydroxycoumarin, 
bupropion, chlorzoxazone, coumarin, paclitaxel and [13C6] 7 hydroxycoumarin were obtained 
from Novartis Pharma AG (Basel, Switzerland); hydroxybupropion, [2H6] hydroxybupropion 
and [2H9] 1‟-hydroxybufuralol were purchased from BD Biosciences (Pty) Ltd (San Jose, 
USA) and 6α-hydroxypaclitaxel from Gentest BD Biosciences (Woburn, USA). All other 
chemicals used were of analytical grade. 
 
6.3.2. Methods 
6.3.2.1. Incubation to determine the inhibitory effects of herbal extracts on the CYPs 
Using similar methodology as in Chapter 5 (Section 5.3), test substrates were co-incubated 
with graded concentrations of herbal extracts in HLM mixture. The concentration of 
substrates used was less than the literature Km value (Table 24). Isozyme-specific inhibitors 
were employed as positive controls. The results were analyzed similarly (see Chapter 5). A 
summary of the incubation conditions is provided in Table 24. Table 25 provides the 
summary of the LC/MS conditions for analysis. 
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Table 24: Microsomal incubation conditions for the CYP-catalyzed reactions 
Parameters Values 
Concentration of potassium phosphate buffer, pH 7.4 in incubation mixture  50 mM 
Concentration of magnesium chloride in incubation mixture 5 mM 
Incubation pH 7.4 
Final graded concentration of herbal extracts 0 – 100 µg/mL 
Concentration of DMSO/methanol in incubation mixture 0.5%(
v
/v)  
Final concentration of NADPH in the incubation mixture 1 mM  
Incubation time 20 min 
CYP2A6 
CYP2A6-specific metabolite 7-hydroxycoumarin    
HLM Concentration 0.2mg protein/mL 
Positive control Sulfaphenazole 
Initial coumarin concentration  2.5 µM 
Literature Km values 
a
0.5-3 
 
CYP2B6  
CYP2B6-specific metabolite Hydroxybupropion  
HLM Concentration 0.1mg protein/mL  
Positive control Sertraline  
Initial bupropion concentration  25 µM  
Literature Km values 
b
76, 
c
89,
d 
130  
 
CYP2C8  
CYP2C8-specific metabolite 6-hydroxypaclitaxel  
HLM Concentration 0.2mg protein/mL  
Positive control Sulfaphenazole  
Initial paclitaxel concentration  10 µM  
Literature Km values 
e
4.0, 
f
15  
 
CYP2D6 
CYP2D6-specific metabolite 1‟-hydroxybufuralol  
HLM Concentration 0.2mg protein/mL  
Positive control Quinidine  
Initial bufuralol concentration  5 µM  
Literature Km values 
g
13, 
h
44  
 
CYP2E1  
CYP2E1-specific metabolite 6-hydroxychlorzoxazone  
HLM Concentration 0.5mg protein/mL  
Positive control Diethyl-dithiocarbamate  
Initial chlorzoxazone concentration  10 µM  
Literature Km values 
i
22-49  
 
a 
Shimada et al., 1996, Draper et al., 1997; 
b 
Faucette et al., 2000; 
c 
Hesse et al., 2000; 
d 
Li et al., 2003; 
e
 Rahman et al., 1994; 
f
 Cresteil et al., 1994; 
g
 Boobis et al., 1985; 
h
 Yamazaki et al., 1994; 
i
 Peter et 
al., 1990 
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Table 25: Summary the LC/MS analytical conditions for the quantitative determination of 
CYP metabolites 
 
 7-hydroxycoumarin    6-
hydroxychlorzoxazone 
Hydroxybupropion 6-
hydroxypaclitaxel 
1’-
hydroxybufuralol 
Instrument 
type 
Agilent Chemstation 1100 HPLC system (Agilent Technologies, Palo Alto, USA) equipped with a capillary 
pump and a triple quadrupole Quattro Ultima mass spectrometer (Waters, Milford, USA) 
Mobile phase  A: Water (plus 0.1% formic acid) 
B: Acetonitrile(plus 0.1% formic acid) 
Mobile phase 
proportion  
Isocratic with 30% solvent B Time (min) Solvent A (%) Solvent B (%) 
0.0 85 15 
0.5 85 15 
2 5 95 
4 5 95 
4.2 85 15 
8 85 15 
 
Flow speed 60 l / min     
Retention time 
(min) 
3.5 4.2 5.2 6.2 4.5 
Column type Luna Phenyl-Hexyl 3 µm, inner dimensions 50 x 1 mm (Phenomenex, Torrance, USA) 
Mode  Positive Negative Positive Positive  Positive 
Retention time 1.8 min 2.2 min 3.4 min 4.8 min 6.3 min 
Total run time 3 min 8 min 
Internal 
standard 
[
13
C6]7-hydroxy-
coumarin 
[
2
H3] 4'-hydroxy-
mephenytoin 
[
2
H6] 
hydroxybupropion 
warfarin [
2
H9] 1-
hydroxybufuralol 
Column 
temperature 
30°C 
Nebulizing 
temperature 
375°C 
Mass- to- 
charge range 
3000 m/z 
MRMs 10 MRM (multiple reaction monitoring) per analyte 
Reference A solution mix of acetaminophen, caffeine, sulfaguanidine, sulfadimethoxine, Val,-Tyr-Val, verapamil, 
terfenadine, leucine-enkephalin and reserpine 
Dwell time 
(msec) 
200 msec 
Injection 
volume 
2 µl 
 
 
6.3.2.2. Analysis of the inhibitory effects on the CYPs 
The CYP activity in the presence of the herbal extracts was profiled against the extract 
concentrations. IC50 values were estimated with the SigmaPlot
® Enzyme Kinetic software 
based on Equation 6.1. 
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      Equation 6.1 
 
6.3.2.3. Statistical analysis 
The percentage inhibition observed for the test extracts is defined in absolute terms.  The 
absolute values were obtained by comparing the metabolite production in the presence of 
test extracts, to metabolite production in the absence of any inhibitor (test extract or known 
inhibitors) (Bjornsson et al., 2003). The nonlinear-regression was generated by profiling the 
extract concentration against observed enzyme activity. The kinetic parameters were 
determined from the generated plot from the SigmaPlot® software with R2 > 0.9 and p < 0.05 
as the minimum level of significance. 
Positive controls are used in in vitro drug metabolism studies for qualitative purposes only. 
The positive controls (known CYP inhibitors) only provide indications that the enzymes can 
be inhibited in the experimental set up. By general standard, the use of HLM is for qualitative 
determination of the ability/potential of chemical substances to inhibit CYP enzymes 
(Brandon et al., 2003). The results obtained may not be linearly related to in vivo situation.  
 
6.4. Results: Influence of the herbal extracts on CYP activity 
Figures 75 - 84 show the results of the inhibitory activity of the herbal extracts on CYP2A6, 
CYP2B6, CYP2C8, CYP2D6 and CYP2E1 activity. Values represent the mean of intra-day 
and inter-day duplicates. Intra-day and Inter-day variations were less that 10%. 
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Figure 75: The profile of CYP2A6-catalyzed 
metabolism of coumarin in the presence of 
graded concentration of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 76: The profile of CYP2A6-catalyzed 
metabolism of coumarin in the presence of 
graded concentration of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 
0.99) 
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Figure 77: The profile of CYP2B6-catalyzed 
metabolism of bupropion in the presence of 
graded concentration of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 78: The profile of CYP2B6-catalyzed 
metabolism of bupropion in the presence of 
graded concentration of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 
0.99) 
IC50 = 210 ± 9.5 g/mL IC50 = 98.5 ± 4.5 g/mL 
IC50 = 570 ± 28.8 g/mL IC50 = 19.7 ± 2.1 g/mL 
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Figure 79: The profile of CYP2C8-catalyzed 
metabolism of paclitaxel in the presence of 
graded concentration of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 80: The profile of CYP2C8-catalyzed 
metabolism of paclitaxel in the presence of 
graded concentration of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 
0.99) 
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Figure 81: The profile of CYP2D6-catalyzed 
metabolism of bufuralol in the presence of 
graded concentration of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 82: The profile of CYP2D6-catalyzed 
metabolism of bufuralol in the presence of 
graded concentration of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 
0.99) 
IC50 = 25.5 ± 1.9 g/mL 
IC50 = No inhibition observed IC50 = 125 ± 4.7 g/mL 
IC50 = 714 ± 44.3 g/mL 
Stellenbosch University  http://scholar.sun.ac.za
119 
 
Lessertia frutescens
Extract Concentration (µg/mL)
10 100
R
e
la
ti
v
e
 C
Y
P
2
E
1
 A
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
120
 
Figure 83: The profile of CYP2E1-catalyzed 
metabolism of chlorzoxazone in the presence 
of graded concentration of crude methanolic 
extracts of Lessertia frutescens (R2 = 0.99) 
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Figure 84: The profile of CYP2E1-catalyzed 
metabolism of chlorzoxazone in the presence 
of graded concentration of crude aqueous 
extracts of Hypoxis hemerocallidea (R2 = 
0.99) 
  
IC50: No inhibition observed  IC50 = >1000 g/mL 
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6.5. Discussion 
Lessertia demonstrated a very strong inhibition of the metabolic activity of CYP2B6 (IC50 = 
19.7 ± 2.1 g/mL) and CYP2C8 (IC50 = 25.5 ± 1.9 g/mL), with a weak inhibition of CYP2A6 
(IC50 = 570 ± 28.8 g/mL) and CYP2D6 (IC50 = 714 ± 44.3 g/mL) and a less potent inhibition 
of CYP2E1 (IC50 >1000 g/mL). Hypoxis on the other hand only inhibited the activity of 
CYP2A6 (IC50 = 210 ± 9.5 g/mL), CYP2B6 (IC50 = 98.5 ± 4.5 g/mL) and CYP2C8 (IC50 = 
125 ± 4.7 g/mL). No inhibitory activity was observed on CYP2D6 and CYP2E1. 
These results are important in the light of the many substrates of the CYP2A6, CYP2B6, 
CYP2C8, CYP2D6 and CYP2E1 isoenzymes and will be clinically relevant for the 
management of patients who concurrently use conventional medicines and Lessertia or 
Hypoxis.   
 
6.6. Conclusion 
The effect of the crude extracts of Lessertia frutescens and Hypoxis hemerocallidea on 
CYP2A6, CYP2B6, CYP2C8, CYP2D6 and CYP2E1 was investigated. Both Lessertia and 
Hypoxis potently inhibited the metabolic activity of CYP2A6, CYP2B6 and CYP2C8. If 
sufficient in vivo concentrations are achieved, Lessertia and Hypoxis possess the potential 
for herb drug interactions with the substrates of CYP2A6, CYP2B6 and CYP2C8.  
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CHAPTER SEVEN 
ASSESSMENT OF THE INFLUENCE OF CRUDE EXTRACTS OF LESSERTIA 
FRUTESCENS AND HYPOXIS HEMEROCALLIDEA ON THE IN VITRO METABOLISM OF 
MIDAZOLAM IN HUMAN HEPATOCYTES 
 
7.0. Summary 
Graded concentrations of crude extracts of Lessertia frutescence (LT) and Hypoxis 
hemerocallidea (HP) were separately co-incubated with 1µM midazolam (MDZ), a 
CYP3A4/5-specific substrate, in human hepatocytes for up to 6 h. The incubate profiles of 
MDZ were analyzed by UPLC and known metabolites were identified by LC-MS/MS. The in 
vitro intrinsic clearance values of MDZ (in the presence and absence of LT and HT) were 
calculated and scaled to hepatic metabolic clearance values in vivo. 
LT inhibited the production of MDZ metabolites with about 40% reduction in upscaled intrinsic 
in vivo clearance of MDZ (24.98 compared to 40.98 (L/h)/kg body mass). However, neither 
LT nor HP reduced hepatocyte viability as measured after 6 hours of incubation.  
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7.1. Introduction and objectives 
The main objective of this study was to assess the influence of LT and HP on the metabolism 
of CYP3A4-mediated metabolism of MDZ in human hepatocytes.  
 
7.2. Material and methods 
7.2.1. Materials 
The sourcing and preparation of Lessertia frutescence and Hypoxis hemerocallidea are as 
described in Chapter Four.  
All chemical compounds used were sourced as described in Chapter Five. 
Pooled, mixed gender cryopreserved hepatocytes prepared from 20 donors were obtained 
from Celsis In vitro technologies (Pty) Ltd (Baltimore, MD, USA),  stored in a liquid nitrogen 
tank (until use), and thawed according to supplier instructions before use. 
 
7.2.1.1. Test solutions used for the incubations 
A 10 mM MDZ solution was prepared and stored at -20°C. A 20μL volume was diluted with 
180μL of DMSO to produce 1mM working solution and stored at -20°C, such that the addition 
of 1 μL of the working solution to 1mL cell incubation mixture would yield a final concentration 
of 1μM MDZ. 
Stock solutions (20mg/mL each) of LT (methanol) and HP (water) were separately prepared, 
such that an addition of 5 μL of each per 1mL incubation mixture will yield a final incubation 
mixture of 100μg/mL concentration.   
 
7.2.1.2. Hepatocytes 
The characteristics of cryopreserved hepatocytes used in this study are described in Table 
26. The hepatocyte mixture was stored in a liquid nitrogen tank. On the day of the 
incubations, it was thawed according to the instructions provided by the supplier. 
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Table 26: Characteristics of cryopreserved hepatocytes used in the study (Appendix H) 
Species Human 
Strain n/a 
Gender Pooled (male and female) 
Supplier Celsis/In vitro Technologies 
Catalog/product number X008000 
Lot number SSB 
Number of individuals pooled 20 
 
7.2.2. Methods 
7.2.2.1. Hepatocyte incubations and viability measurements 
The cryopreserved hepatocytes were thawed and the cells were suspended in HepatoZYME 
buffer. 
The viability of the suspended hepatocytes was determined by a Guava EasyCyte Mini 
system using the ViaCount assay according to the instructions of the supplier (Guava 
Technologies). After cell counting, the cell density was adjusted to approximately 1.3 x 106 
viable cells/mL with HepatoZYME media. The incubation mixture contained 5 μL of 20 mg/mL 
LT and HP (separately) in 1mL cell incubation medium. The metabolic activity of the 
hepatocytes in the incubation mixture was initiated by the addition of 1 μL of 1 mM MDZ into 
the incubation mixture. The initial concentration of MDZ was 1 μM. The final concentration of 
organic solvent (methanol and/or DMSO) was 0.5% (v/v). The final concentration of the test 
inhibitors (LT and HP) was 100 μg/mL. For the cell and MDZ stability test incubation, 12-well 
Nunclon Surface plates were used. For the incubation to determine the effects of LT and HP 
on MDZ metabolism, 25 mL tissue culture flasks (Becton Dickinson Franklin Lakes) were 
used and aliquots of 300 μL were taken at the different time points. Both types of incubations 
were performed at 37°C under a humidified atmosphere of 95% air and 5% CO2 in a 
Heraeus incubator/Cytoperm. During the incubations, the plates or flasks were shaken (70 
rpm). The viability of the hepatocytes was determined after 0 and 6 h for the metabolites 
profiles. The metabolic reactions were stopped by the addition of 2 volumes of acetonitrile. 
Samples were kept at -20°C until analysis. 
To monitor the chemical stability of MDZ under the incubation conditions, the compound was 
incubated in HepatoZYME in the absence of hepatocytes. A second series of control 
incubations was performed with hepatocytes (without MDZ) in the presence of the test 
inhibitor compounds to investigate the effect of the latter on the viability of the cells, and 
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possible cytotoxicity of the compounds. Further details of the incubations are given in Tables 
27, 28 and 29. Post-incubation analysis was performed under the conditions highlighted in 
Tables 30 and 31.  
 
Table 27: Hepatocyte incubation conditions: Incubations for monitoring the effects of test 
compounds on MDZ metabolism 
Hepatocytes Human, cryopreserved 
Initial substrate concentration (µM) 1.0 
Volume of substrate (MDZ) solution added (µL/mL final 
incubate) 
1.0 
Volume of test inhibitor solution added (µL/mL final incubate) 5.0 
Initial density of viable cells (106/mL) 1.3 
Viability at 0 h (%) 78.3 
Incubation times (h) 6 
Incubation volume (mL) 3 
 
 
Table 28: Conditions for control incubation  
Initial substrate concentration (µM) 1.0 
Volume of test inhibitor solution added (µL/mL final incubate) 5.0 
Initial density of viable cells (106/mL) 1.3 
Viability at 0 h (%) 78.3 
Incubation times (h) 6 
Incubation volume (mL) 1 
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Table 29: Summary of the hepatocyte incubation conditions and methodology 
Test compound and 
conditions 
1 mM MDZ, 20 mg/mL LT and HP used for hepatocyte 
incubations. 
Sampling times Kinetic measurements to determine the intrinsic metabolic 
clearances and metabolite profiles of MDZ were performed at 0, 
1, 2, 4 and 6 h incubation. 
Incubation methods for 
intrinsic clearance 
calculations and 
metabolite profiles 
For the kinetic evaluations, 1 μM MDZ was mixed in a serum-free 
culture medium containing approximately 1.3 x 106 
hepatocytes/mL. Sample from each time point was analyzed by 
HPLC. From these kinetic data, intrinsic clearance was 
calculated. 
Incubation methods for 
metabolite profiles 
Determination of MDZ metabolites was accomplished by LC-
MS/MS analysis (including accurate mass measurements) using 
incubation supernatants from hepatocytes. 
Stop solution containing 
internal standard (d4-
1‟hydroxymidazolam) 
 
50μL of a solution of d4-hydroxymidazolam was prepared in 
methanol and stored at -20°C. 15μL of the solution was diluted to 
15mL with methanol to give a 0.1μg/mL (0.3μM). This was used 
as stop solution for enzymatic reactions (stored at 4°C) 
Post-incubation sample 
preparation for analysis 
At the end of the incubation period, a 300 µL aliquot was mixed 
with two volumes of ice-cold acetonitrile (containing 0.3M d4-
hydroxymidazolam as internal standard) to stop the enzymatic 
reactions. The mixture was vortex-mixed and then stored at -20°C 
(for at least 4 hr) until analysis to complete the protein 
precipitation.  Before use, the samples were thawed and 
centrifuged (centrifuge 3K30, Sigma) for 20 min at 15,800 g and 
the supernatant was decanted. 
The supernatants were evaporated under N2 flow. The dried 
samples were reconstituted with 25 μL of acetonitrile and 475 μL 
water. The solution was shaken and sonicated for 10 minutes. 
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Table 30: HPLC methods for MDZ analysis and metabolite profiling/identification 
LC instrumentation Acquity UPLC system (Waters Corporation, Manchester, U.K.), 
equipped with a binary solvent manager, a sample manager, a 
column manager and a photodiode array detector (PDA). UV 
spectra were monitored in the range of 210-400 nm. The operating 
software for the UPLC system was MassLynx V4.1. 
Guard column Acquity UPLC HSS T3 2.1 x 5 mm, 1.8 µm (Waters) 
Analytical column Acquity HSS T3 1.8 μm, 2.1 x 150 mm (Waters) 
Column conditions Thermostated at 50°C  
Injection volume Up to 125 µL  
Mobile phase A: Water/Acetonitrile: (90/10 v/v) + 0.1% formic acid 
B: Acetonitrile + 0.1% formic acid  
Flow rate 0.5 mL/min 
Gradient 0 min: 0 % B 
1 min: 0 % B 
17 min: 50 % B 
20.1 min: 95% B 
25 min: 95% B 
25.1 min: 0% B 
30 min: 0 % B 
Flow splitting and 
Radioactivity detection 
- offline 
The LC flow post column was directed to the UV detector, after 
which it was split (approximately 1:5), as follows. 
LC-MS analysis: The minor split was directed to the LC-MS ESI 
interface.  
The major split was diverted to waste  
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Table 31: MS conditions used for metabolite analysis 
Instrument Time-of-flight mass spectrometer model Synapt G2 HDMS 
operated under MassLynx, Version 4.1. (Waters Corporation, 
Manchester, U.K.) 
Ionization mode Electrospray in positive ion mode 
Ion source Spray capillary: 3.0 kV 
Cone voltage: 30 V 
Nebulizer gas: Nitrogen (7 bar) 
Cone gas: Nitrogen (25 L/h) 
Desolvation gas: Nitrogen (800 L/h) 
Source block temperature: 120°C 
Desolvation temperature : 450°C 
Collision energy for 
LC-MS and LC-MSE 
or LC-MS/MS 
fragmentation 
Trap cell MS  
MSE or MS/MS 
4 eV  
ramping 10-45 V 
Transfer cell MS  
MSE or MS/MS 
0 eV 
30 eV  
Time-of-flight mass 
analyzer 
Mass resolution ~10‟000 (full-width at half-maximum definition), 
Sensitivity-mode 
Accurate mass 
measurement 
The reference channel of the LockSpray interface was operated 
with a solution of Leucine-Enkephaline (0.2 µg/mL) in acetonitrile 
at a flow rate of 5 µL/min. The [M+H]+ ion of Leucine-enkephaline 
at m/z 556.2771 was used as lock mass for recalibration of the 
spectra to obtain exact mass data. The following Lock Spray 
configuration was set up. 
Cone voltage: 50 V 
Capillary voltage: 2.4 kV 
Scan frequency: 20 sec. 
Trap collision energy: 4 eV 
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7.2.2.2. Clearance calculations 
Initial half-life (T1/2) and elimination rate constants (lambda=ln2/T
1/2) of MDZ in hepatocyte 
incubates were calculated by log-linear regression of MDZ concentrations vs time using data 
from the sampling points of the 1 µM MDZ incubates showing a linear decrease on the semi-
logarithmic plot.  
The intrinsic clearance in vitro (CLint in vitro) was calculated from lambda and the cell density 
in the respective incubation (number of viable hepatocytes per mL at time zero) and scaled 
up to the intrinsic clearance in vivo (CLint in vivo) using the liver mass and the 
hepatocellularity (number of hepatocytes per gram of liver)  of the respective species: 
CLint in vitro = Lambda / cell density 
CLint in vivo = CLint in vitro x liver mass  x  heptocellularity 
From CLint in vivo and the hepatic blood flow (Q), the hepatic metabolic blood clearance 
(CLh,b) was predicted using the well-stirred model: 
CLh,b = (CLint in vivo  x  Q) /  (CLint in vivo + Q) 
No corrections were made for the free fractions in vitro or in vivo i.e. they were assumed to 
be identical. 
The value for liver mass, hepatocellularity and hepatic blood flow used in these calculations 
are given in Table 32. 
 
Table 32: Values for liver mass, hepatocellularity and hepatic blood flow (See Davies and 
Morris, 1993) 
Species Human 
Liver mass (g/kg body mass) 25.7 
Hepatocellularity (millions cells/g liver) 99 
Hepatic blood flow ((mL/min)/kg body mass) 20.7 
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7.3. Results and discussion 
7.3.1. Intrinsic metabolic clearance of MDZ in hepatocytes in the presence of LT and 
HP 
The intrinsic metabolic clearance of MDZ in the presence and absence of LT and HP was 
measured using human hepatocytes (Table 26). Extrapolation to hepatic blood clearance 
was performed using the well-stirred liver model (Davies and Morris, 1993). LT reduced the 
clearance of MDZ by 40% while the presence of HP did not alter the metabolism/clearance of 
MDZ (Figure 85, Table 33). The viability of the cells was not affected by the presence of the 
test compounds. Structural characterization of the metabolites was carried out by LC-MS2 
and the results are discussed below. 
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Figure 85: The influence of LT and HP on the in vitro clearance of MDZ in hepatocytes. 
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Table 33: The intrinsic clearance of MDZ in hepatocytes in the presence and absence of LT 
and HP 
Hepatocytes MDZ MDZ + ST MDZ + HP 
Half-life (h)1) 0.72 1.18 0.70 
CLint (µL/min/million cells)2) 16 10 16 
CLint, scaled (mL/min/kg)3) 40.98 24.98 41.85 
CLh,b (hepatic blood clearance) (mL/min/kg 
body weight)4,5) 
14 11 14 
1) Half-lives were evaluated by linear extrapolation 
2) (ln2/T1/2) / mio viable cells x 1000 
3) (CLint / 1000) * (cells / g liver) * (g liver / kg body weight) 
4) CLh = (Qh * CLint, scaled) / (Qh + CLint, scaled), Qh: hepatic blood flow; (well-stirred liver model) 
5) Qh (mL/min/kg body weight): 55 (rat); 30.9 (dog); 43.6 (monkey) ; 20.7 (human)  
 
 
 
7.3.1.1. Interpretation of mass fragmentation of MDZ 
Following the analysis of aliquots of human hepatocyte incubates with MDZ (t = 6h) by LC-
MS2, four metabolites were detected and were assigned as M1, M2, M3 and M4 (Figure 86)   
Using a combination of accurate mass measurement, elemental composition and MS/MS 
analysis, the 4 metabolites were identified as a combination of oxygenation and 
glucuronidation (M1), direct glucuronidation (M2) and a single oxygenation of MDZ (M3 and 
M4). These metabolites are consistent with previously published data on the metabolism of 
MDZ (Kronbach et al., 1989; Zhu et al., 2008; Seo et al., 2010).  
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Figure 86: Extracted ion chromatograms showing formation of metabolites M1 (RT = 10.17 min), M2 (RT = 10.62 min), M3 (RT = 11.85 min) 
and M4 (RT = 12.32 min) of MDZ following incubation with hepatocytes 
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7.3.1.2. Influence of LT and HP on metabolite production 
LT was specifically found to slow the formation of metabolites M1, M3 and M4 of MDZ while 
HP had no effects compared to controls (Figure 87 and 88). LC-MS peak areas for each 
compound were measured at 5 time points.  The time-course (0-6 hr) influence of LT and HP 
on the formation of MDZ metabolites is shown in Figures 89 to 95. 
 
Figure 87: Extracted ion chromatograms showing formation of metabolites M1, M2, M3 and 
M4 of MDZ in human hepatocytes in the presence of LT 
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Figure 88: Extracted ion chromatograms showing formation of metabolites M1, M2, M3 and 
M4 of MDZ in human hepatocytes in the presence of HP 
  
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
134 
 
Time (Hours)
0 1 2 3 4 5 6 7
A
re
a
/I
S
 A
re
a
0.0
0.5
1.0
1.5
2.0
2.5
MDZ
M1
M2
M3
M4
 
Figure 89: Time course over 6 hours showing the disappearance of MDZ and the formation 
of metabolites M1, M2, M3 and M4 in human hepatocyte incubations 
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Figure 90: Time course over 6 hours showing the disappearance of MDZ and the formation 
of metabolites M1, M2, M3 and M4 in human hepatocyte incubations in the presence of ST. 
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Figure 91: Time course over 6 hours showing the disappearance of MDZ and the formation 
of metabolites M1, M2, M3 and M4 in human hepatocyte incubations in the presence of HP 
 
Time (Hours)
0 1 2 3 4 5 6 7
A
re
a
/I
S
 A
re
a
0.0
0.2
0.4
0.6
0.8
MDZ Incubation
MDZ + LT
MDZ + HP
 
Figure 92: Time course showing the influence of LT and HP on the formation of metabolite 
M1 in human hepatocyte incubations 
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Figure 93: Time course showing the influence of LT and HP on the formation of metabolite 
M2 in human hepatocyte incubations 
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Figure 94: Time course showing the influence of LT and HP on the formation of metabolite 
M3 in human hepatocyte incubations 
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Figure 95: Time course showing the influence of LT and HP on the formation of metabolite 
M3 in human hepatocyte incubations 
 
7.3.2. Viability data 
During the incubation with MDZ, the viability of the hepatocytes (viable cells relative to total 
cells) decreased from 78.3% at time zero, to 42.7 without test inhibitor, 45.6 with LT and 42.7 
with HP. Thus, no major difference was observed in the presence or absence of the 
compound (Table 34). 
 
Table 34: Viability of hepatocytes at time 0 and 6 h incubation times, determined by the 
Guava EasyCyte Mini system using the ViaCount assay. 
Time point (h) MDZ MDZ+ST MDZ+HP 
0 78.3% - - 
6 42.7% 42.7% 45.6% 
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7.3.3. Stability of midazolam in the incubation media 
As determined at time 0 and 6 h in the negative control, MDZ concentration in the cell media 
(without hepatocytes) remained the same. Normalization of MDZ LC-MS peak area to the d4-
1‟hydroxymidazolam internal standard showed that the peak area ratio did not change 
between 0 and 6 hours of incubation, indicating that MDZ was stable in the incubation media 
over the time course of the experiments. This implies the absence of other forms of 
degradation (Figure 96).  
 
Figure 96: Extracted ion chromatograms showing the stability of MDZ over 6 hours in a 
no-hepatocyte control incubation 
 
7.4. Discussion 
Graded concentrations of the crude extracts of Lessertia frutescence and Hypoxis 
hemerocallidea were separately co-incubated with 1µM MDZ in human hepatocytes for up to 
6 h. The in vitro intrinsic clearance values of MDZ as calculated (in the presence and 
absence of LT and HP) were scaled to hepatic metabolic clearance values in vivo. 
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LT inhibited the production of MDZ metabolites with about 40% reduction in upscaled intrinsic 
in vivo clearance of MDZ (24.98 compared to 40.98 (L/h)/kg body mass). However, neither 
LT nor HP reduced hepatocyte viability as measured after 6 hours of incubation. 
The use of hepatocyte for in vitro drug metabolism is considered very close to in vivo reality 
because of the total expression of metabolic enzymes in the whole cells. The results from the 
use of hepatocytes have been variously employed for in vivo extrapolation. Thus, LT is a 
potential inhibitor of CYP3A4. It should also be noted that, the 40% reduction in MDZ 
clearance observed in this study is a reflection of a single dosage. In practice where herbal 
preparations are taken concomitantly with prescription medicines over a long period of time, 
the inhibitory effects of LT could be cumulative, and higher. 
 
7.5. Conclusion 
LT caused 40% inhibition of CYP3A4-dependent MDZ metabolism in hepatocytes over 6 
hour period, following a single addition. HP did not exert any inhibitory effects on MDZ 
metabolism in this study. If sufficient concentrations of the phytochemical constituents of LT 
are achieved in vivo, there is a potential for HDI. 
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CHAPTER EIGHT 
ASSESSMENT OF THE INHIBITORY EFFECTS OF LESSERTIA FRUTESCENS AND 
HYPOXIS HEMEROCALLIDEA ON EFFLUX PROTEINS (ABC TRANSPORTERS): P-
GLYCOPROTEIN AND BCRP 
 
8.0. Summary 
The influence of Lessertia frutescens and Hypoxis hemerocallidea on the activity of efflux 
(ABC) transporters (P-glycoprotein and BCRP) was investigated in monolayers of LLC-PK1 
cells expressing human P-gp; and monolayers of MDCKII cells expressing human BCRP 
monolayers. This was performed by determining the concentration dependent ability of the 
crude extracts (LT and HP) of the two herbs to inhibit efflux transporters leading to increased 
cellular uptake of radiolabeled probe substrates ([3H]Digoxin for P-gp and [14C]PhIP for 
BCRP).  
 
Within the concentrations tested, LT inhibited P-glycoprotein (IC50 = 324.31 µg/mL; Ki = 
324.31 µg/mL; maximum observed inhibition = 75.85 ± 7.45 %) with no inhibition observed 
for BCRP. HP did not inhibit the activity of any of the two transporters. 
 
Thus Lessertia frutescens may inhibit P-gp if sufficiently high concentrations of its extracts 
are achieved in vivo. It may not inhibit BCRP transporters at therapeutic concentrations 
(provided such concentrations are within the tested range).  In vivo inhibition of P-gp and 
BCRP transporters at therapeutic concentrations of Hypoxis corresponding to concentrations 
tested is not expected. 
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8.1. Introduction and objectives  
The roles of transport proteins have been well established in the pharmacokinetic profiles of 
drugs. ABC transporters particularly play significant roles in drug interactions including HDI. 
Two important ABC transporters are the human P-glycoproteins (P-gp) and human breast 
cancer resistant polypeptide (BCRP) which are expressed in several human tissues including 
the gastrointestinal tracts and the liver. As discussed in Chapter three, the inhibition of the 
activity of these transporters alters the absorption, distribution and clearance of administered 
drugs. 
The objective of this in vitro study was to determine the potential of Lessertia frutescence 
(Lessertia, LT) and Hypoxis hemerocallidea (Hypoxis, HP) to inhibit human ABC 
transporters-mediated drug efflux via P-gp) and BCRP.  
 
8.2. Materials and methods 
8.2.1. Materials 
The procedure for sourcing and preparation of Lessertia and Hypoxis were detailed in 
Chapter Four.  
The necessary chemical compounds were obtained as indicated: digoxin and cyclosporin A 
from Sigma-Aldrich (Pty) Ltd (St. Louis, USA); (3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-
methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 
1,1-dimethylethyl ester (Ko143) from Tocris Bioscience (Pty) Ltd (Ellisville, MI); 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine-2 (PhIP) and its radio-labeled from (1.85 MBq/nmol, 
radiochemical purity >99%) from Toronto Research Chemicals (Pty) Ltd (North York, 
Canada); radio-labeled [3H]Digoxin (1.103 MBq/nmol, radiochemical purity >97%) and 
[3H]estradiol-17β-D-glucuronide (1.72 MBq/nmol, radiochemical purity >97% from Perkin 
Elmer Radiochemicals (Pty) Ltd (Waltham, MA, USA)  
All other chemicals and materials were sourced as described in earlier chapters. 
8.2.2. Methods 
8.2.2.1. Working solutions 
Incubation solutions were prepared by serial dilution of Lessertia in assay buffer (see Table 
35) to obtain the final incubation concentrations of 5, 10, 50, 100, 150, 200, 250, 300, 350, 
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400, 450, 500, 550, 600, 650 and 700µg/mL for P-gp and 0.2, 0.4, 0.6, 0.8, 1, 2, 4, 6, 8, 10, 
20, 40, 60, 80, 100, 125, 150, 175 and 200µg/mL for BCRP. Lessertia was soluble up to a 
final concentration of 700µg/mL in P-gp uptake buffer and 200µg/mL in BCRP uptake buffer.  
Similar dilutions of Hypoxis were made in assay buffer to obtain the final incubation 
concentrations of 0.5, 1, 2, 5, 7.5, 10, 20, 50, 75, 100, 200, 300 and 500 µg/mL for P-gp and 
1, 5, 10, 20, 50, 100, 200, 300, and 500µg/mL for BCRP. Hypoxis was soluble up to a final 
concentration of 500µg/mL in both P-gp and BCRP uptake buffer (Table 35).  
Transporter inhibitors were added at concentrations given in Table 36. Methanol/DMSO was 
always below 1% of the total volume (v/v). All solutions used in cell growth were maintained 
at pH 7.4. Solutions for P-gp transporter studies were maintained at pH 7.4 whereas 
solutions for BCRP transporter assays were maintained at pH 7.8. 
 
Table 35: Probe substrate concentrations and incubation conditions 
Probe 
substrate 
ABC 
transporter 
Conc 
(µM) 
Literature 
Km value 
(µM) 
Incubation 
time (min) 
Buffer 
system 
pH 
adjustment 
Digoxin P-gp 1 650 a) 40 
HBSS + 12.5 
mM HEPES 
7.4 
PhIP BCRP 1 
not 
assessed b) 
40 
OPTI-MEM I 
+ 12.5 mM 
HEPES 
7.8 
a) (Cavet et al., 1996) b) (Van Herwaarden et al., 2003)  
 
8.2.2.2. Cell Culture 
MDCKII cells stably transfected with human BCRP were grown and maintained in DMEM 
supplemented with 10% FBS, 1% L-Glutamine and 1% penicillin/streptomycin at 37°C under 
an atmosphere of 5% CO2. Once they were defrosted, cells were not cultured for more than 2 
months. 
LLC-PK1 cells stably transfected with human P-gp were grown and maintained in Medium 
199 supplemented with 10% FBS, 50 ng/µL Gentamycin and 100 ng/µL Hygromycin B at 
37°C under an atmosphere of 5% CO2. Once they were defrosted cells were not cultured for 
more than 2 months. 
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8.2.2.3. Drug uptake/efflux studies 
Cells (~0.6 x 105 cells per well for LLC-PK1-P-gp and MDCKII-BCRP transfectants) were 
seeded into Falcon® clear bottom 96 well plates (Becton Dickinson) with 200 µL of culture 
medium. The assay was performed after 24 hr of seeding to allow for confluencing. On the 
day of the study, the culture medium was aspirated and replaced by pre-incubation solution 
(buffer system of choice containing the herbal extracts or the positive control inhibitor of 
interest) (Tables 11.1 and 11.2). Plates were subsequently incubated at 37°C for 10 min. To 
start the uptake experiment, the pre-incubation solution was replaced with the final incubation 
solution (buffer system of choice containing the probe substrate of choice and herbal extract 
or the positive control inhibitor of interest) (Tables 35 and 36). The experiment was 
terminated at designated time-points (Table 35) by removing the incubation solution. 
Subsequently, the cells were washed twice with ice-cold PBS buffer. Cell viability was 
assessed optically. The cells were then dissolved by the addition of 0.2 mL of 0.2 N NaOH 
solution to each well.  
After a further incubation for 20 min at 37°C (to dissolve the cells), aliquots (0.195 mL) were 
transferred into scintillation vials containing a scintillation cocktail solution, followed by the 
liquid scintillation counting to determine the radioactive substrates in the cells. All uptake 
studies were performed in triplicate in an incubator without shaking. In control experiments, 
incubations were performed using the same incubation conditions in the absence of cellular 
material. Based on this control data, unspecific binding to the plastic support was negligible. 
 
Table 36: Positive control inhibitor compounds 
Inhibitor Conc (µM) ABC 
transporter(s) 
Literature Ki value 
(µM) 
Substrate 
Cyclosporin 
A 
10  P-gp 1.3; 2.2a) yes 
Ko143 1 BCRP 0.2 (IC50) 
b, c) no 
LY335979 1  P-gp 0.5 (IC50) 
d)  yes 
a) (Ekins et al., 2002) b (Allen et al., 2002)  c) (Matsson et al., 2009) d) (Weiss et al., 2003), et al 
2002)  
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8.2.2.4. Drug uptake clearance calculations 
Probe substrate uptake clearance (nL/min/mg protein) by LLC-PK1 or MDCKII cells stably 
expressing P-gp or BCRP, respectively, was determined from the specific amount of 
radiolabeled probe substrate inside the cells divided by the concentration in the incubation 
medium and normalized to the incubation time and the mean protein concentration measured 
in test wells. 
 
8.2.2.5. Method suitability and limit of quantitation 
To assess the passive cellular uptake (= background permeation) and to demonstrate the 
functional expression of the transporter system of interest in the recombinant cellular uptake 
models; the inhibition of uptake activity was assessed against that afforded by positive 
control transporter inhibitors shown in Table 36. 
For labeled compounds, the limit of quantitation (LOQ) was taken as the lowest 
measurement from the radioactive scale which was statistically seen to be significantly higher 
than the measured blank value and for which the standard error of the measurement is lower 
than 20%. Under the conditions of this study, the LOQ of absolute radioactivity was 60 dpm 
for [3H]-labeled probe substrates and 20 dpm for [14C]-labeled probe substrates. 
 
8.2.2.6. Sample and data analysis 
The probe substrate transport in the presence of a competitive and non-competitive inhibitor 
can be described as follows (Gao et al., 2001): 
)/1(
max
KiIKmS
V
PSmPSapp


     Equation 8.1 
 
Where, PSapp represents the overall membrane permeability (nL/min/mg protein) of a probe 
substrate of choice (Table 35) at 37°C. S is the concentration (µM) of the probe compound in 
the medium, Vmax is the maximal uptake velocity/rate (pmol/min/mg protein), Km is the 
Michaelis-Menten constant (µM), PSm is the nonspecific (passive) membrane permeability 
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(nL/min/mg protein), Ki is the inhibition constant (µM) and I is the concentration of the 
inhibitor in the medium (µM). 
 
8.2.2.7. IC50 and kinetic parameter calculations 
All absolute transporter uptake data were converted into relative inhibition values (y) by 
defining membrane permeability of the probe substrate without addition of inhibitor (baseline) 
as 0% inhibition and with addition of positive control inhibitor as 100% transporter inhibition 
and recalculating all the other uptake data relative to this number.  
 
))),,)(0,,/((100(100 iPSapppPSappPSapppPSappy    Equation 8.2 
 
Where, PSapp,0 represents the initial membrane permeability without addition of inhibitor 
(=baseline) whereas PSapp,i and PSapp,p represent the membrane permeability in the 
presence of test inhibitor and positive control inhibitor, respectively. 
The IC50 values (inhibitor concentration that causes 50% inhibition of the maximal drug effect) 
were calculated using the equation 11.3 (Rautio et al., 2006): 
nInIC
nIa
yy



50
0       Equation 8.3 
Where, n is the slope factor (Hill coefficient), y0 is the relative baseline inhibition and a is the 
maximal transporter inhibition (%). 
To obtain estimates of the kinetic parameters, data were fitted to the above mentioned 
equations by a nonlinear least-square method using SigmaPlot® Version 12.1. All figures 
were drawn using SigmaPlot® Version 12.1. 
 
8.2.2.8. Statistical analysis 
The nonlinear-regression method of least squares was used to calculate the kinetic 
parameters from the respective uptake versus concentration curves. Testing for significant 
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differences between means was performed by unpaired Student‟s t test statistics, with p < 
0.05 as the minimum level of significance. 
 
8.3. Results  
8.3.1. Influence of Lessertia on P-gp 
The effect of the varying Lessertia concentrations on digoxin [nominal 1 µM] uptake by P-gp-
expressing LLC-PK1 cells is shown in Figure 97. Data are given as relative values by 
defining the transporter activities in the absence of Lessertia as 0% inhibition. The data are 
averages of triplicate determinations and the bars represent the standard deviations. The line 
represents the “best fit” of the data to the equation 8.3 (IC50 = 324.8 ± 27.8 µg/mL, a = 69.5 ± 
7.7 %, n = 7.9 ± 4.7, R2 = 0.88). The inhibitory activity of Lessertia is compared to standard 
inhibitor in Figure 98a and 98b. 
 
 
Figure 97: Concentration-dependent effect of Lessertia on probe substrate uptake by P-gp 
transporter-expressing LLC-PK1 cells. The data are averages of triplicate determinations and 
the bars represent the standard deviations 
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Figure 98: Comparison of the inhibitory activity of LT and cyclosporine A on P-gp mediated 
drug uptake in LLC-PK1 cells: a) digoxin (1 µM) uptake in the presence of no inhibitor 
compared to uptake in the presence of 700 µg/mL ST, positive control inhibitor LY335979 [1 
µM]/CsA [10 µM]; b) effects of graded LT concentration on digoxin uptake. The data are 
averages of triplicate determinations and the bars represent the standard deviations 
 
8.3.2. Influence of Lessertia on BCRP 
The effect of the extracts of Lessertia on PhIP [1 µM] uptake by BCRP expressing MDCKII 
cells as compared to known BCRP inhibitor is shown in Figure 99a and Figure 99b. Data are 
given as relative values by defining the transporter activities in the absence of Lessertia as 
0% inhibition. The data are averages of triplicate determinations and the bars represent the 
standard deviations. 
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Figure 99: Concentration-dependent effect of LT on probe substrate uptake by BCRP 
transporter-expressing MDCKII cells: a) comparison of the effects of 200 µg/mL LT and 
standard control and b) effects of varying LT concentrations on PhIP [1 µM] uptake by BCRP-
expressing MDCKII cells. The data are averages of triplicate determinations and the bars 
represent the standard deviations  
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8.3.3. Influence of Hypoxis on P-gp 
The effect of varying Hypoxis concentrations on Digoxin [nominal 1 µM] uptake by P-gp 
expressing LLC-PK1 cells as compared to standard P-gp inhibitor is shown in Figure 100a 
and 100b.  Data are given as relative values by defining the transporter activities in the 
absence of Hypoxis as 0% inhibition.  
 
 
 
Figure 100: a) Comparison of the inhibitory activity of HP and cyclosporine A on P-gp 
mediated drug uptake in LLC-PK1 cells: a) digoxin (1 µM) uptake in the presence of no 
inhibitor compared to uptake in the presence of 500 µg/mL HP, positive control inhibitor 
LY335979 [1 µM]/CsA [10 µM]; b) effects of graded HP concentration on digoxin uptake. The 
data are averages of triplicate determinations and the bars represent the standard deviations 
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8.3.4. Influence of Hypoxis on BCRP 
The effect of the extracts on PhIP [1 µM] uptake by BCRP expressing MDCKII cells as 
compared to known BCRP inhibitor is shown in Figure 101a and 101b. Data are given as 
relative values by defining the transporter activities in the absence of Lessertia as 0% 
inhibition.  
 
 
Figure 101: Concentration-dependent effect of HP on probe substrate uptake by BCRP 
transporter-expressing MDCKII cells: a) comparison of the effects of 500 µg/mL HP and 
standard control and b) effects of varying HP concentrations on PhIP [1 µM] uptake by 
BCRP-expressing MDCKII cells. The data are averages of triplicate determinations and the 
bars represent the standard deviations. 
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8.4. Discussion 
P-gp- or BCRP-transporter expressing cells were incubated with probe substrates in the 
absence and presence of increasing concentrations of the crude herbal extracts: Lessertia - 
up to 700 µg/mL for P-gp and up to 200 µg/mL for BCRP, respectively; and Hypoxis - up to 
500 µg/mL for both transpoters. The transporter activities without addition of test substances 
represent the control values (100% activity, 0% inhibition, baseline). Maximum inhibition of 
transporter activity was accomplished by the addition of known inhibitors of P-gp (LY335979, 
1 µM/CsA, 10 µM) and of BCRP (Ko143, 1 µM). The effect of the increasing LT and HP 
concentrations on the uptake of probe substrate by the ABC transporters is summarized in 
Table 37.   
 
 
Table 37: Summary of the influence of Lessertia and Hypoxis on the uptake activity of ABC 
transporters  
 
ABC transporter 
Probe 
substrate 
IC50 value 
a, 
b) (µg/mL) 
Ki 
c)  
(µg/mL) 
Max. inhibition b)   
(%) 
ST 
P-gp Digoxin 324.8 324.31 75.85 ± 7.45d 
BCRP PhIP 
not 
observed 
not applicable f) not observed e 
HYP 
P-gp Digoxin 
not 
observed 
not applicable f) not observed e 
BCRP PhIP 
not 
observed 
not applicable f) not observed e 
a) 
 Extract concentration estimated to inhibit transporter activity by 50% 
b) 
 Data used for  curve fitting are mean ± SD of N = 3 
c)  
Calculated with Ki= IC50/(1+S/ Km), where S is the substrate concentration of the probe substrate and Km is  the 
transporter affinity of the probe substrate according to Michaelis-Menten (see Table 35) 
d) 
 Maximal observed inhibition with respect to positive control (CsA/LY335979) 
e) 
 Maximal observed inhibition with respect to positive control (Ko143) 
f) 
 
 
Ki determination not applicable since Km of PhIP is unknown 
 
 
Based on these in vitro inhibition results, Lessertia was found to be an inhibitor of P-gp with 
an IC50 of 324.8 µg/mL with a maximal inhibition of 75.85 %. None of Lessertia and Hypoxis 
(up to the highest concentration 200 and 500 µg/mL respectively) was found to be an 
inhibitor of BCRP. Hypoxis did not inhibit the activity of P-gp. 
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8.5. Conclusion 
Lessertia may inhibit P-gp if sufficiently high concentrations are achieved in vivo. Based on 
the present data, it will not inhibit BCRP transporters at in vivo concentrations similar to those 
investigated. In vivo inhibition of P-gp and BCRP transporters by Hypoxis, within the 
concentrantions tested is not expected. 
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CHAPTER NINE 
ASSESSMENT OF THE INHIBITORY EFFECTS OF LESSERTIA FRUTESCENCE AND 
HYPOXIS HEMEROCALLIDEA ON DRUG UPTAKE TRANSPORTERS (OATP1B1, 
OATP1B3) 
 
9.0. Summary 
The influence of Lessertia frutescence and Hypoxis hemerocallidea on the human solute 
carrier (SLC) transporter-mediated uptake activity via the human organic anion transporting 
polypeptide family (OATPs) was investigated in monolayers of HEK293 cells expressing 
human OATP1B1 or human OATP1B3. This was performed by determining the 
concentration-dependent ability of the crude extracts (LT and HP) of the two herbs to inhibit 
cellular uptake of radiolabeled probe substrates ([3H]Estradiol-17β-D-glucuronide) of the 
OATP-transporters  
 
Within the concentrations tested, LT inhibited OATP1B1 (IC50 = 10.4 ± 0.6 µg/mL; Ki = 8.19 ± 
0.47 µg/mL; maximum observed inhibition = 100.08 ± 0.16 %) and OATP1B3 (IC50 = 6.6 ± 
0.9 µg/mL; Ki = 5.57 ± 0.76 µg/mL; maximum observed inhibition = 88.2 ± 2.27 %). Similarly, 
HP inhibited OATP1B1 (IC50 = 118.7 ± 33.3 µg/mL; Ki = 93.44 ± 26.21 µg/mL; maximum 
observed inhibition = 71.291 ± 5.22 %) and OATP1B3 (IC50 = 290.1 ± 59.7 µg/mL; Ki = 
244.79 ± 50.38 µg/mL; maximum observed inhibition = 93.95 ± 0.68 %). 
 
Thus, both Lessertia frutescens and Hypoxis hemerocallidea may inhibit OATP1B1 and 
OATP1B3 if sufficiently high concentrations of their extracts are achieved in vivo. They may 
not inhibit BCRP transporters at therapeutic concentrations (provided such concentrations 
are within the tested range).  In vivo inhibition of P-gp and BCRP transporters at therapeutic 
concentrations of Hypoxis corresponding to concentrations tested is not expected. 
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9.1. Introduction and objectives  
The solute carrier (SLC) group of membrane transport proteins are drug uptake transporters 
responsible for the movement of drug molecules across the cell membranes into the cell. 
They are present in the liver (and not in the gastrointestinal tract) (Tamai et al., 2001). They 
play roles in drug distribution and clearance, and are also responsible for carrier-mediated 
DDI and HDI. 
The objective of this in vitro study was to determine the potential of the crude extracts of 
Lessertia and Hypoxis to inhibit the human SLC transporter-mediated uptake via the human 
organic anion transporting polypeptide family (OATPs). 
 
9.2. Materials and Methods 
9.2.1. Material 
The procedure for sourcing and preparation of Lessertia and Hypoxis were detailed in 
Chapter Four.  
The chemical compounds were obtained as indicated: atorvastatin calcium (MW 1155.3 
g/mol; purity > 98%) from AK Scientific (Pty) Ltd (CA, USA), estradiol-17β-D-glucuronide 
(sodium salt; MW 470.5 g/mol; purity = 98%) and rifamycin SV (sodium salt; MW 719.8 
g/mol; purity = 98.8%) from Sigma-Aldrich (Pty) Ltd (St. Louis, USA), [3H]estradiol-17β-D-
glucuronide (1.72 MBq/nmol; MW 448 g/mol; radiochemical purity > 97%) from Perkin Elmer 
Radiochemicals (Pty) Ltd (Waltham, MA, USA). All other chemicals used were of analytical 
grade. 
 
9.2.2. Methods 
9.2.2.1. Working solutions 
Incubation solutions were prepared by serial dilution of the crude extracts of Lessertia in 
assay buffer (Table 38) to obtain the final incubation concentrations of 0.5; 1; 2; 5; 7.5; 10; 
20; 50; 75; 100; 200; 300 and 500 µg/mL for OATP1B1 and 0.5; 1; 2; 5; 7.5; 10; 20; 50; 75; 
100; 200; 300; 500 µg/mL for OATP1B3. Similar dilutions for Hypoxis was carried out in the 
assay buffer to yield final incubation concentrations of 0.5, 1, 2,5, 7.5, 10, 20, 50, 75, 100, 
200, 300, 500 µg/mL for OATP1B1 and 1, 2, 5, 10, 20, 50, 100, 200, 300, 400, 500, 600 and 
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800µg/mL for OATP1B3. The solubility of the crude extracts uptake buffer, up to the highest 
concentrations employed was ascertained by optical inspection. 
Transporter inhibitors were added at concentrations given in Table 39. Methanol was always 
below 1% of the total volume (v/v) and all solutions used in cell growth and transporter 
studies were maintained at pH 7.4. 
 
Table 38: Probe substrate concentrations and incubation conditions 
Probe 
substrate 
OATP 
transporter 
Conc 
(µM) 
Literature 
Km value 
(µM) 
Incubation 
time (min) 
Buffer 
system 
pH 
adjustment 
Estradiol-17β-
D-glucuronide 
OATP1B1 1 3.7 a) 5 
HBSS with 
12.5 mM 
HEPES  
7.4 
Estradiol-17β-
D-glucuronide 
OATP1B3 1 5.4 b) 5 
HBSS with 
12.5 mM 
HEPES  
7.4 
a) (Tamai et al., 2001) b) (Koenig et al., 2000)  
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Table 39: Inhibitors of the uptake transporters 
Inhibitor Conc (µM) OATP 
transporter(s) 
Literature Ki value 
(µM) 
Substrate 
Rifamycin SV 
(RSV) 
20  OATP family 2-3 a) no 
Atorvastatin 
(ATO)  
10  OATP1B1 2.6 b) (IC50) 
 
yes 
 
a) (Vavricka et al., 2002) b) (Chen et al., 2005) 
 
 
9.2.2.2. Cell Culture 
HEK293 cells stably transfected with human OATP1B1 were grown and maintained in DMEM 
supplemented with 10% FBS, 1% L-glutamine, 1% penicillin/streptomycin, and 50 ng/µL 
hygromycin B at 37°C under an atmosphere of 5% CO2. HEK293 cells stably transfected with 
human OATP1B3 were grown and maintained in DMEM supplemented with 10% FBS, 1% L-
glutamine, 1% penicillin/streptomycin and 0.8 mg/mL G418 at 37°C under an atmosphere of 
5% CO2. Once they were defrosted, cells were not cultured for more than 2 months. 
 
9.2.2.3. Drug uptake studies 
Cells (~0.2 x 106 cells per well for OATP1B1 and OATP1B3 overexpressing cells) were 
seeded into pre-coated (poly-L-lysine, poly-L-ornitin, 0.1 mg/mL) clear bottom 96 well plates 
(Corning Product No 734-1795) with 200 µL of culture medium. Uptake studies were 
performed 72 h after seeding. 
On the day of the study, the culture medium was aspirated and replaced with the final 
incubation solution (buffer system of choice containing the probe substrate of choice and 
Lessertia or the positive control inhibitor of interest) (Table 38 and 39). The experiment was 
terminated at designated time-points (Table 38) by removing the incubation solution. 
Subsequently, the wells were washed twice with ice-cold PBS buffer. Cell viability was 
assessed optically. The cells were then dissolved by the addition of 0.2 mL of 0.2 N NaOH 
solution to each well.  After incubation for 20 min at 37°C, aliquots (0.195 mL) were 
transferred into scintillation vials containing scintillation cocktail. All uptake studies were 
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performed in triplicate in an incubator without shaking. In control experiments incubations 
were performed using the same incubation conditions in the absence of cellular material. 
Based on this control data, unspecific binding to the plastic support was negligible. 
 
9.2.2.4. Drug uptake Clearance calculations 
Drug uptake (nL/min/mg protein) by the stably transfected OATP1B1, OATP1B3 cells was 
determined from the specific amount of radiolabeled probe substrate inside the cells divided 
by the concentration in the incubation medium and normalized to the incubation time and the 
mean protein concentration measured in test wells. 
 
9.2.2.5. Method suitability and limit of quantitation 
To assess the passive cellular uptake (= background permeation) and to demonstrate the 
functional expression of the transporter system of interest in the recombinant cellular uptake 
models known transporter inhibitors along with the above mentioned probe substrates for 
active carrier mechanism were included (Table 39). 
For labeled compounds, the limit of quantitation (LOQ) was taken as the lowest 
measurement from the radioactive scale which was statistically seen to be significantly higher 
than the measured blank value and for which the standard error of the measurement is lower 
than 20%. Under the conditions of this study, the LOQ of absolute radioactivity was 60 dpm 
for [3H] estradiol-17β-D-glucuronide. 
 
9.2.2.6. Analysis of inhibition kinetics 
The inhibition kinetics were analyzed employing the procedure and formula expressed in 
section 8.2.2.6.  
 
9.2.2.7. IC50 and Kinetic parameter calculations 
All absolute transporter uptake data were converted into relative inhibition values (y) by 
defining membrane permeability of the probe substrate without addition of inhibitor (baseline) 
as 0% inhibition and with addition of positive control inhibitor as 100% transporter inhibition 
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and recalculating all the other uptake data relative to this number. Further determinations 
were done as presented in section 8.2.2.7. 
 
9.2.2.8. Statistical analysis 
The nonlinear-regression method of least squares was used as described earlier in section 
8.2.2.8.  
 
9.3. Results  
9.3.1. The influence of Lessertia on OATP1B1 and OATP1B3 
The transporter activities without the addition of test substances represent the control values 
(100% activity, 0% inhibition, baseline). The inhibitory effect of increasing Lessertia extract 
concentrations on the OATP-transporter dependent uptake is presented in Figures 102 to 
105. The extracts inhibited the uptake activity of both OATP1B1 and of OATP1B3.  
The profile, in comparison with known inhibitors is provided in Figure 103 and 105. The 
calculated IC50 values were 10.4 µg/mL for OATP1B1 and 6.6 µg/mLM for OATP1B3, 
respectively. 
 
The effect of varying Lessertia concentrations on estradiol-17β-D-glucuronide [nominal 1 µM] 
uptake by OATP1B1 expressing HEK293 cells is shown in Figure 102. Data are given as 
relative values by defining the transporter activities in the absence of Lessertia as 0% 
inhibition. The line represents the “best fit” of the data to the equation 9.3 (IC50 = 10.4 ± 0.6 
µg/mL, a = 101.4 ± 1.7 %, n = 1.2 ± 0.08, R2 = 0.99).  
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Figure 102: A concentration dependent effect of LT on probe substrate uptake by OATP1B1 
transporter-expressing HEK293 cells. The data are averages of triplicate determinations and 
the bars represent the standard deviations. 
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Figure 103: OATP1B1-mediated estradiol-17β-D-glucuronide [nominal: 1 µM] uptake a) in 
the presence of 500 µg/mL LT extract compared to positive controls; and b) in the presence 
of increasing concentration of LT extract positive control inhibitor 20 µM rifamycin SV and 10 
µM atorvastatin (RSV/ATO). The data are averages of triplicate determinations and the bars 
represent the standard deviations 
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The inhibitory effects (%) of Lessertia on estradiol-17β-D-glucuronide [nominal 1 µM] uptake 
by OATP1B3 expressing HEK293 cells as profiled against extract concentration is shown in 
Figure 104. Data are given as relative values by defining the transporter activities in the 
absence of Lessertia as 0% inhibition. The line represents the “best fit” of the data to the 
equation 9.3 (IC50 = 6.6 ± 0.9 µg/mL, a = 85.3 ± 5.3 %, n = 1.16 ± 0.2, R
2 = 0.98). The data 
are averages of triplicate determinations and the bars represent the standard deviations. 
 
 
Figure 104: A concentration dependent effect of LT on probe substrate uptake by OATP1B3 
transporter-expressing HEK293 cells. The data are averages of triplicate determinations and 
the bars represent the standard deviations.  
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Figure 105: OATP1B3-mediated estradiol-17β-D-glucuronide [nominal: 1 µM] uptake a) in 
the presence of 500 µg/mL LT extract compared to positive controls; and b) in the presence 
of increasing concentration of LT extract positive control inhibitor 20 µM rifamycin SV and 10 
µM atorvastatin (RSV/ATO). The data are averages of triplicate determinations and the bars 
represent the standard deviations 
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9.3.2. The influence of Hypoxis on OATP1B1 and OATP1B3 
Extracts of Hypoxis inhibited OATP1B1 and of OATP1B3 (Figures 106 - 109). The calculated 
IC50 values were 118.7 µg/mL for OATP1B1 and 290.1 µg/mL for OATP1B3, respectively. 
The effect of varying Hypoxis concentrations on Estradiol-17β-D-glucuronide [nominal 1 µM] 
uptake by OATP1B1-expressing HEK293 cells is shown in Figure 106. Data are given as 
relative values by defining the transporter activities in the absence of Hypoxis as 0% 
inhibition. The line represents the “best fit” of the data to the equation 9.5 (IC50 = 118.7 ± 33.3 
µg/mL, a = 62.9 ± 7.5 %, n = 67.8 ± 20.8.1, R2 = 0.86).  
 
 
Figure 106: A concentration dependent effect of Hypoxis extracts on probe substrate uptake 
by OATP1B1 transporter-expressing HEK293 cells. The data are averages of triplicate 
determinations and the bars represent the standard deviations. 
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Figure 107: OATP1B1-mediated estradiol-17β-D-glucuronide [nominal: 1 µM] uptake a) in 
the presence of 500 µg/mL Hypoxis extract compared to positive controls; and b) in the 
presence of increasing concentration of LT extract positive control inhibitor 20 µM rifamycin 
SV and 10 µM atorvastatin (RSV/ATO). The data are averages of triplicate determinations 
and the bars represent the standard deviations 
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Figure 108. Data are given as relative values by defining the transporter activities in the 
absence of Lessertia as 0% inhibition. The line represents the “best fit” of the data to the 
equation 9.5 (IC50 = 290.1 ± 59.7 µg/mL, a = 99.2 ± 10.3 %, n = 195.5 ± 33.7, R
2 = 0.95).  
 
 
Figure 108: A concentration dependent effect of Hypoxis extracts on probe substrate uptake 
by OATP1B3 transporter-expressing HEK293 cells. The data are averages of triplicate 
determinations and the bars represent the standard deviations 
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Figure 109: OATP1B3-mediated estradiol-17β-D-glucuronide [nominal: 1 µM] uptake a) in 
the presence of 500 µg/mL Hypoxis extract compared to positive controls; and b) in the 
presence of increasing concentration of LT extract positive control inhibitor 20 µM rifamycin 
SV and 10 µM atorvastatin (RSV/ATO). The data are averages of triplicate determinations 
and the bars represent the standard deviations. 
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9.4. Discussion 
OATP1B1 and OATP1B3 are important drug transporters. Both Lessertia and Hypoxis 
inhibited uptake activity of these uptake drug transporters (Table 40).  
 
Table 40: Summary of the influence of Lessertia and Hypoxis on the uptake activity of ABC 
transporters 
 OATP 
transporter 
Probe substrate 
IC50 value 
a, b) 
(µg/mL) 
Ki 
c) 
(µg/mL) 
Max. inhibition b)  
(%) 
ST OATP1B1 Estradiol-17β-D-
glucuronide 
10.4 ± 0.6 8.19 100 d) 
OATP1B3 Estradiol-17β-D-
glucuronide 
6.6 ± 0.9 5.57 88.2 d) 
HYP OATP1B1 Estradiol-17β-D-
glucuronide 
118.7 ± 33.3 93.44 71.29 d) 
OATP1B3 Estradiol-17β-D-
glucuronide 
290.1 ± 59.7 244.79 93.95 d) 
 a)  Lessertia  concentration estimated to inhibit probe substrate uptake by 50% 
b) 
 Mean ± SD of N = 3 
c)  
Calculated with Ki= IC50/(1+S/ Km), where S is the substrate concentration of the probe 
substrate and Km is  the transporter affinity of the probe substrate according to Michaelis-
Menten (see Table 38) 
d) 
 Maximal observed inhibition with respect to positive control (RSV/ATO) 
 
The OATP transporter families are not expressed in the gastrointestinal tract. Their rich 
expression in the liver however, makes their effects on the pharmacokinetics of drugs very 
important (Emami-Riedmaier et al., 2012). Thus, any Lessertia- and/or Hypoxis-induced 
interaction with OATP transporter family will depend on the extent of the absorption of the 
herbs. Information on the absorption and bioavailability of Lessertia and Hypoxis 
phytoconstituents is currently not available. However, the long history of the use of Lessertia 
and Hypoxis for systemic disorders can be an indication of substantial systemic 
bioavailability (See Chapter 4). Caution should therefore be taken in combining Lessertia 
and/or Hypoxis with conventional medicines, especially OATP substrates. The systemic 
inhibition of OATP can prevent cellular uptake of important drugs with the potential of therapy 
failure, especially drugs intended for intracellular activity. Such inhibition can also lead to 
drug accumulation, and alteration in the intra- and extra-cellular concentration of drugs.   
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9.5. Conclusion 
Lessertia and Hypoxis may inhibit OATP1B1 and OATP1B3 if sufficiently high concentrations 
are achieved in vivo. This indicates a potential for herb-drug interactions. 
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CHAPTER TEN 
DISCUSSION, STUDY LIMITATION, CONCLUSION AND RECOMMENDATIONS 
 
10.1. General Discussion 
This study has demonstrated the potential of commonly consumed medicinal herbs in South 
Africa to inhibit metabolic enzymes and drug transporters. A summary of the results 
demonstrates the high likelihood of in vivo inhibitory effects, as shown in Table 41. 
In traditional practice, all selected herbs are taken as aqueous extracts, as gathered from the 
THPs. Thus, an aqueous extraction was used in this study to reflect what most consumers 
are exposed to during medical use of the plants. Lessertia and a growing number of 
medicinal herbs are available commercially in capsule formulations. A difference in the 
nature and quantity of phytochemicals exposed to in the body following the consumption of 
aqueous extract compared to whole-leaf capsules can be anticipated. This is because, 
phytoconstituents that are not water-soluble may be extracted from whole-leaf (or root, stem, 
bulb, rhizome) preparations by the gastrointestinal fluids. 50% methanol was thus used in a 
separate experiment to extract Lessertia, to facilitate the extraction of constituents that are 
not soluble in water. 
As shown in Table 41, both aqueous and methanolic extracts of Lessertia inhibited CYP1A2, 
2C9, 2C19 and 3A4. Table 42 further shows the inhibitory effects of methanolic extracts of 
Lessertia on all the CYP isozymes and transport proteins except BCRP. 
The extent of inhibition of the enzymes has been presented in relative terms in Table 41 and 
Table 42. Using arbitrary range of potency, inhibition with IC50 value of less than 100 g/mL 
is considered potent (+++), IC50 values between 100 and 1000 g/mL are considered 
moderate (++) and values greater than 1000 g/mL mild/negligible (+). This is because, such 
high concentrations are not likely achievable in vivo.  
In Table 41 and Table 42, traditional doses of the medicinal herbs are provided based mainly 
on the information gathered from the THPs. According to the THPs, the traditional doses are 
estimated and not subjected to conventional weighing in practice. While single-dose (Tables 
41) decoctions are common as dosage regimes, higher amounts of herbal products (about 
10 -50 g) are often decocted and taken several days in the course of treatment. Thus, it is 
difficult to determine uniform doses of traditional medications. The estimates provided 
however, are determined based on the information gathered from the THPs and the 
determined weight of sample doses. 
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Based on the approximated intestinal fluid volume of 250 mL and the laboratory extraction 
yields, putative achievable concentrations of the herbal extracts in the GIT were determined 
as shown in Table 41. The extent and efficiency of extraction of the herbs in the intestine 
may vary from laboratory extraction due to several factors: intestinal fluid composition, GIT 
transit time, disease state and dosage form (whole leaf/root, ground herbs or refined 
products as in capsules, tablets etc). The putative values of achievable intestinal 
concentration of the extractds are higher than the determined IC50 of the herbal extracts. This 
is important because of the rich expression of CYP and ABC transporters in the intestines 
(Ufer et al., 2008). Information on the absorption and bioavailability of the herbs is not 
available in literature. However, with the high putative GIT concentrations, high systemic 
blood levels are likely with the potential for post-absorption HDI. 
Lessertia and Hypoxis are popular among people living with HIV/AIDS. The combination of 
Lessertia and/or Hypoxis with antiretroviral drugs presents the potential for HDI (Mills et al., 
2005b). This is because, most antiretroviral drugs are substrates of the enzymes and 
transporters inhibited by the two herbs. 
All herbs investigated in this study inhibited at least one metabolic enzyme. Considering the 
traditional use of such herbs, and conventional medications, important HDI can be inferred. 
For example, Ranunculus multifidus is traditionally used for the treatment of STIs, genital 
sores, warts and haemorrhoids (See Table 4.1 in Chapter 4). Patients who consume this 
herb for these indications may combine them with antibiotics. Results from this study (Table 
41) showed that extract of Ranunculus multifidus is a potent inhibitor of CYP3A4. Antibiotics 
like erythromycin are substrates of CYP3A4. 
Within the context of the literature, similar but limited investigations have been conducted 
most of which agree with the findings of the current study. A study by Mills and co-workers 
(2005b) had suggested that extracts of Hypoxis hemerocallidea and Lessertia frutescens 
may inhibit CYP3A4 and P-gp. The study investigated the potential of Hypoxis 
hemerocallidea and Lessertia frutescens to inhibit CYP3A4-mediated metabolism and P-gp-
dependent drug transport as a way of assessing potential HDI with ARVs. While a number of 
ARVs are metabolized by CYP3A4 and/or transported by P-gp, others are not. There are 6 
major classes of drugs approved by the US-FDA for the treatment of HIV/AIDS which include 
nucleotide reverse transcriptase inhibitors (NRTI), non-nucleotide reverse transcriptase 
inhibitors (NNRTI), protease inhibitors (PI), fusion inhibitors, integrase inhibitors, and 
chemochine receptor CCR5 antagonists. Entry inhibitor, maraviroc, is a CYP3A4 substrate 
making it a potential candidate for CYP3A4-dependent drug interactions. While protease 
inhibitors (PIs) are known substrates of both CYP3A4 and p-glycoprotein, other enzymes are 
involved in their metabolism. These include CYP2C19, 2D6, 2C9 and 2E1. Etravirine inhibits 
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CYP2C9 and CYP2C19. Efavirenz is a substrate of CYP2B6. In addition to these, most 
HIV/AIDS patients have co-morbidities managed with other drugs. These other drugs are 
substrates of a wide range of enzymes/transporters which were not covered in the study by 
Mills and others. 
The findings of the current study however, agree with those of Mills and co-workers (2005b) 
with both herbs inhibiting the activity of CYP3A4. Only Lessertia frutescens inhibited the 
transport activity of P-gp. The difference in methodology (sourcing of herbal specimen, 
extraction and incubation method, concentration range etc) may account for why Mills and 
co-workers observed inhibition of P-gp by Hypoxis hemerocallidea while similar inhibition 
was not observed in this study. For example, HLM and standard recommended probe 
reactions of the various CYP isozymes were used in this study. This presents a major 
difference when compared to the inhibition of the conversion of dibenzylfluorescein to 
fluorescein with a measurement of fluorescence at 538 used by Mills and co-workers to 
probe CYP3A4-dependent reactions. Such reaction has not been sufficiently proven to be 
exclusively CYP3A4-catalysed in a microsome mixture containing all CYP isoforms 
(Bjornsson et al., 2003). The assessment of the influence of the herbal extracts on most CYP 
enzymes, BCRP, OATP1B1 and OATP1B3 makes this study more extensive than that of 
Mills and co-workers.  
In a study to investigate the effect of the aqueous extracts of Hypoxis hemerocallidea and 
Lessertia frutescens on the transport of nevirapine across human intestinal epithelial cells 
using caco-2 cell monolayers model, Brown and co-workers (2008) reported that the extracts 
of Hypoxis hemerocallidea inhibited nevirapine transport. The effect of Lessertia frutescens 
on nevirapine transport was not significantly different from the control. Compared to the 
current study, extracts of Lessertia frutescens inhibited the acitivity of P-gp although in a 
different in vitro model.  
Nair and co-workers (2007) investigated the influence of the phytochemical constituents 
(hypoxoside, rooperol, β-sitosterol, stigmasterol and stigmastanol) of Hypoxis hemerocallidea 
on the metabolic activity of CYP 3A4/5, CYP2C19 using in vitro fluorometric microtitre plate 
assay with isolated CYP isozymes. The potential interaction with P-gp was investigated by 
measuring the efflux of the fluorescent dye rhodamine 123 (Rh 123) in the caco-2 cell line 
model.  The study reported that stigmasterol and rooperol inhibited the activity of CYP3A4/5 
and CYP2C19 while hypoxoside induced P-gp. The use of phytochemical constituents for 
HDI studies is common but often non-reflective of the method of herbal use. Thus, apart from 
the extensive coverage of the CYP and transporters, the use of crude extracts in the current 
study makes a major difference from the work of Nair and colleagues (2007). Both studies 
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however, demonstrated the inhibitory activity of Hypoxis hemerocallidea on CYP3A4/5 and 
CYP2C19. 
Gwaza and co-workers (2009) investigated the inhibitory activity of the extracts of a different 
specie of Hypoxis (Hypoxis obtusa) on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 
using HLM. Inhibitory effect of the extracts on P-gp using caco-2 cell monolayers model was 
also assessed. The authors reported that the extracts inhibited the CYP isozymes tested with 
no significant activity on P-gp. Compared to the current study, the inhibitory behaviour is 
similar except for CYP2C9 where no inhibition was observed in the current study.  
In another study, Mogatle and co-workers (2008) evaluated the effect of Hypoxis 
hemerocallidea on the pharmacokinetics of efavirenz in a single-dose, two-phase sequential 
study conducted over 31 days in 10 healthy volunteers. Subjects were administered with a 
600 mg single-dose efavirenz on Day 1 followed by blood sampling for analysis. From Day 
16 to 30, subjects consumed preparations of Hypoxis hemerocallidea with 600 mg efavirenz 
added on Day 29. No significant pharmacokinetic HDI between Hypoxis hemerocallidea and 
efavirenz was observed. The finding from this study is important but may be difficult to 
generalize. This is because efaviranz is metabolized by both CYP2B6 and CYP3A4. Other 
substrates of each of the enzymes may behave differently. 
Two more studies conducted on Lessertia frutescens are those by Minocha and colleagues 
(2011) and Müller and co-workers (2012). Müller and co-workers investigated the effects of 
the extracts and phytochemical components on the in vitro absorption and metabolism of 
atazanavir, a protease inhibitor, in HLM and caco-2 cell monolayers. The authors reported 
that aqueous extract and D-pinitol (a phytoconstituent of Lessertia frutescens) significantly 
reduced atazanavir accumulation by caco-2 cells (which implied a decrease in atazanavir 
absorption). Both the aqueous and methanolic extracts inhibited atazanavir metabolism in 
HLM. 
Minocha and colleagues (2011) investigated the effects of short term and chronic exposure 
of Lessertia frutescence on the oral bioavailability and pharmacokinetics of nevirapine in 
Sprague Dawley rats. No significant difference in the pharmacokinetic parameters of 
nevirapine was found upon short-term co-administration. However, there was a 50% 
decrease in the AUC and C(max) values of nevirapine after 5 days of chronic exposure with 
Lessertia frutescens. The quantitative reverse transcription polymerase chain reaction (RT-
PCR) studies demonstrated a 2-3-fold increase in the hepatic and intestinal mRNA 
expression of CYP3A2, relative to control. Employing LS-180 cells as an in vitro induction 
model for human CYP3A4, and using rifampicin as a positive control, extracts of Lessertia 
frutescens elevated m-RNA expression levels and functional activity of CYP3A4 (human 
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homologue of rodent CYP3A2). The results suggested a potential for HDI between Lessertia 
frutescens and nevirapine on chronic administration.  
The findings of the current study agree with those of Minocha, Müller and co-workers. By 
inhibiting the activity of CYP3A4, other enzymes and transporters involved in the metabolism 
of ARVs, Lessertia frutescens has been shown to be a potential candidate for HDI in 
HIV/AIDS drug management. The popularity of Hypoxis Hemerocallidea and Lessertia 
Frutescens in Africa, and the various interests involved in their use and promotion make 
them deserving herbal products for multiple scientific studies.  
Apart from Hypoxis hemerocallidea and Lessertia frutescens, information on the potential of 
other herbal products used in this study for HDI potential is sparse. Extracts of Spirostachys 
africana has previously shown inhibitory activity against CYP2C9, CYP2C19 and CYP3A4 in 
a study conducted using CYP inhibition screening that employed pregnane X (PXR) receptor 
in Chinese hamster ovary cell lines expressing human PXR (van den Bout-van den Beukel et 
al., 2008). The study reported induced CYP3A4 mRNA levels in the presence of the extracts. 
The current study reports a potent inhibitory effect of the aqueous extracts of Spirostachys 
africana on CYP3A4.  
Diosmetin, a phytochemical constituent of a different specie of Acacia (Acacia farnesiana) 
has been shown to be a potent inhibitor of CYP1A1 and CYP1B1 enzyme activity by 
Androutsopoulos and co-workers (2009). Its crude extracts have been shown to inhibit 
xanthine oxidase (Chang and Yu-tang, 2012). 
In general, the findings of the current study agree largely with previous studies (where 
available). This study thus provides a more elaborate assessment of HDI potential in 
commonly used South African medicinal herbs. 
From the foregoing discussion, it is important to put the findings of this study in the following 
perspective: 
1. Medicinal herbs are widely used and their indications vary from place to place. 
2. Methods of use also vary. All the herbs investigated in this study are taken 
traditionally as aqueous decoction/infusions. 
3. Conventional medications that may be combined with herbal products vary widely. 
4. The in vitro inhibition of metabolic enzymes can reliably predict similar effects in vivo, 
with variations in the extent of inhibition, as earlier studies have shown. 
5. The long history of the folkloric use of the medicinal herbs used in this study, for 
systemic disorders is an indication of their potential systemic availability. Systemic 
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availability of phytoconstituents increases the potential for enzyme/transporter 
inhibition and HDI. 
6. In the absence of systemic availability of phytoconstituents of the selected herbs, the 
effects of high GIT concentrations on drug absorption can be clinically potent 
especially with drugs with high presystemic intestinal metabolism, and narrow 
therapeutic window. 
7. Compared to microsomes, results from in vitro use of cryopreserved hepatocytes are 
closer to in vivo condition due to the complete expression of the cell matrix and the 
presence of other enzymes.  Thus, the predicted reduction of midazolam clearance 
by 40% by Lessertia, as shown with the in vitro-in vivo correlation may be clinically 
relevant. 
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Table 41: Summary of the findings of this study, in vivo predictions and possible clinical significance: extent of enzyme inhibition is provided as strong 
inhibition with IC50 of 0-100 g/mL (+++); moderate inhibition with IC50 of 100-1000 g/mL (++); mild/negligible inhibition with IC50 greater than 1000 
g/mL (+); and no inhibition (-). 
Scientific name CYP1A2 CYP2C9 CYP2C19 CYP3A4 Yielda 
(%w/w) 
Usual (single) 
dose (mg)b 
Estimated extract 
per dose (mg)c 
Putative GIT 
conc (g/mL)d 
Acacia karroo  ++ ++ +++ +++ 15.3 1000 153 612 
Alepidea 
amatymbica  
 
++ +++ + - 14.5 1000 145 580 
Bowiea volubilis  +++ - + +++ 15.6 1000 156 624 
Capparis sepiaria  ++ +++ +++ +++ 17.3 1000 173 692 
Chenopodium album 
 
+++ - +++ ++ 17.7 1000 177 708 
Emex australis  - +++ + +++ 19.0 1000 190 760 
Hypoxis 
hemerocallidea 
+++ - ++ +++ 12.6 1000 126 504 
Kedrostis africana  +++ +++ ++ +++ 20.6 1000 206 824 
Pachycarpus 
concolor  
- +++ +++ +++ 16.5 1000 165 660 
Pentanisia 
prunelloides  
- +++ + +++ 19.2 1000 192 768 
Ranunculus 
multifidus  
 
++ ++ +++ +++ 14.1 1000 141 564 
Spirostachys 
africana  
+++ - - +++ 18.1 1000 181 724 
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Scientific name CYP1A2 CYP2C9 CYP2C19 CYP3A4 Yielda 
(%w/w) 
Usual (single) 
dose (mg)b 
Estimated extract 
per dose (mg)c 
Putative GIT 
conc (g/mL)d 
 
Lessertia frutescens  
(Methanolic) 
+++ +++ +++ +++ 28.5 300
e
 85.5 340 
Lessertia frutescens 
(aqueous) 
 
+++ +++ +++ +++ 20 1000 200 800 
Tulbaghia violacea ++ ++ + + 16.4 1000 164 656 
Zantedeschia 
aethiopica 
 
+ ++ +++ +++ 15.2 1000 152 608 
a
 This is laboratory extraction yield using water in all cases except with Lessertia where both water and methanol were used as extraction solvents 
b
 Usual traditional doses vary widely. On the average, up to 10g of the herbal materials are extracted and the decoctions are taken over time (3-6 times). Thus each 
consumption represent an extract of >1g 
c
 This is based on the assumption that similar yield is obtained in the traditional process of decoction or extraction 
d
 The estimation of putative GIT concentration is based on the average volume of GIT fluid (250mL) 
e 
The 300mg traditional dose is based on the commercially available 300mg capsules of Lessertia made of its dried leaves. Aqueous extraction will not be a close 
reflection of a whole-leave consumption, as the patients are exposed to non-aqueous-soluble contents, thus the choice of 50% methanol for extraction 
Note: Extent of CYP inhibition is given in relative terms: no inhibition (-); strong inhibition with IC50 of 0-100 g/mL (+++); moderate inhibition with IC50 of 100-1000 g/mL 
(++); and mild/negligible inhibition with IC50 greater than 1000 g/mL (+) 
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Table 42: The relative inhibitory effect of Lessertia and Hypoxis on CYP isozymes and transport 
proteins: extent of inhibition is provided as follows: strong inhibition with IC50 of 0-100 g/mL 
(+++); moderate inhibition with IC50 of 100-1000 g/mL (++); mild/negligible inhibition with IC50 
greater than 1000 g/mL (+); and no inhibition (-). 
 
Enzyme/transporter Relative inhibitory effect of  
Lessertia Hypoxis 
CYP2A6 ++ ++ 
CYP2B6 +++ +++ 
CYP2C8 +++ ++ 
CYP2D6 ++ - 
CYP2E1 + - 
P-gp ++ - 
BCRP - - 
OATP1B1 +++ ++ 
OATP1B3 +++ ++ 
 
 
10.2. Study Limitation 
For this study, all herbal samples were obtained from THPs, just as consumers/clients do. It is 
important to note that many other consumers of herbal products obtain them commercially (for 
instance, in the open markets). The phytochemical composition of herbs is known to vary 
depending on the place and time of harvesting. Thus, as representative as the collection 
procedure in this study may be (within the South African context), same herbs obtained from 
other provinces and localities may exhibit variations in phytochemical constituents. Modern 
commercialization of medicinal herbs involves the deliberate cultivation (including nursing, 
application of fertilizers/organic manure, irrigation and shedding) of the herbs of interest. Since 
THPs rely principally on wild sources, the extent of phytochemical composition from the 
different sources may vary. 
Another important limitation to the generalization of the findings in this study is the known 
variation of the phytochemical composition of medicinal plants due to time of harvest. A study 
conducted by Ozkan and co-workers (2010) found that the chemical compositions, free radical 
scavenging activities and reducing/antioxidant capacities of the extracts and essential oils of the 
studied plant (Turkish oregano) changed significantly depending on the vegetative periods of 
growing season. Thus, such quantitative and qualitative differences in the phytochemical 
expression of medicinal plants may lead to variations in the inhibitory activity of the herbal 
extracts on metabolic enzymes. 
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In traditional use, estimates of dosages are often consumed. There can be variation on the 
extraction/decoction process (temperature, time). This may lead to variation in the concentration 
of extracts consumed by the individual patients. The yield from laboratory extraction may vary 
from the actual yield from the consumers‟ decoctions. Thus, values and correlations made 
herein are estimates only. The non-standardized dosage system of the THPs makes it 
practically difficult to predict what GIT concentration may have important interaction with 
metabolic enzymes and transporters. 
It is important to note that, there may be variations in what THPs indicate for various medicinal 
herbs. What is consumed for a particular ailment in a province may be indicated for a different 
or additional disease in another locality. This will influence the conventional drugs that are 
candidates for concomitant administration. 
There was no analysis of the individual phytochemical composition of the extracts. The findings 
in this study are based on crude extracts only. The determination of the exact compounds 
exerting inhibitory activity on the drug metabolism and/or transport process was beyond the 
scope of this study.  
The extracts that may be systemically available in significant quantities are not known. With no 
information on the extent of oral absorption of the crude extracts of the individual herbs, the 
extent of systemic inhibition of enzymes/transporters, especially in the liver could not be 
estimated. These herb-specific factors have been recognised as major limitations of in vitro 
assessment of herb-drug interactions (Markowitz and Zhu, 2012). 
Certain limitations are associated with the in vitro models employed in this study. Ideally, clinical 
pharmacology studies should comprehensively investigate drug biotransformation and 
interaction in humans. This will ensure the most reliable clinical data. Some of the major 
setbacks of such studies are the risk to the human subjects and the stringent ethical and 
regulatory requirements. The use of in vitro technologies has thus evolved and advanced as 
suitable alternative. In the current study, human liver microsomes, cryopreserved hepatocytes 
and transfected mammalian cell lines were used.  
In all models, there is a continuous contact between the test inhibitors, enzyme/transporters and 
their substrates. This is not representative of the in vivo system where blood circulation 
provides mobility to the drugs and the inhibitors. Non-specific plasma protein binding, organ 
perfusion, concentration of drugs in body areas with no or less metabolic activity, solubility in 
the surrounding lipid layers, the contribution of other enzyme systems and non-metabolic 
clearance are not reflected in in vitro systems (Poulin, 2013).   
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HLM has poor quantitative extrapolative values. Microsomes consist of the vesicles of the 
hepatocyte endoplasmic reticulum prepared by differential centrifugation (Brandon et al., 2003). 
As a result, they contain almost only CYP and UGT enzymes. The absence of other enzymes in 
the microsomes makes in vitro metabolism faster compared to in vivo scenario. The artificiality 
of exogenous supply of co-factors to the microsomal incubation is a major variation from in vivo 
reality (Ong et al., 2013). The relevance of the drug concentration employed in microsomal 
incubations is often questionable as only microsomal binding is available compared to 
additional and often more pronounced plasma protein binding in vivo (Poulin, 2013). The choice 
of incubation conditions may influence the outcomes of in vitro studies. In the in vivo scenario, 
for example, the ionic strength and pH are kept constant through homeostatic processes. 
Maintaining these same conditions in vitro is difficult. While the initial pH can be regulated, the 
addition of water, methanol, extract solution and co-factors can greatly alter the 
physicochemical conditions (Ong et al., 2013).  
Organic solvent, although used at the minimum permissible level, may still influence the activity 
of the enzyme system. This is because of its continuous and persistent presence in the 
incubation mixture unlike in the in vivo setting. Although the use of pooled HLM and 
hepatocytes is supposed to neutralize the donor-to-donor variations, the efficiency of pooling 
depends to a large extent on the balanced blend of donors from various racial, gender and 
genetic groups. This is difficult to achieve. Further limitations in extrapolating in vitro data to 
predict in vivo relevance is the implicit assumption that the drug candidate to be affected is 
solely metabolized in the liver. In reality, multiple enzymes are responsible for the metabolism of 
a large number of drugs (Camenisch and Umehara, 2013).   
Although cryopreserved hepatocytes often retain their metabolic enzyme activity, the effect of 
cryoprotectants on the primary hepatocytes is not completely understood. There has been no 
characterization of cryopreserved hepatocytes, including the quantitation of transcription 
factors, co-activators and co-repressors, the effectiveness of the inherent co-factors and the 
maintenance of cellular integrity, all of which are important regulators of drug metabolizing 
enzymes (Hariparsad et al., 2006). The cycle of freezing and thawing of the cryopreserved 
hepatocytes is known to reduce their viability (Terry et al., 2010). In vitro use of hepatocytes 
does not require an exogenous supply of co-factors. Unlike the in vivo situation where energy 
supply for metabolic activity is consistent, the viability of hepatocytes decreases with time of 
activity during incubation. This may influence outcomes of rate and extent of metabolism in in 
vitro settings, and make in vivo extrapolations inaccurate. The absence of other liver-based 
cells such as Kupffer cells in this model makes the metabolic environment different and non-
representative of the liver. 
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In vitro drug transport assays employ cell lines transfected with the desired transporter protein. 
This study used Madin-Darby canine kidney (MDCK-II and LLC-PK1), transfected with human 
MDR1 (ABCB1) as a recombinant models for efflux transport. Human Embryonic Kidney 
(HEK293) cells transfected with human OATP1B1 and OATP1B3 were used for the drug uptake 
transport assays. Endogenous transporters in these cells may contribute to the activities of the 
recombinant transporters. The expression of such endogenous transporters may vary from cell 
to cell, and therefore difficult to account for in the result interpretation. According to Kuteykin-
Teplyakov and co-workers (2010), this difference in the expression of endogenous efflux 
transporters provide a potential bias for in vitro studies on drug transport.  
In the liver, hepatocytes express both metabolic enzymes and transport proteins. The absence 
of metabolic enzymes in transfected cell lines thus, is at variance with in vivo scenario. The 
isolation and concentration of the transport proteins in the transfected cells provides a high drug 
transport rate which is not the case in vivo (Masimirembwa et al., 2012; Alqahtani et al., 2013).  
Due to these highlighted limitations, accurate measurement of kinetic parameters to correspond 
with values in vivo or through extrapolation is difficult. The results obtained from this study are 
largely qualitative, and only provide indications for the potential for herb-drug interactions. 
While in vitro HDI studies provide the indication for in vivo relevance, in vivo human studies are 
the ultimate proof of clinically significant HDI. 
 
10.3. Conclusion 
All the selected medicinal herbs inhibited one or more of the CYP isozymes and drug transport 
proteins. The confirmation of inhibitory effects of Lessertia using human hepatocytes is a 
stronger indication of in vivo reflection of the findings of this study. The study clearly shows 
potential for clinically relevant HDI between the studied herbs and conventional medicines. It is 
important for health practitioners, patients and policy makers to be aware of HDI potential in 
concurrent herb-drug use. 
 
10.4. Recommendations 
In vitro liver-based drug metabolism is still the standard for drug interaction studies especially 
for new chemical entities and poorly understood compounds like phytochemicals. However, due 
to the increasing knowledge in phytopharmacology, in vivo human studies can be 
recommended to expand the knowledge of HDI with respect to the medicinal herbs selected in 
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this study. Such study will provide definite clinical significance of the observed inhibition of 
metabolic enzymes and transport proteins. 
There is also a need to research into the identification of the active phytochemical entities in the 
herbal products. A further understanding of the systemic bioavailability of such phytochemicals 
will be beneficial in elucidating clinical benefits, and open opportunities in drug discovery. 
Future findings in this regard will also be important in understanding phytotoxicity and drug 
safety.   
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Liver-Based In Vitro Technologies for Drug Biotransformation Studies-A Review 
Pius Fa simi'-', Patrick J. Bouic2·3 and Bernd Rosenkranz1 
1Division of Phannacology, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, Cape Town, South Afiica, 2Synexa 
Life Sciences, Montague Gardens, Cape Town South Afiica, 3 DMsion of Medical Microbiology, F acuity of Health Sciences, Univer-
sity ofStellenbosch, Tygerberg, Cape Town, South Afi·ica 
Abstract: Early understanding of the metabolic pathway and potential interaction of new dmg candidates witl1 other dmgs is one of tl1e 
goals of preclinical studies in the dmg discovery process. Although other body organs are involved in dmg biotransfonnation, the liver is 
tl1e predominant organ of metaboliSill for a wide range of endogenous compounds and xenobiotics. T11e set of enzymes contained in the 
cytochrome P4 50 superfallllly present predominantly in the liver have been 1dentified as the single most important agent of dmg metabo-
lism and have fom1ed the bedrock of most matured tedUJologies for in vitro dmg biotramformation studies. Witl1 the development of a 
number of liver-based technologies, in vitro metabolism has gained significant popularity in the past three decades. Tilis has come in re-
sponse to several demanding factors inch1ding the questionable relevance of data from aninlal studies; d1e lllgh cost and stringent regula-
tory and etlllcal requirement, as well as safety issues involved with studies using human subjects; and the need for lll~1 throughput due to 
d1e wide range of chemical entities for routine investigati01t~. TI!ese technologies which vary from whole liver to subcellular fractio1t~ 
have found ready application in generating the desired infom1ation on the substrate and inllibitor specificity of most metabolic enzymes. 
Tilis paper reviews such teclu10logies as isolated fresh liver; liver slices; prinlary, cultured and cryopreserved hepatocytes; microsomes; 
cytosolic fractions; and purified or heterologous~ expressed dmg-metabolizing enzymes. It lli~1lights the general principles of in vitro 
enzyme kinetics and the factors that determine tl1e choice of each in vitro technology for biotransfonnation studies. 
215 
K~ywords : biotransfonnation, cytochrome P450, in vitro metabolism, liver cytosol, liver slices, microsomes, S9 fi·actions, subcellular frac-
tions, UDT -glucuronosyltransferase. 
INTRODUCTION 
Dmg biob·ru1sfonnation study ~ ru1 integral prut of preclinic-al 
screening for new dmg cru1didates [1]. This assessment usually 
involves botl1 in vitro ru1d in 1~VO models in ruumal species where 
the main phrumacokinetic, phannacodynru1uc ru1d toxicologic-al 
The use of human subjects for comprehensive clinical phruma· 
cology studies seems to be ideal. However, the t1sks involved, ru1d 
rl1e stringent regulat01y demands make tl1is practically challenging 
with attendru1t high cost ru1d longtime duration. Results fi'Om ru1imal 
studies also pose cotrelation challenges ru1d clinical sigtuficru1ce. 
. . 
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An overview of the evidence and mechanisms of 
herb-drug interactions 
Pius S. Fasinu 1, Patrick J. Bouic2.3 and Bernd Rosenkranz'* 
' Divisioo of F!Jarmacology, fiiCU/ty ci Health Sciences, University ci SteNenoosc/1 Cape Town, South Aflic;~ 
1 Divisioo of Medical Microbidogy, Faculyof Health Sciences, University of Stellenbosch, Dlpa lilwn, South Africa 
' $ynQKa Life Sciences, Mont:Jgus Giln:IMs, caps To.vn, South Africa 
Edirsdby: 
Javed S. Shaikh, Ctlldiff ResetllCh 
Consortium: A CAPffA Group Pic 
Compsny. India 
Reviewed by: 
Simjudh69nAnWilf. UriWJrsffy of 
Messina. Italy 
Domanico CliSCJJolo, Genovax; Italy 
Roger Verbaeck. Univarsitll 
CathoNcpe de Lowain, Belgium 
•comJspondence: 
Bemd RosenkfllllZ, Division of 
Pmrmacology, Departmant of 
Medicine. UniWJrsffy of St916nbosch. 
PO Ba' 19063, Tygerberg, Dlpa To.vn 
7505, SouthAfrica. 
e.rnaH: rosenkftlflltisun.ac.za 
Despite the lack of sufficient information on the safety of herbal products. their use as 
alternative and/or complemGntary medicine is globally popular. There is also an increasing 
interest in medicinal herbs as precursor for pharmacological actives. Of serious concern is 
the concurrent consumption of herbal products and conventional drugs. Herb-drug inter-
action (HDI) is the single most important clinical consequence of this practice. Using a 
structured assessment procedure. the evidence of HDI presents with varying degree of 
clinical significance. While the potential for HDI for a number of herbal products is inferred 
from non-human studies. certain HDis are well established through human studies and 
documented case reports. Various mechanisms of pharmacokinetic HDI have been iden-
tified and include the alteraliion in the gastrointestinal functions with consequent effects 
on drug absorption; induction and inhibition of metabolic enzymes and transport proteins; 
and alteration of renal excretion of drugs and their metabolites. Due to the intrinsic phar-
macologic properties of phytochemicals. pharmacodynamic HDis are also known to occur. 
The effects could be synergistic. additive. and/or antagonistic. Poor reporting on the part of 
patients and the inability to promptly identify HDI by health providers are identified as major 
factors limiting the extensive compilation of clinically relevant HDis. A general overview 
and the significance of pharmacokinetic and pharmacodynamic HDI are provided. detailing 
basic mechanism. and nature of evidence available. An increased level of awareness of HDI 
is necessary among health professionals and drug discovery scientists. With the increasing 
number of plant-sourced pharmacological actives. the potential for HDI should always be 
assessed in the non-clinical safety assessment phase of drug development process. More 
clinically relevant research is also required in this area as current information on HDI is 
insufficient for clin ical applications. 
Keywords: Her~rug Interaction, tradit ional medicine, phytochemlcals, transport proteins, cytochrome P450 
INTRODUCTION Canada (Calixto, 2000), Australia (Bensoussan et al., 2004),as well 
There is increasing consumptions of medicinal herbs and herbal as Europe where the highest sales of herbal products have been 
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APPENDIX B1 
H ub-drug interac-tion pot~tial of popular South Afric:m mf:dicin.'1.) herbs: :m in Titro 
as.-s.e.ssmen1 
f asinu P'*: Guunann H1, SehillN" H:, Birlingu B:, B ijasson L :, f aDerS:: Sei.fart H', Bouie P"", 
and Rosu.krruu: 8 1 
1Dirisioo. ofPh:lnn:aC'ology, f acuity of Medicine :llld Health Scien<-e-;, t7ninr$iC:y of Stdlenbo-;ch: 
Cape- To"'·~ South . .Vrica ~-;ion of Drug metabolism u d Pharmarokinerics, r\o,.artis 
lnsri:tute of Biome-dical resear<"h: Bawl, Snittuland, lt>his:ioo of ~ledical ~Jierobiology, f aC"ulry 
of Medicine and H nltb Sdtm('es. Uo.inrsity of S1e.Uenbo~h. CalM Town. South . .vrica. ~Syuen. 
Ufe Scien«s, l.lootague- Gudws, Cape T O"l''l: South .-\.hica 
*'Cone-;pouding .\.uthor: Pius faUn~ email: 16669967@sttll.aC".za 
Td.: +: 7 : 193S.9336;Fax: +Zi Zl 93l -69S8 
Background and Purpose 
The incidence of coucwTettt use of herbal pre-paration and orthodox medicine has been sho"'-n to be 
high (about 70o/•) in South Africa. Ph.an:oacokir:etic ~interaction (HDI) is known to result 
from such practices v."itb. clinically sigllifican.t aherations in dru.g efficacy « toxicity. \Vbile studies in 
de\·eloped countries have lugely documented common HDI. infonnation on d:::e potential of Africatl 
medicinal herbs to interact 'With cotJCOmitamly administered drugs is largely tlll:lvailable.. C}"1ochroa:t.e 
P450 (C\''"P) and transport proteins are responsible few most phanmcokinetic drug interactions. The 
aim o f this smdy was to io.'\-estigate the i:nfl:uenee of popular South Afrie:J.D medicinal herbs on these 
enzymes and tr'a.llSpOrW."S. 
Me·thods 
With the approval of the Health Re<:.eatth Ethics Committee of the Ulliversity ofSoillenbosch, 
medicinal herbs were sourced from badirional medic:al practitionas ar:.d identified.. Extracts were 
freeze~ed (aqueous) or dried using vacuum rotary evaporator (methauolic). Graded coucetrations 
were incubated v.-ith b:um.an li\.-a· mic:rosomes to mooitor phen.ac:e:tin 0-deethyb.tion, cot:anarin 7 -
bydroxyiation. bupropiou hydroxylation, paclitaxel 6a.-hydro~lation, diclofenac 4 • -hydroxylation, S-
mepheuytoin 4• ·bydro~larion, bufura!ol t • -hydroxylation, chlo:r20xaz.on'E': 6-h:ydr-oxylati.on. 
michzolam 1' -hydroxylation and testo-:;w-one 66-hydro:q:i ation as :w.ukers for Ehe metabolic acti'\'i.ties 
ofCYPlA2, 2A6~ 2B6, 2CS, 2C9, 2Cl9, 206, 2El, and 3A415 r espectively . Substrate cons:w:nption 
and generation ofmetabo!L.~s li\-et-e monitored and quantified v.·itb the aid ofLOMSJl..ts. Each 
substrate was incubated at coocentrations below pre -detennil::ed Km '\<llue. All assays v..-ere petfcwmed 
in duplicates. The inflnen.ce on oan:spon proteills - eftlw:: (p-g:!ycoprotein and BCRP) and uptake 
(OATPlB l and OATP1B3) v.-ere also in'~g:ated using radiolabel!ed substrateS. 
R esults and DisC"nssion 
Of the 15 plants investigail'<i, Suthorlan:diafrutcrsccms. T ulbaghia liolac8a... Hyporis hOMerocallide.a 
Spirostachys .:tfTicam~o. Rammculus n1u/rifidw. Chtt:nopodium albrnt~ and Emt:tX australis demousttated 
,·ery potent iclUbitory acti'\'i.ty against different CYP enzymes. Tlw:e was wide differecce in the 
inlubitory acti'\:ity of aqueous and metbanolic: e:aract o f Hyporfs he.morocaJJ;dro. All emacts inl:u.Oited 
at least 3 of the enzymes teSted in a coDCentration-depeodent tnalll.lel. with JC10 '\-a.l:ues '\-aryi.ng from 
10.6 to 240.3 J.lg{mL. ~ear-total enzyme inlnOirion (9S%) '1\·as obs.e.t"\-ed in a number of extracts. Time-
dependent (irreversible) inhibition by StLJhorlancbafrutc;scens \\'aS ob<-...en·ed fer Ci'"P3A4/5 (K1 = 
295.653 p.g/mL, K_, = 0.0632 min-1) . Suchc:rlandia.frutc.soens andliypoxis henurroc-..allidea inhibited 
the acti,ityofp-glyc:opt-otein, O ATPlBl and OATP1A3 to nrying degrees. 
C oudusious: 
The result showed significant pot &!rial for rele'l.cnt HDI beM-een popular SA medicinal herbs and 
orthodox medici.nes wbicb shoald be considered during concwnat herb-drug administration. 
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ABSTRACT NUMBER / ABSTRAKNOMMER 24 
THE POTENTIAL OF H. HEM EROCALLIOEA AN O S. FRUTESCENS FOR HERB-ORUG 
I NTERACTION WITH ANTIRETROVI RAL ORUGS 
MR PS FASINU (Phamutco/ogy) 
Background(Purpose: 
Two of the most popular he,·bs widely consumed l'o1· medicinal purposes among HIV(AIOS patients who 
a1·e on ART a1·e Hypoxis heme1·ocallidea and Suthel'landia f1·utescens. Cytochrome P3A4 is responsible fo1· 
the metabolism of majority of drugs including the protease inhibitors (PI) and non-nucleotide reverse 
b·anscr iptase inhibitors (NNRI ). The international standard for in vib·o assessment of CYP3A4 activity and 
potential interaction consist:s of monitoning testosterone metabolism in a liver -based medium. Thus, the 
CUI1"ent study was aimed at investloating the potential f01· HOI between the extracts ol the two he1·bs and 
CYPJA4 ~ubstrates employing human live1· miCI'osomes (HLM) 
70 
Methods: 
Aqueous extracts of fresh herbal samples, sourced from two b·aditional heatth practitioners, were freeze-
dried. In vib·o metabolism was optimized by the incubation of graded concentrations of testosterone in 
NAOPH·regenerating system and 0.25mg/mL HLM suspension where kinetic parameters (Km and Vmax) 
we1·e determined. Metabolic 1·eactlon was halted by the addition ol lce·cold acetonlt1·lle and the l'eGultino 
mixture centrifuged (SOOOrpm, 10 mins) to pred pitate microsomal proteins. Supematants were analyzed 
by LC/t-15. FUit her incubations were performed in the presence of graded concentrations (IJg/mL) of the 
herbal extracts. Control incubations with ketoconazole, a CYP3A4·specific inhibitor, were pe1f ormed 
concurrently . The influence of the aqueous herbal exb·acts on CYP3A4 activity was determined and 
compared. All determinations were performed In duplicates (Intra-day and lnte1·-day). 
Results and Discussion: 
Both H. hemerocallidea and S. frutescens demonstrated concenb·ation" ependent inhibition of CYP3A4 
activity with ICSO values of 25.7 and 21·.3~g/ml respectively. At lOO~g/mL, a concentration estimated to 
fall within the put..tive In vivo situation, CYP3A4 activity was Inhibited by 91% and 85% reopecUvely. 
Conclusions: 
The result showed significant potential f or relevant HOI between CYP3A4 substrates and H. 
hemerocallidea and S. f1·utescens. Concomittant he1·b and ART consumption may lead to HOI p1·ecipitated 
by CYP3A1 1nhlbitlon. 
Acknowledgement : 
SURMEPI and Hope Cape Town, for fina ncial support. 
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Irr >itro Inns~ lion of the Effects of Common~· Used South African Medicinal Herbs 
on CYPLU acthity Emplo)ing Hwnan LiYer ~licrosomes 
Pius F.asinuh~ He-ine-r Seif.11rtl, Patrick Bouic1, and Bernd Rosenkranz1 
1Unh·e-rsity of Stellenbosch, Dhision of Pharmacology_, F acuity of Health Sciences, 
Tyge-rbe-rg, Cape Town: South Africa; 1S~-ue-xa Life Sdenc·es, ~.fontague- Gardens, Cape 
Town, Sourh . .\ftica 
*Con·espondence: 16669967@sun.ac.za 
Purpo-.~: 
H.e.rl:Hirug interaction (HDI) is a major clinical cocceu especially ~-ith concomitant cotlS1.llllption of 
medicinal herbs and prescription medicines. In l.-"itro li\-er-bas.ed teclmologies present sciedifically 
reln;mt medinm for investigating the potenrial for HDl CYP1A2 is one of the major metabolic 
~mes accCJW:lting for 1 1~~ of all CYP-me<iiateddrug metabolism. The pwpo-;e of the current study 
therefore, was to izn.-estigate the e:fmcts of 15 commonly w:.ed herbal medications in Sourh Africa on 
the metabolic actn.ity o f CYP1A2 employing hl.Wl30. li\-er m.icrosomes (lfi..._'\f) and phenacetin as a 
standard probe substrate.. 
~lnhods: 
Graded concentrations of phenacetin (0.25 - 50~i) were incubated v.;th 025mgfmL HLT\i in 
Eppendoatubes to< 15 miD in a shaking .,..,.., bath (Ul<hpm; 3r C). A.n N.-'.DPH-n genetating system 
prepared lNith glucose-6-pho.<;pb.ate debydrogeo.ase and reduced ~tWP+ in a cofactor solution v.-as 
used to initiate the metabolie ruction. The reaccian '\\-as halted by the addition o f ice-cold acetoninile 
( -20°C) contaicing 2J.tgfml. thiacetazone as an intema.l standatd. The remlcing mixture v.-as 
cenbifuged (5000g, 10 min) ro precipitate the microscxn.al proteins. Supematants v.-ere an..aly-;ed by 
HPLC&.fS. The methodo!o gy was oprimized by profilir:.g: the rate of metabolism against the substrate 
concentrations to determine the enz)me kinetic parameters. (K. and Y -). Further incubations were 
performed a t the detennin:ed K. in the presence o f the herbal extracts, prepared in percentage 
dilutions, ~rd:ing to the recipe of the traditional healer:s.. Control incubations with a -
naphihotbso!J4, a CYPIA2~ inhibitor, wete perfonned concummtly. The in£...,.,. o { the 
aqueom herbal extracts on CYP1A2 acti,:i.ty was determined ard compared. All detel.'Ulioatiom. were 
performed in oiplicates. 
Re-s-ulu a.ud Discussion.: 
The results showed that 7 out of the 15 herbal extracts investigated demonstrated 'Significant inhibition 
of phenacetin metabolism ro 10-arying dep-ees (30-86~~). Th~e included ll)'ptn:is he:merocallidM. 
Spirostachys .4,/ricana. Bcrn-ieca l---olubilis,. Cho1opodium album.. Kedrostis _{fricmla. Lauridia 
taragonia and Pac:#()'Ctupus conc:olor. 
Cooclusiou.s: 
Gi'-en the role o f CYPL.U in the metabolism of a -wide range of therapeutically important dru~ the 
results sb.owed a potenti.al for herb-chug: interaction especially if such chugs are administered 
concomitantly mth rhe herbal medications in..-e<:tiga:ted. 
E lhies: 
This ~ lOS appro10·ed by the University of Stelleobosch Human Research Ethics Committee 
"'ith Etbks Reference=berNl 0/09/307 
Reference<>: 
Fugj>-Berman A. He·b-drog U:taactio=. Lancet 2000; 355:134-138 
YanG, Caldwell GW (2005). Optimization io Drug Discovery: In \-ilTo Me&.ods (231-244), HUJDJ..na 
Press 
.--\.C'kuowledgeme.ut: 
Hope Cape To~ for financial support. 
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!RESEARCH ARTICLE 
Flavonoids and Polymer Derivatives as CYP3A4 Inhibitors for 
Improved Oral Drug B ioavai lab i I ity 
PIUS FASINU,1 YAH VA E. CHOONARA,1 RIAZ A. KHAN,' USA C. OU TOIT,1 PRAOEEP KUMAR,' VALENCE M. K. NOES:N00 ,1 
VI NESS Pll.AY1 
1 Un;.,ersiti ~ the WiM itrslird. Fic:ulti of Heilth ~ien::es, Oepi1trrentof Pharrraq.o an:l Pharrrac:olog)l Johanre:bufi2 l93, 
Soulh Aff~a 
•Qassim Un~ersi\', Col~~ of Phaunacv, Oepa1trrentof r.kdCimiCherrislly, QassimS 1452, Saudi Ar.bia 
RM!tlt1Q Sf{/Hr!bq 21112; rwisttt 2QO<f.of>q 21112; ~1 Nowmw 21112 
Puhlis""don/i"" in Wiley OnliM ~ (wile)Onli~am). D0/ 10.1002/j ps23382 
ABS'I'RAO'l': Molewlar roodelirlg comput.Umo w<:re ~tilioed to g<:neralo pmrmaontioil 
srw CYP3A4~reyme in!libi!ors. In oil>o rrel<boliml <4 fclodipiM in h.lroan W.sliMI irul 
llV<:r rrooro.orre•OILM irul HI~Q w.,op\iJ<W>lclyicl<Iirlgi Mi<l~Wi>-M•IWI pbtfromwh<:re 
tJ\e IGt. iJ\d V,...1111 vilues WeN titirnated bynol'l1.irtil' Nghli:Sion. The t\i.~ na.~ narin· 
~ irul querootiJl, • ..,.. subo>q"""tl,y inwbal>d mill fi>lodipiM •t U.. dolorminod R;, vilue 
inHLM. Comp~ ,.,\11\ooblairu;d from• kro\>TICYP3A4 iMibilol; V<:ripa!YW, tho flovoroi<lo 
iMibiwd fobdipirut rutliOO!ism In~plh computo tionil.,..zyoio <4 u.. .. flovoroi<lo in wrmo 
<4CYP3A4~,.q~iruli1!'ulil.y,OOillj)~tionil~w.,e~dtovil· 
idili thi P>l<nlii!CYP3A4 inhibitors. Tho roodtkd oompouro• •• re companlivt(y wil~lod 
by inlubation mlh foiOOipiu! in roth HLM m1 HIM. Ilirulli wwollhit lh! P>l,ymlrs 8· 
orm·PElJ, o{li-tllyl)~·l'Ml\YI ·PElJ, 4-inn·PEO {1rok0\llar u'Oig)lt • IO,OOl gftMI irul 
lll,OOlg!rrol, ruptolivt(y~ irul P>i.Y(L·~ '""' •bl<t to in!libil. thi fobdipirut m>tooolism 
mill lh! m l maximal inhibitory OOMent.ration ao,., vilu.s r~ from 122 to JO.OpM 
(IILM) iru16.18 to 41.00 , M (111M). Mol<!oulardool<ing oontirmld drug-enz;ym> inleraolions 
by com~ lh! free.,.,~ of bird~ (llEl irul inhibition constonw (/lj) <4 \he dool<>d 
compounds ~tilil:ing a Lamalok WI Oenelio Alg< ritllm Oompaxali10 correlalions be l>Neen lh! 
compuled iid experimlnlil ~ vi!U>s were oblained. Oornpulel.i>nil mOO>~ ofOYP3A4 in· 
hibilors provided a s uilibl> sin~ to .,.en pmrmaowtioil srade oompouros \hat rruy 
P>lont.iilly inhibit P""Y'i>mio OYP3A4~pend"t drug m>tooolism mlh lha ~pee\ ofim· 
pro~orald~ biomil4biliiU. <!>2012 VilleyP,riodioaiJ, I ro. irullha Amlrioan Pharmaoisls 
Assooi>.U.. J Pharm &i 
Keywords: or a! bioav.U.biliiu; drug delivery; P>lyroor<; 0 YP 3114 iMibim; compul4 tionil 
roo~oular roodeling; ~ P4SIJ; compuln aidol drug do~ do~ s\W.~ d~ 
roo14oolisrn; kinelios. 
I NTRO DUCTIO N 
Research in dru,i ~bolism has oll<aoled more at,. 
P41ll (CYP) enzyme syslem present in lhe li',.. Mid 
inl!!sline is responsible ror the rneio.bolism of .. wide 
.. .... _ ,..t ._... ....... ;,..,. ;,..,. (~ •• - ..... - ; ... ,.._,. .... ..~ ... _ 
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African Journal of Pharmacy and Pharmacology Vol. 6(38). pp. 271 (}.2723, 15 October, 2012 
Available online at http:/lwww.academicjoumals.org/AJPP 
001: 10.5897/AJPP12.487 
ISSN 199~16 ~ 2012 Academic Journals 
Review 
Drug-drug interactions in ageing HIV-infected 
individuals 
Pius S. Fasinu* and Bernd Rosenkranz 
Division of Pharmacology, Facutty of Medicine and Heatth Sciences, University of Stellenbosch, Tygerberg, Cape Town, 
South Africa. 
Accepted 24 September. 20 t2 
The effectiveness of antiretroviral therapy has significantly improved life expectancy of HIV-infected 
individuals. Global campaigns and awareness programmes have led to substantial drop in the rate of 
new infections. Consequently, the proportion of ageing HIV-infected individuals continues to increase. 
HIV.associated and age-related comorbidity necessitates polypharmacy in ageing individuals living 
with HIVIAIDS. The risk of drug-drug interaction increases with the number of administered drugs. Age-
related changes in the body physiology are known to influence pham1acokinetic and pharmacodynamic 
profi le of administered drugs. These changes include reduction in blood flow to major organs, decline 
in metabolic activities, body mass shrinking and changes in body water and fat proportion. These 
factors contribute to the t>erceived and ret>orted higher incidence of drug-drug interaction in this 
population. The current paper reviews the reported incidence of drug-drug interactions in ageing HIV-
infected individuals, providing relative mechanisms and possible factors responsible in comparison to 
younger population. Health professionals should be aware of the drug interaction risks involved in the 
management of HIVIAIDS in the ageing population; be able to anticipate them based on concomitant 
medications and manage them as necessary. 
Key words: Drug-drug interaction, drug metabolism, drugs, ageing, HIVIAIDS, cytochrome P450. 
INTRODUCTION 
Since the advent of highly active antiretroviral therapy 
(HAART) in 1990s, the management of HIV has resulted 
in improved quality of life, survival and life expectancy of 
infected individuals (Antiretroviral Therapy Cohort 
Collaboration, 2008; van Sighem et al., 2010; Mills et al. , 
201 1; Nakagawa et al., 2012). Although without a cure, 
HIV infection with early diagnosis and treatment 
::uthoronro h~~ hornmo !:a rhrnnir rl i~o~~o ::21lhoit lifo.. 
gaining prominence as the number of affected people 
continues to increase (Grabar et al., 2006). However, 
there are no specific guidelines targeted at drug 
management of HIV in older patients. Information on the 
safety and efficacy of current antiretroviral (ARV) regimen 
in older patients are not sufficiently available. Clinical 
trials have often excluded older individuals until recently 
fl imh Jn11 \ Mo.:u'lwhilo littlo ro~::trrh h::ac: h~n rtnno tn 
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ICo:mparatin: e:,~amboDOf11iarfarm n tiliza DoD in hv0 primary he:aJth i~N; cJinies m fhl!: 
C ap e Tow.n ar ea 
Xolani \'\ . Nj ovane., :MBGbB" BSc (Hons)" Pius S. Fasinu, M& k !ED " B...~ R.osenhanz, 
1\ID" PhD" FFPM 
Division of Phanna.oology" Faoult}~ of Medicine and Health Sci:ence<s" Univet"sity of 
St,eJ.lenb o soh, TygMbe:rg, Capa To,.,-n., South ~-\.fr"ica 
.~.'\hitract 
Bacltg;round.: \\ a:r.farin :remain.s the anticoagulant drug of choicet in a "N-ide :t:an§21 of pati: nts . 
Its narrow the:rap:eutic '\vindow maker5 pati: nts susceptible! to high risk of ble-~in,g 
c omplications o:r failure to prevent clotting. This has necessitated the:rap:eutic monitoring in 
~~ patients . Faoto:rs that c ould be :responsibl:e f o:r the fluctuating :re sponse5 to 
\va:t:farin "irs.:t:y :from ~fu:: to oonoomi.tant morbidity= d i:et and medication. In order 
to asse ss the quality of the ma.na.§~ment of ,va.:rfa:rin treatment in a local pri.ma.ty care settin.g, 
the current study evaluat,!!d warfarin utiliz.s.tion and monitoring :records in hvo hospitals .,.,ith 
different pati: nt groups . 
:lh t:ho.d.oS: A :retro sp~tive study was undertaken in the sp;ecial w·arl'a:rin clinics at ~..Skl.U: 
and~~t.h.JJ. hospitals (\VestMn Cape., S outh A.:f:rica) c overing all ,va:rfa:rin :related therapy 
:reoo:rds in a 12-month period. Data extracted :from the patients ' f olders included aga, s~ 
:raoe., weight, add:res s~ concuU'ent oh:ron:ic illnesses" treatment and me:dication, indication f o:r 
wa:rfarin and JNR hi sto:ry. 
Rre&nlts: A total of ll9 patient's f olde:rs w.e:re analy sed. AttendBn~ at the clinics :refl.eds the 
demogaphic and :racial distribution of the host location of the hospitals. \Vhile all the patients 
\ve:re maintaine-d above the minimum 1NR value of 2" about )0% had at l e!a.st one :record of 
1NR above the cut-<oflf "i"S.lue of 3 . 5. None of the patient :records sho,o,.-.ed a JNR.les s than 2 ; 
ho\\ilei'>-"e1'0 ove:ra third of thepati:ents (32 .2%) had at ~stone :record ofiNR. g:reat.."'!' than 3.5 
in ~ !b.o spital oompa:red to over half (5 B .3%) in ~~ hospital. 
In to~ atrial fi.b:rillation wa s the most common indication f o:r ~~ while 
hyp:arlen sion '!,VS.S thr9 most c omm.on c oncll!'Rnt chronic c ondition in  patients. All 
pati: nts who :received quinolone antibiotics had INR values above the cut-<off point of 3 .) 
'"ithin the same month of the initiation of the antibiotic therapy su E:s..."<Stin_g drug-induced 
\varla:rin p ot,!!-ntiation. Other eo-medications including b:etarlactam antibiotic s, NS. .. '\JD s and 
anti-ule...11:1:s app-eared to alter ...,"a:t:f.arin :re sponses as measured by :recorded 1NR ' talue s . 
'Co:nclunoD: The study f ound inte:r-indh'idrual variability in the :resp on.se to ,va:rf.arin therapy 
which cut aero s 5 the :racial clas sifi.cations . It also oonfi:rms the p o 5 sib1:~~ influence of 
conc omitant morbidity on patir:-nt :respon5r~ to antic oagulant th..."'!'apy . 
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810 PI IARMACiillTr::S & OR~ Of.l i'(JJrri::>N 
Slof.\'ol• • .,.,.., P&rp!A ~ I~ Q.OIIJ 
~\'lo:l Ol'lllnol 7 Aprl l )U In \\';ltyOtlliM l.h~.y 
(wil~nli 'l'l"hhnr~fl\) 001: 10.1002/ldd.?!i.l 
Review 
Diverse approaches for the enhancement of oral 
drug bioava ilabi I ity 
Pius F:~.s.inu, Vineti f'ill :.y •. V:..le.net M. K. Ndesendo, Lis:! C: du 1bit., :.nd Y:.h)':. £. Choon:.a 
IJnitW'iliity of lhtl \\'ilvut61Wlu(. ~J'•bJIDi t af Phlnml')' an1 PhlnJIIfmbgy, 7 V!d hd.. P,utm._.,, 21!U, fnh-eul~'f• ~w.&l! ltjrie.ll 
A 8S1'ltAC1~ In (X'.ntd01$and()()-()p!!r.lling JXt lit!I1~0ral drugddl\.'t!ry' Mnains 81e prdenbl.: n>u~ ()( 
d rugadn1int)1r,\tion. HoWt>wor, •'oOl aD d ruS$ ~ thrd~irt•bl to physi()()r.hrmiQ~l tu'od ph.1nnnc;xi:inrlic 
fHOpU 111ts w hlch ftwor or,t 1 ad mb11S:Irllllon 11\ll inl y due 10 poor bl()tlval b bO h y. This h,1!l b1 80n'llf ~ ltd 
10 UH!chola~or oUH.'I' •Oults <J admlnh.lrllliC.n, which ll'l.,yc:omprom~ 0H!C:On'ltlnk.'l1a!ll•'od b1CI"l!t! lhll 
rb.k or nc.tHomplla.'IOI!. Poor blo.waUbblll ty Iu s nOOI'SSitbl~ the ac.hnbtbtrbllon or ltlsher llu n •tO•nu Uy 
required()"&) d(J)iS which ofk n leNS t> t!OOnomic wa~~ risk of tOlddty, en"Mic and unpredlcbbl.: 
re>po•~· Tht: d'1.'1l lt: ng.'! Mt! r tht: yt%'11$ h~ ))!'*. n to de>ign t~h•tiq~ 81111. will allow Or.'! I ad n1btistrMion 
of 11'1).'1 d •u&t' ir~t<Sp«:t iv~: <1 01dr IHOI~'I"'i..'S, •> .chi~, a lherll~:uli csyst~.-·mic avaihbililr n,~ wlll l t 11 
w011hy N:hl llYt..,l'lll nl &b1<"! Ovt! r 9:)'.\ o ( lhc..'l'lii"'·'UIIc c:ompou ndj ftnl ki\OW n 10 pO!!il!l•st 01\\ blo.waUabiU ty 
I bnl U.lb\'J. In lhls ~ "'{. ll l\ a tltWipt hM bet:n n'l.v.le to ecplore Vtlliouu ppn).1thes tl\.'tl 1'1.'1\~ lx~ n u56J 
l1t nlU': •11. )'U\ IS •> b)IJ)n>W: or.l l drug blo.'l'ltl Ubbllit y, btclud b1g physical a •'od cl'le •nlea I 1)'1001\$ Tl\k n!\.'lew 
stn~~to pn>\11&! a eonlpn:hi!!ti;h't!O~~wd adv&10e$ 1'1'13de ().'t!r 81e p$1 10 ~~:!.'110) intl'lt: 
i mprovt•mt, 'll <I I hr < .. nl biowaih bffit y of d nJ~ Bril• 8 y, I hr d":i:'Sn of pu·J nJS$ to bYJX'S$ 11ltott.1)()11Sm or 
10 ('1\hflllOi! 801ubilhy • ~II • m0016Cllllon of fonnuhllon lilchnlqUtS such • I hi! uttl (I 41ddh iv~!f. 
p..,·n...,ulon t., \I'I.,•'IM"ft ~)lubOltA...S. .:mul~ t'k.,.. and non"'lqut..-o~ Vtlhk:lts 1'1.'\.'tl bt.'-,' dt;cu~,J, Ar"'b'S 
appn)3CI~ such M fonnubtlon ,,'l()()lfleatlon ta:h•\lques.; 1\0Yel d rugdell\..:.y ~ten\5., which exploit tl'le 
gaSb"<)btliSlbu l R:gion.1lhyof dru~ and include tl'le plu n'I'I."'Ieutical appliellllon of 1\.111~mology asM 
t>n""8ing lln'a in drug dtollvt-ry; inhibition of toi'OuJC pum~ 111-.d inhibition of pr\1~)'"'....,"'ic n\t'lal)()li~n 
ht~\, 1,.._'-, ' 11'()1\: .:,-te,_,~h'tly tldd•\:it<d. Th~ c;rilla~l ,,,.vlc:w J()IJShl 10 ~~~ ~c;h n'II}OlCd ft in'lt(J 111 
t:ni'I.UICblg lhll or,\1 blo.wlllbbltily or d i'Uj9J In lt., U'4 or ll'll! IJUfJ.-Ok, !dt.'llli fi c hl.!o~ timillllif:n1t 
c:omn'li!ICbl a pplleallol\ M well M lhe IU'Mi In which CUfM\l ~h d't'o•IS are bdng: f~ a1'od 
s i'IOUld be~ b1 tl'le future O>pyrigllt t1 Xlll Jol'll1 \\\ley & &'.11~ Ud. 
Kt!f wbrd$: llll$0rpti 01'1; bio.waihbllity;q'(OdUQini' f\l!'l); toi'Ow: tr,\l't:if!Ori torS; t'll 'lfiUe;,); inhib ilo-s; P"""' 
11'lt\"'ll(t1 ('1\hllnCX.'I"S; f\.gly«>pn.)ldn~; l)()(•·ly ~lil~ublt~d i'Utf,: l;lffi,.)'S.h" .. 'll\lc mt-of~ll"'' 
IntrcKiucticm 
The nbaity o( 31\ i\dmilliSierOO d rug to elicit the 
desil\..'d phal'm!K'Oiogtcal ~pcll\!e and revme a 
d isease oond.ilion is J.he ultimate g oal or d rug 
l herapy (1). Such pham\aa)log:im l response 
depend<; on I he availability Q( the d rug al the 
receptor sil'e., w hich ill tum is influenced ~ 
p l.asma drug OOilCOl lT<Hions 121. The gonl of an 
erfecti\'e d rug de livay system is lhe~erore to 
a chieve and suslain therapeutic blood le\'els o( 
I he d r ug excepl in 5C)nle p alhc;llogral a;md itic;ms 
where d rugs 3re intendOO for IOOll 3CI:i01t, e.g. 
an !adds. Drug deli\'tl')' lw tradilio n.aJiy lll~n the 
ronn or ingeslion., in hala liOI\ il~oclion., in fusion 
~~·red 2'i Moy 2010 
'Riviwvl 2.1 NOMnbt:J' 2010 
ltl'tt~td 28/,tniNtry l)J I 
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YOUNG SCIENTIST 
YS 09 Pharmacokinetic Drug Interactions as a Root e for Improving Oral Drug Bioavailability 
PS F:.asinu 
Oo:p ;;t"tn"cnt of M«<icin.e, Oivi:ion of Phar~!o;y, St ellc.nboY..cl\ U'f"c.r::ity, Ty£_c.rber' C;mpu:, Sovtl\ Afric:i 
16669967@~un .. ;c.:; 
The poor bioavailability of drugs has been iden tified as the single most important challenge 
in oral drug delivery. Prominent among the factors responsible for this are the metabolic 
activity of the intestinal and hepatic cytochrome P450 (CYP} enzyme family. In the current 
study. novel CYP inhibitors were generated through the application of computational 
modeling of known CYP3A4·substrate and CYP3A4·inhibitor interactions. In vitro 
metabolism of felodi pine by CYP3A4-expressed human liver microsomes (HLM} was 
optimized yielding a typical M ichaelis-Menten plot through the application of Enzyme 
Kinetic Module software from where the enzyme kinetic param eters were detennined. 
Phytochemical components o f grapefruit ju ice, a well known CYP3A4 inhibitor, were 
separ ately incubated in HLM together with felodip ine at concentration equlvalent to the 
detennined Michaelis-Menten Constant (Km) value. AU of quercet in, nar ingin and 
naringenin inhibited felodipine metabolism wit h /CS&values of 208.65, 177.81 and 121.971lM 
respectively. Following a detailed study of the quantitative structure- activity relationship of 
these f lavonoids, their b inding properties with CYP3A4, the amino ad d sequence and 
binding affin ity of CYP3A4, comput ational modeling software on a non-silicon graphic 
system was employed to generate phannaceutical grade and commercially available 
polymer s based on activity prediction aided by computational b iomimetlsm and simulations. 
The modeled compounds including 8-arm-poly(ethy1ene glycol), o-{2-aminoethyl)-o-methyl 
poly(ethylene glycol), 4-arm-poly(ethylene glycol) !Mw=l OOOOgfmol and 20000g/mol) and 
poly (l -tysine} were investigated for inhibitory activity against felodipine metabolism by 
HLM and human intestinal microsomes (HIM) where 8-arm-poly(ethylene glycol) 
demonstrated the h ighest inhibitory potency with an IC50 value of 7.22~M. In vivo studies of 
the effects of 8-arm-poly(ethy1ene gtycol} on the oral bioavailab ility of felodip ine were 
performed on the l arge White pig model. Compared to contr ols, a >l OO'Yo increase in 
plasma felodipine levels was observed. The outcome of this research presents 8-ann-
poly(ethelyne glycol} as a promising oral bioavailab ility enhancer. 
45 
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APPENDIX D: ETHICS APPROVAL 
 
 
04 November 2010 
Mr P Fasinu 
Department of Pharmacology 
7th Floor Clinical Building 
Room 7070 
Dear Mr Fasinu 
" In Vitro Assessment of Some Traditional Medications Used in South Africa for Phanmacokinetic Drug Interaction 
Potential." 
ETHICS REFERENCE NO: N10/09/307 
RE :APPROVAL 
At a meeting of the Health Research Ethics Committee that was held on 20 October 2010, the above project was approved on 
condition that further information is submitted. 
This information was supplied and the project was finally approved on 3 November 2010 for a period of one year from this 
date. This project is therefore now registered and you can proceed with the work. 
Please quote the above-mentioned project number in ALL future correspondence. 
Please note that a progress report (obtainable on the website of our Division: www.sun.ac.za/rds should be submitted to the 
Committee before the year has expired. The Committee will then consider the continuation of the project for a further year (if 
necessary). Annually a number of projects may be selected randomly and subjected to an external audit. 
Translations of the consent document in the languages applicable to the study participants should be submitted. 
Federal Wide Assurance Number: 00001372 
Institutional Review Board (IRS) Number: IRB0005239 
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research 
and the United States Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and 
principles for research, established by the Declaration of Helsinki, the South African Medical Research Council Guidelines as 
well as the Guidelines for Ethical Research: Principles Structures and Processes 2004 (Department of Health). 
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant 
authorities (Western Cape Department of Health and/or City Health) to conduct the research as stated in the protocol. Contact 
persons are Ms Claudette Abrahams at Western Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) 
and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel: +27 21 400 3981). Research that will be 
conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics approval is 
required BEFORE approval can be obtained from these health authorities. 
Approval Date: 3 November 2010 Expiry Date: 3 November 2011 
04 November 2010 13:01 Page 1 of 2 
Verb~nd tot Optimale Gesondheid · Committed to Optimal HeaHh 
Afdeling Navorsingsontwikkeling en -steun · Division of Research Development and Support 
Posbus/PO Box 19063 · Tygerberg 7505 · Suid-Afrika/South Africa 
Tel.: +27 21 938 9075 · Faks/Fax: +27 21 931 3352 
\ 
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MS CARLl SAGER 
RESEARCH DEVELOPMENT AND SUPPORT 
Tel: +27 21 938 9140 I E-mail: carlis@sun.ac.za 
Fax: +27 21 931 3352 
04 November 2010 13:01 
Verbind tot Optimale Gesondheid · Committed to Optimal Heaijh 
Afdeting Navorsingsontwikkeling en -steun · Division of Research Development and Support 
Posbus/PO Box 19063 · Tygerberg 7505 · Suid-Afrika/South Africa 
Tel.: +27 21 938 9075 · Faks/Fax: +27 21 931 3352 
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15 March 2012 
Mr P Fasinu 
Department of Pharmacology 
7th Floor Clinical Building 
Room 7070 
Dear Mr Fasinu 
"In Vitro Assessment of Some Traditional Medications Used in South Africa for Pharmacokinetic Drug Interaction 
Potential." 
ETHICS REFERENCE NO: N10/09/307 
RE : PROGRESS REPORT 
At a meeting o f the Health Research Ethics Committee that was held on 14 March 2012, the progress report for the 
abovementioned project has been approved and the study has been granted an extension for a period of one year from this 
date. 
Please remember to submit progress reports in good time for annual renewal in the standard HREC format. 
Approval Date: 14 March 2012 
Yours faithfully 
MRS~ DAVIDS 
RESEARCH DEVELOPMENT AND SUPPORT 
Tel: 021 938 9207 I E-mail: mertrude@sun.ac.za 
Fax: 021 931 3352 
15 March 2012 15:35 
Expiry Date: 14 March 2013 
Verbind tot Optimale Gesondheid · Committed to Optimal Health 
Afdeting Navorsingsontwikkeling en -steun · Division of Research Development and Support 
Posbus/PO Box 19063 · Tygerberg 7505 · Suid-Afnka/Soulh Africa 
Tel · +27 21 938 9075 · Faks/Fax: +27 21 931 3352 
Page 1 of 1 
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19 March 2012 
Mr P Fasinu 
Department of Pharmacology 
7th Floor Clinical Building 
Room 7070 
Dear Mr Fasinu 
"In Vitro Assessment of Some Traditional Medications Used in South Africa for Pharmacokinetic Drug Interaction 
Potential." 
ETHICS REFERENCE NO: N10/09/307 
RE : AMENDMENT 
Your letter dated 24 February 2012 refer~. 
The Chairperson of the Health Research Ethics Committee approved the amended documentation in accordance with the 
authority given to him by the Committee. 
The following amendments were approved: 
1. The amendments as stipulated in your letter dated 12 March 2012. 
Please note STIPULATION: Explain in lay terms the concept 'human metabolic enzymes' in the informed consent form. 
Fax: 021 931 3352 
19 March 2012 11:14 
E-mail: mertrude@sun.ac.za 
Verbind tot Optimale Gesondheid · Commttled to Optimal Health 
Afdeling Navorsingsontwikkeling en -steun · Division of Research Development and Support 
Posbus/PO Box 19063 · Tygerberg 7505 · Suid-Afrika/South Africa 
Tel.: +27 21 938 9075 · Faks/Fax· +27 21 931 3352 
Page 1 of 1 
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APPENDIX E: PLANT MATERIALS TRANSFER AGREEMENT 
 
Agreement for Transfer of Plant Material 
 
Stellenbosch University through its Division of Pharmacology, , Tygerberg Campus 
 
and 
 
____________________________________________________________________________
____ 
 
PROVIDER:  
 
Organization:   
 
Address:  
 
 
RECIPIENT: 
 
Organization:  Stellenbosch Unversity  
  
Address:   Administration B, B3223, Victoria Street, Stellenbosch, 7602 
  
In response to the RECIPIENT's request for the PLANT MATERIAL identified as  
plant and herbal products 
 
 
 
the PROVIDER and the RECIPIENT agree to the following before the RECIPIENT receives the PLANT 
MATERIAL: 
 
1. The PLANT MATERIAL is the property of PROVIDER's institution and is made available only as a 
service to the research community. The RECIPIENT shall not represent to any person that it is the 
owner of the PLANT MATERIAL. 
 
2. The PLANT MATERIAL will be used for non-commercial research purposes only.  The 
RECIPIENT will not use the PLANT MATERIAL except pursuant to this Agreement.     
     
3. The RECIPIENT agrees to maintain in confidence PROVIDER‟S PLANT MATERIAL with the 
same degree of care it holds its own confidential and proprietary information, but not less than a 
reasonable degree of care.   
 
4. The PLANT MATERIAL will not be further distributed to others without the PROVIDER's written 
consent. The RECIPIENT will either return or destroy PROVIDER‟S PLANT MATERIAL upon 
termination of this Agreement. 
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5. The RECIPIENT agrees to acknowledge the source of the PLANT MATERIAL in any publications 
reporting use of it. Notwithstanding anything else in this agreement, the RECIPIENT may publish 
the results of the research individually, or in joint collaboration with the PROVIDER. 
 
6. The PROVIDER retains ownership of the PLANT MATERIAL, including any PLANT MATERIAL 
contained or incorporated in substances created by RECIPIENT (hereinafter, 
“MODIFICATIONS”).  The RECIPIENT retains ownership of: (a) MODIFICATIONS (except that, 
the PROVIDER retains ownership rights to the PLANT MATERIAL included therein), and (b) 
those substances created through the use of the PLANT MATERIAL or MODIFICATIONS, but 
which are not unmodified descendant(s) from the PLANT MATERIAL (hereinafter, “PROGENY”), 
or substances created by RECIPIENT that constitute an unmodified functional sub-unit or an 
expression product of the PLANT MATERIAL (hereinafter, “UNMODIFIED DERIVATIVES”). If 
either 6 (a) or 6 (b) result from the collaborative efforts of the PROVIDER and the RECIPIENT, 
joint ownership may be negotiated. 
 
7. Any PLANT MATERIAL delivered pursuant to this Agreement is understood to be experimental in 
nature and may have hazardous properties. The PROVIDER MAKES NO REPRESENTATIONS 
AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE 
ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A 
PARTICULAR PURPOSE, OR THAT THE USE OF THE PLANT MATERIAL WILL NOT 
INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. 
The RECIPIENT agrees to be responsible for all claims and damages that directly result from the 
negligent acts or omissions of the RECIPIENT, its employees, or agents, to the extent permitted 
by law. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made 
by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the 
use of the PLANT MATERIAL by the RECIPIENT, except to the extent permitted by law when 
caused by the gross negligence or willful misconduct of the PROVIDER. 
  
8. The RECIPIENT acknowledges that the PLANT MATERIAL is or may be the subject of a patent 
application. Except as provided in this Agreement, no express or implied licenses or other rights 
are provided to the RECIPIENT under any patents, patent applications, trade secrets or other 
proprietary rights of the PROVIDER, including any altered forms of the PLANT MATERIAL made 
by the PROVIDER. In particular, no express or implied licenses or other rights are provided to use 
the PLANT MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for 
commercial purposes. If RECIPIENT desires to use the PLANT MATERIAL or MODIFICATIONS 
for a commercial purpose, RECIPIENT agrees, in advance of such use, to negotiate in good faith 
with PROVIDER to establish the terms of a commercial license. 
 
9. The RECIPIENT agrees to use the PLANT MATERIAL in compliance with all applicable statutes 
and regulations, including, for example, those relating to research involving the use of human and 
animal subjects or recombinant DNA. 
 
10. This Agreement shall expire three (3) years from the last signature date indicated below, unless 
terminated by either party upon sixty (60) days prior written notice, or unless extended by mutual 
written agreement. 
 
If the terms and conditions set forth above are acceptable, please sign and return two copies to: 
_____________________________________________________________________________ 
 
Upon execution of both copies of this document by all parties, the BIOLOGICAL MATERIAL will be 
forwarded to the RECIPIENT SCIENTIST. 
 
PROVIDER:  
 
Organization:   
 
Address:  
 
Name:   
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Title:   
 
Signature: ___________________________________________________  
 
Date:         ___________________________________________________  
 
 
WITNESS OF PROVIDER: 
 
Organization:   
 
Address:   
  
Name:   
 
Title:   
 
Signature: _____________________________________________________ 
 
Date:  _____________________________________________________ 
 
RECIPIENT:  
 
Organization:   
 
Address:  
 
Name:   
 
Title:   
 
Signature: ___________________________________________________  
 
Date:         ___________________________________________________  
 
 
WITNESS OF RECIPIENT: 
 
Organization:   
 
Address:   
  
Name:   
 
Title:   
 
Signature: _____________________________________________________ 
 
Date:  _____________________________________________________ 
 
RECIPIENT SCIENTIST:  
 
Organization:  
  
Address:    
 
Name:   
 
Title:       
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Signature: _____________________________________________________ 
 
Date:  _____________________________________________________ 
 
 
WITNESS OF RECIPIENT: 
 
Organization:  
  
Address:    
    
Name:   
 
Title:   
 
Signature: ___________________________________________________    
 
Date:                 ___________________________________________________ 
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APPENDIX F: PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM 
 
 
TITLE OF THE RESEARCH PROJECT: In vitro Assessment of Some Traditional 
Medications Used in South Africa for Pharmacokinetic Drug Interaction Potential 
 
 
 
REFERENCE NUMBER: N10/09/307 
 
PRINCIPAL INVESTIGATOR: Mr Pius Fasinu 
 
ADDRESS: Division of Pharmacology, 7th Floor, Clinical Building, Faculty of Health 
Sciences, University of Stellenbosch, Tygerberg 19063 
 
 
 
CONTACT NUMBER: 021 938 9336 
 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
the study staff any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
 
 
What is this research study all about? 
This study is designed to assess the effects of traditional herbal medicine on human 
metabolic enzymes. This type of laboratory-based study is generally used to investigate 
interaction between traditional and orthodox medicine. It is applicable to infer on the 
safety or otherwise, of the concurrent use of traditional and orthodox medicines. It 
involves laboratory tests between the traditional and orthodox medicines to find out if 
the metabolism of one is affected by the presence of the other. 
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The study will be conducted in the laboratories in the Division of Pharmacology, 
University of Stellenbosch. The researchers will like to source for certain medicinal 
herbs and document the traditional use of these samples, to be used in the study. This 
is why people with knowledge in traditional health practice will be needed to voluntarily 
help to provide information on the use of these medicinal herbs. 
At least two traditional health practitioners will be needed to participate in this study. 
The study does not involve the administration of any medication or enquiries on the 
medication/health records of the participants. 
 
Why have you been invited to participate? 
You have been invited to participate in this study because you are identified as a 
traditional health practitioner with knowledge on the use of medicinal herbs. 
 
 
What will your responsibilities be? 
If you volunteer to participate in this study, we would ask you to do the following things: 
 
We will ask you to assist us with providing any or all of the following herbal plants (a – 
o) and ask you 
1. What medicinal use do they serve in your practice? 
2. How are they used? 
3. In case of publications or public presentations arising from this study, will you like 
to be acknowledged in person? 
 
a. Hypoxis hemerocallidea (African Potato (Eng) Afrika patat (Afrk), Inkomfe, 
ilabatheka, sterblom, lotsane, molikharatsa) 
b. Spirostachys africana Sond. (Mthombothi) 
c. Bowiea volubilis Harv. Ex Hook. F (Umagaqana) 
d. Zantedeschia aethiopica L. Spreng. (Inyibiba) 
e. Chenopodium album L. (Imbikicane embomvu) 
f. Kedrostis Africana L. Cogn. (uTuvana) 
g. Alepidea amatymbica Eckl & Zeyh. (Iqwili) 
h. Lessertia frutescens (Cancer bush, Umnwele) 
i. Acacia karroo (Sweet thorn, UmNga) 
j. Emex australis (Inkunzane) 
k. Pachycarpus concolor E. May. (Itshongwe) 
l. Ranunculus multifidus Forssk (Igangashane) 
m. Capparis sepiaria L. var citrifolia (Lam) Toelken (Isihlo esimbovu) 
n. Pentanisia prunelloides (Isicimamlilo, Itshamlilo) 
o. Tulbaghia violacea (Harv) (Wild garlic, wildenoflok, wilde knoffel (Afr) 
 
 
Will you benefit from taking part in this research? 
There will be no direct and immediate benefit of this study to the participants. However, 
in the long term, this study will benefit the participants and the general society. The 
findings from this study will contribute to the available knowledge on the safety of 
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concomitant use of traditional and orthodox medicine. It will help the practice of the 
traditional health practitioner as in the future, such information will translate to 
applicable advice to patients if the administration of traditional medicines should be 
spaced from orthodox medicine for risk of interaction.  
 
The presentations of the results of this study either in conferences or as published 
academic articles will acknowledge the participants‟ contribution. The identities of the 
participants will be disclosed only if they expressly permit so. 
 
Are there any risks involved in your taking part in this research? 
There is no direct risk or harm in participating in this study. However, participation may 
look like divulging professional and indigenous information to non-practitioner of 
traditional healing. Information should be voluntary and if you feel uncomfortable in 
disclosing the indication of any of the herbs, you are free not to do so. Any information 
provided will be used for research purposes only. There will be no commercial 
application of the information so provided whatsoever. 
 
If you do not agree to take part, what alternatives do you have? 
Your participation in this study is absolutely voluntary. You therefore have the right to 
decline participating in this study with no consequence whatsoever. 
 
 
Who will have access to your medical records? 
The participants will not be asked any personal questions relating to their medical 
records. The researchers will not have any access to the medical records of the 
participants. 
 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission or as 
required by law. Confidentiality will be maintained by means of describing participants 
with letter codes „a‟, „b‟, „c‟ etc while the true identities of the participants will be known 
to the investigator only. The data generated from individual participants will be kept in 
the Division of Pharmacology, safeguarded from public.  
 
Published results will acknowledge participants as a whole. The identities of participants 
will be disclosed in acknowledgment sections of such publications only if they expressly 
permit. 
 
What will happen in the unlikely event of some form injury occurring as a direct result of your 
taking part in this research study? 
No possible injury is anticipated in this study. There will not be personal and invasive 
questions to be asked the participants.  
 
Will you be paid to take part in this study and are there any costs involved? 
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The participants will be compensated for participating in this study. The investigator 
understands that traditional health practitioners charge their clients who consult them.  
R10 will be paid for each of the samples provided and a compensation for the 
consultation and information will be paid for at a flat rate of R100.  
 
Is there any thing else that you should know or do? 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your study 
staff. 
You will receive a copy of this information and consent form for your own records. 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled „In vitro Assessment of Some Traditional Medications Used in 
South Africa for Pharmacokinetic Drug Interaction Potential‟. 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, 
as agreed to. 
 
 
Signed at......................…........…………….. on …………....……….. 20…. 
 
 
 
 ...............................................................  ............................................................. 
Signature of participant Signature of witness 
 
 
 
Declaration by investigator 
 
I ……………………………………………..……… declare that: 
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 I explained the information in this document to ……………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use a interpreter.  (If a interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at......................…........…………….. on …………....……….. 20... 
 
 
 
 ...............................................................  ............................................................. 
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at......................…........…………….. on …………....…………… 20….. 
 
 
 
 ...............................................................  ............................................................. 
Signature of interpreter Signature of witness 
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APPENDIX G: SOME OF THE MEDICINAL HERBS USED IN THIS STUDY 
 
 
Hypoxis hemerocallidea in its natural habitat 
 
Lessertia frutescens germinating in a nursery 
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Tulbaghia violacea in a natural habitat 
 
 
A wild tree of Acacia karoo 
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Botanical parts of a) Hypoxis hemerocallidea (corm) and b) Tulbaghia violacea (bulb) used in 
traditional medical practice 
 
 
 
  
a) b) 
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APPENDIX H: HEPATOCYTES CHARACTERISTICS 
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